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Abstract: Investigation of the genetic aetiology and pathogenetic mechanism of 
disease in patients with late-onset FGD 
 
Familial Glucocorticoid Deficiency (FGD) is an autosomal recessive form of adrenal 
failure characterized by isolated glucocorticoid deficiency with preserved 
mineralocorticoid secretion. I studied two cohorts of patients who presented with late 
onset FGD. 
 
Firstly I investigated 2 families of Turkish ethnicity who presented with delayed onset 
adrenal insufficiency and identified two novel missense mutations in the melanocortin 
2 receptor accessory protein (MRAP). I characterised both these mutations in vitro 
and confirmed that both mutant MRAPs demonstrated reduced rather than absent 
function consistent with the phenotype of delayed presentation.  
 
Secondly I studied 3 families from a genetically isolated Irish population who had an 
interesting variant of adrenal failure. Patients had typical biochemical features of 
FGD with isolated glucocorticoid deficiency, raised ACTH and normal renin and 
aldosterone levels. Unlike other forms of FGD, cortisol deficiency was often not as 
severe and onset was usually in childhood following a period of normal adrenal 
function. Affected children develop hypocortisolaemia but also growth failure, 
increased chromosomal breakage and natural killer (NK) cell deficiency.   
 
Targeted exome sequencing identified a variant (c.71-1insG) in mini chromosome 
maintenance homologue 4 (MCM4) that segregated with the disease in all 3 families. 
RT-PCR of patient leucocyte RNA revealed this mutation leads to aberrant splicing of 
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exon 2 and a foreshortened ORF encoding a prematurely terminated translation 
product (p. Pro24ArgfsX4). Western blotting of patient lymphocytes revealed loss of 
the full length MCM4 protein but two smaller MCM4 isoforms were preserved. 
 
Histological examination of the adrenals of an MCM4 depletion mouse model 
revealed an abnormal adrenal morphology. Small, spindle-shaped cells were present 
throughout the adrenal cortex. These cells did not express either CYP11A1 or 
CYP11B1 and significantly reduced the number of steroidogenic cells in the zona 
fasciculata. Further staining showed these cells expressed GATA4, a transcription 
factor expressed in foetal but not adult adrenals, and capsular markers, indicating that 
they may be non-steroidogenic capsular cells infiltrating the cortex. 
 
MCM4 is one part of a heterohexameric complex essential for normal DNA 
replication and genome stability in all eukaryotes and no MCM mutation has ever 
been described in humans. I have identified a mutation in MCM4 that results in 
adrenal failure, growth retardation, increased chromosomal fragility and NK cell 
deficiency. Animal models indicate that loss of MCM4 is lethal, but it is likely that 
the smaller isoforms I observe may rescue the patients from a lethal phenotype. 
 
This research has revealed a novel mechanism of adrenal failure and potentially a 
novel function of MCM4. The seemingly specific impact on adrenal function may 
reflect a defect in adrenal stem cell differentiation and the inability of capsular cells to 
differentiate into steroidogenic cells.  
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Chapter 1: Introduction 
1.1: Introduction 
Familial Glucocorticoid Deficiency (FGD) is an autosomal recessive form of adrenal 
failure characterized by adrenocorticotrophin (ACTH) resistant isolated 
glucocorticoid deficiency with preserved mineralocorticoid secretion [1-3]. Patients 
with FGD usually present in the neonatal period or early childhood with symptoms 
relating to cortisol deficiency including hypoglycaemia, jaundice, recurrent infection 
and failure to thrive.  Patients are hyperpigmented due to grossly elevated ACTH 
levels. A unique variant of FGD exists in the Irish travelling community, a genetically 
isolated population with high levels of consanguinity [4].  Affected children develop 
hypocortisolaemia and compensatory elevated ACTH, but retain normal renin and 
aldosterone levels as expected. However patients also have short stature, evidence of 
increased chromosomal breakage and natural killer (NK) cell deficiency. 
  
FGD was first described in 1959 by Shepard et al. who reported 2 sisters as having 
Addison’s disease without hypoaldosteronism [1].  Subsequently a number of patients 
were reported with an inherited form of adrenal insufficiency also without 
hypoaldosteronism [2, 3, 5, 6]. In contrast to Addison’s Disease, FGD is a genetic 
disorder resulting from mutations in genes encoding essential proteins involved in the 
early response to ACTH.  
 
1.2: Hypothalamic pituitary adrenal axis 
1.2.1: Mechanisms controlling cortisol production 
The adrenal gland consists of an outer adrenal cortex surrounding an inner adrenal 
medulla. The adrenal cortex comprises the zona glomerulosa secreting aldosterone, 
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the zona fasciculata secreting cortisol and the inner zona reticularis secreting adrenal 
androgen precursors. The anterior pituitary hormone ACTH controls cortisol 
synthesis and secretion from the zona fasciculata. ACTH secretion is stimulated by 
corticotrophin releasing hormone (CRH) from the hypothalamus and follows a 
circadian pattern. Cortisol secretion is an example of one of the classical endocrine 
feedback loops; it is under negative feedback control from the hypothalamic-pituitary-
adrenal (HPA) axis (Figure 1.1). ACTH release occurs in response to low circulating 
cortisol levels and is inhibited by high circulating levels of cortisol or synthetic 
glucocorticoid. This negative feedback occurs at both the hypothalamic and pituitary 
level. ACTH is also released in response to stress such as trauma, hypoglycaemia, 
infection/fever, surgery or anxiety. 
 
ACTH acts by binding to its specific cell-surface receptor, the ACTH receptor or 
melanocortin 2 receptor (MC2R) to induce adrenal steroidogenesis in all three zones 
of the adrenal cortex.  The MC2R is the smallest member of the melanocortin receptor 
family, which includes five members MC1R – MC5R.  The melanocortin receptors 
are seven transmembrane domain G protein-coupled receptors (GPCRs) which are 
involved in diverse functions including adrenal steroidogenesis, pigmentation and 
weight and energy homeostasis [7]. The sole natural ligand for MC2R is ACTH, in 
contrast to the other melanocortin receptors that show varying affinity to ACTH and 
α-, β- and γ-MSH [8]. 
 
ACTH binding to MC2R induces intracellular production of cyclic adenosine 
monophosphate (cAMP), one of the major actions of which is to stimulate cAMP-
dependent protein kinase (protein kinase A).  As a consequence of this stimulus 
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cholesterol ester is imported into the cell via the scavenger receptor B1 and hydrolysis 
of the ester by hormone sensitive lipase occurs.  Cholesterol is then taken up into the 
mitochondrion by a complex including the steroidogenic acute regulatory protein 
(StAR). ACTH stimulates increased steroidogenic enzyme expression via a number of 
mechanisms including the activation of the cAMP response element binding protein 
(CREB), and ultimately results in an increased rate of cortisol synthesis. ACTH has 
also recently been shown to specifically increase StAR transcription via cAMP 
inhibition of salt inducible kinase (SIK), allowing phosphorylation of TORC 
(transducer of regulated CREB activity), which activates CREB and induces StAR 
transcription [9].  
 
Figure 1.1 
 
 
Figure 1.1. A. Hypothalamic Pituitary Adrenal Axis. Negative feedback regulation of cortisol 
secretion. B. POMC processing. The POMC gene leads to the generation of a prohormone 
POMC, which undergoes a series of proteolytic cleavages to give rise to ACTH as indicated. 
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1.2.2: Mechanisms controlling aldosterone production 
The control of mineralocorticoid production is entirely separate from glucocorticoid 
production. This has important clinical consequences as some patients may have 
disorders affecting only one system or may have combined glucocorticoid and 
mineralocorticoid deficiency due to adrenal hypoplasia or destruction. The main 
factor controlling aldosterone production is angiotensin through the renin-
angiotensin-aldosterone system.  
 
Renin synthesis occurs from the juxtaglomerular cells of the kidney in response to 
low renal arteriolar pressure, hyponatraemia, hyperkalaemia, upright posture, 
vasodilatory drugs and β-adrenergic stimulation. Renin cleaves Angiotensinogen to 
form Angiotensin I, which in turn is converted to Angiotensin II by angiotensinogen 
converting enzyme (ACE). Angiotensin II has two principal actions both of which are 
mediated through the AT1 receptor and both increase blood pressure. Firstly 
Angiotensin II stimulates arteriolar vasoconstriction within seconds. Secondly it is a 
potent stimulator of aldosterone secretion by increasing transcription of the 
cytochrome P450 enzyme, CYP11B2 within the zona glomerulosa cells of the adrenal 
cortex [10].  Increased plasma potassium is also a powerful stimulator of aldosterone 
production via membrane depolarization, calcium channel alteration and ultimately 
increased transcription of CYP11B2 [11]. Aldosterone causes renal sodium retention 
and potassium loss and consequently increases intravascular volume and blood 
pressure.   
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1.2.3: Mechanisms controlling adrenal androgen production 
ACTH is capable of stimulating adrenal androgen synthesis however the pattern of 
secretion is very different from cortisol secretion. Androgen secretion is high in 
infancy, low during childhood and rises again in adolescence and early adulthood. 
This is in contrast to cortisol secretion which has a diurnal variation but levels remain 
similar throughout life. The exact control of adrenal androgen secretion together with 
the development of the zona reticularis (discussed below) remains to be elucidated. 
 
1.3: Adrenal development 
1.3.1: Embryology 
The adrenal glands consist of an outer cortex and an inner medulla that are 
embryologically and physiologically distinct but often act together to coordinate the 
fight/flight response.  The medulla consists of neuroectodermally derived chromaffin 
cells and secretes catecholamines including epinephrine and norepinephrine. During 
foetal life clusters of chromaffin cells are scattered throughout the adrenal cortex only 
coalescing into a separate identity after birth [12]. The adrenal cortex is derived from 
the intermediate mesoderm and produces many steroid hormones including 
mineralocorticoids, glucocorticoids and adrenal androgens.  
 
The human foetus has very large adrenal glands relative to its size; by 20 weeks 
gestation the adrenal gland is approximately the same size as the foetal kidney. At 
birth the adrenal glands are approximately twice the weight of adult adrenals (8-9g) 
[13]. The growth of the foetal adrenal involves proliferation, migration, differentiation, 
hypertrophy and apoptosis of adrenal cells. The first evidence of adrenal development 
and adrenal specific cells in utero occurs at 4 weeks gestation when the 
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adrenogonadal primordium can be distinguished and identified by steroidogenic 
factor-1 (SF1) expression [14]. At approximately 8 weeks gestation the adrenal 
primordium separates from the gonadal primordium. At this stage the adrenal 
primordium consists of 2 zones, the definitive zone and the foetal zone both 
surrounded by a mesenchymal capsule [14]. The foetal zone consisting of large 
eosinophilic cells secretes vast quantities of steroids throughout pregnancy, 
principally DHEA and DHEAS. The placenta does not synthesise oestrogen from 
cholesterol but instead converts the DHEA and DHEAS from the foetal adrenal into 
oestrogen using placentally expressed aromatase.  Oestrogen is important for the 
development of placental villous blood vessels and foetal ovarian development. The 
definitive zone consists of a thin layer of basophilic cells and is thought to act as a 
reservoir for progenitor cells which can then migrate into the foetal zone and 
differentiate into steroidogenic cells [15]. The transitional zone, lying between the 
definitive zone and the foetal zone, develops at approximately 24-28 weeks of 
gestation [16]. Transitional zone cells resemble those of the adult adrenal zona 
fasciculata and are capable of secreting small quantities of cortisol in late gestation. 
Postnatally the foetal zone regresses, presumably due to apoptosis, and the definitive 
zone differentiates into the zona glomerulosa, secreting mineralocorticoids and the 
zona fasciculata secreting glucocorticoids. Different studies provide conflicting 
evidence suggesting the regression of the foetal zone may be determined either by 
gestation or delivery [17, 18]. Later in childhood the zona reticularis develops and 
secretes adrenal androgens with the onset of adrenarche at around 6-8 years.  
 
Most mechanistic studies on adrenal development have used rodent models, 
principally rats and, more recently, mice. Murine adrenal development proceeds in a 
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similar manner to the human, with the SF-1 positive adrenogonadal primordium first 
being identified in a thickening of the coelomic epithelium overlying the genital ridge 
at around embryonic day E9.5 [19]. At approximately E10.5 a subset of SF1 positive 
cells have coalesced into the adrenal anlagen which is then invaded by neural crest 
medullary precursors before mesenchymal cells encapsulate the gland by E13.5.  By 
E16 the adrenal cortex and medulla are a distinct entity. As the adrenal grows SF1 
dependent steroidogenic enzyme expression begins and steroidogenic zones segregate. 
In mice the zona glomerulosa forms perinatally.  At birth a transient zone, termed the 
X-zone is detectable in the innermost part of the mouse adrenal cortex, this regresses 
at puberty in male mice and after the first pregnancy in females [20]. This zone has 
been postulated as being equivalent to the foetal zone in humans.  
 
A number of different models have been proposed to explain growth of the foetal 
adrenal gland; the centripetal cell migration model, the transformation field model 
and the zonal model (Figure 1.2) [21]. The transformational field model suggests that 
there are two transformational fields; one located between the zona glomerulosa and 
the zona fasciculata and one between the zona fasciculata and the zona reticularis. 
Progressive transformation results in a proliferative increase of the fasciculata zone, 
regressive transformation leads to a narrowing and functional restriction.  The zonal 
model postulates that specific undifferentiated stem cells exist for all zones.  However 
most recent studies support the cell migration model, this model postulates that stem 
cell populations reside either in the adrenal subcapsular region or in the zona 
glomerulosa or zona glomerulosa/zona fasciculata border. These populations can 
proliferate and then migrate into the zona glomerulosa or zona fasciculata and 
differentiate into steroidogenic cells [22, 23]. Enucleation experiments indicate that 
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capsule and/or adherent subcapsular cells can differentiate to recreate an adrenal 
cortex with normal zonation. Although the exact origin of the stem cell population is 
unclear it has been suggested that these stem cells are SF1 negative cells that reside in 
the capsule or subcapsular region and that can migrate into the adrenal cortex in 
response to some unknown mitogenic signals, gain SF1 expression and differentiate 
into steroidogenic cells [24]. Studies have shown increased proliferation within the 
periphery of the gland and the definitive zone with hypertrophy predominantly 
occurring in the foetal zone in humans. Further studies show increased apoptosis 
occurring in the centre of the gland [25]. Taken together this indicates that cells 
proliferate in the periphery of the foetal adrenal gland and migrate centripetally 
differentiating into the different zones before undergoing senescence near the centre 
of the gland. In addition lineage tracing studies have demonstrated that both sonic 
hedgehog (Shh) expressing cells in the subcapsular mouse cortex and Shh signal 
receiving capsule mesenchyme cells have properties of adrenocortical stem/progenitor 
cells with their progeny populating the entire cortex [21]. Recent preliminary work 
has further supported this hypothesis; genetically engineered mice expressing Cre-
recombinase under the control of aldosterone synthase, a specific zona glomerulosa 
cell marker were created. These mice had GFP labeled cells in the zona glomerulosa 
on postnatal day 1, these cells encompassed most of the zona glomerulosa by 3 weeks 
of age and by 5 weeks of age there was considerable GFP labeling in the zona 
fasciculata suggesting the zona fasciculata cells arise from the zona glomerulosa. 
However when zona glomerulosa cells were ablated the zona fasciculata was still able 
to develop normally suggesting an alternative mechanism independent of the zona 
glomerulosa can also give rise to a functional zona fasciculata [26].  
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Figure 1.2 
 
Figure 1.2. Different models proposed to explain growth of the fetal adrenal gland. The origin 
of the arrows indicate the place of cell renewal and proliferation. The tips of the arrows 
indicate the direction of growth and / or migration. ZG, zona glomerulosa; ZF, zona 
fasciculata; ZR, zona reticularis; ZU; undifferentiated zone. 
 
1.3.2: ACTH 
ACTH is accepted as one of the primary regulators of adrenal development. However 
this is not mediated solely by MC2R. ACTH stimulates proliferation of adrenocortical 
cells in vivo but not in vitro suggesting that it acts through other mitogenic factors 
produced locally [27]. This has important implications for children with familial 
glucocorticoid deficiency (described in detail below) due to ACTH receptor pathway 
defects. These children present postnatally with isolated glucocorticoid deficiency but 
importantly they have had some degree of normal adrenal development. Although the 
adrenals are reported as being small these children have an intact renin – aldosterone 
system and can produce mineralocorticoids as normal from the zona glomerulosa, 
indicating that ACTH driven adrenal development is not only mediated through 
MC2R [28]. Babies with anencephaly (and therefore presumably very low levels of 
ACTH) have normal adrenal development at 10-15 weeks gestation indicating that 
early development of the foetal adrenal is ACTH independent [29].  
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Mutations in the proopiomelanocortin (POMC) gene or the prohormone convertase 1 
(PC1), which cleaves POMC to ACTH, give rise to a similar phenotype as that seen in 
FGD. However patients with POMC mutations also have red hair, pale skin and 
obesity as well as adrenal insufficiency as melanotrophin stimulating hormone (MSH) 
and β-endorphin will also be affected. Those patients with mutations in PC1 can also 
present with abnormalities in glucose metabolism, obesity, hypogonadotrophic 
hypogonadism and malabsorptive diarrhoea [30]. ACTH deficiency can also exist as 
part of multiple pituitary hormone deficiency or as an isolated deficiency secondary to 
TPIT mutations, a T-box factor that controls transcription of the POMC gene [31].    
 
ACTH up-regulates vascular endothelial growth factor (VEGF)-A, a pro-angiogenic 
factor and potent mitogen for endothelial cells. ACTH also increases expression of 
Angiopoietin (Ang)-1 and Ang-2 growth factors that mediate angiogenesis allowing 
increased blood supply to the rapidly enlarging foetal adrenal gland [32]. In addition 
ACTH can up-regulate expression of FGF-2, and IGF-II which act as growth factors 
stimulating adrenocortical cell growth. Each zone of the foetal adrenal gland 
expresses ACTH receptors and it has been postulated that different expression levels 
of the ACTH receptor and therefore different responsiveness to ACTH between the 
zones may help control zonation of the adrenal cortex [33].   
 
1.3.3: SF1 and DAX1 
Adrenal development and the appropriate differentiation of progenitor cells within the 
adrenal cortex depend on the normal spatiotemporal expression of a wide range of 
signalling molecules. Steroidogenic Factor 1 (SF1) and Dosage sensitive sex reversal 
Adrenal hypoplasia congenital critical region on the X chromosome (DAX1) are 
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members of the nuclear hormone receptor family of transcription factors. Both are 
expressed in the adrenal primordium from its earliest stages in development, 
throughout prenatal life and postnatally in the adult adrenal cortex [14, 34]. Although 
both are essential for normal adrenal (and gonadal) development they seem to have 
antagonistic actions as well as synergistic actions.  
 
SF1 expression is initiated by Pbx1 (pre-B-cell leukaemia transcription factor 1) 
within a complex with Prep1, a homeobox protein, and Hox (Homeobox gene) 9b that 
together activate a Foetal Adrenal Enhancer (FAdE), which lies within intron 4 of SF1 
[34]. This initially occurs on separation of the adrenogonadal primordium after which 
SF1 autoregulates its own expression. FAdE is an adrenal specific promoter and is not 
active in other SF1 expressing tissues, for example the gonad, hypothalamus or 
pituitary gonadotropes. SF1 regulates the transcription of many genes involved in 
steroidogenesis [35]. SF1 knock out mice have adrenal agenesis and gonadal 
dysgenesis. A recent paper from Achermann’s group has reviewed the wide clinical 
spectrum of human disease associated with SF1 mutations [36]. Two case reports 
describe the classical human phenotype of primary adrenal failure and gonadal 
dysgenesis in XY individuals (1 homozygous and 1 heterozygous mutation in SF1) 
and one reports primary adrenal failure but normal gonadal development in a 46XX 
individual with a heterozygous mutation in SF1. Conversely 46XX patients with SF1 
mutations have also been reported as having normal adrenal function but primary 
ovarian failure. Interestingly a number of cases with heterozygous mutations in SF1 
have been reported in 46XY patients who have gonadal anomalies ranging from 
gonadal dysgenesis and sex reversal to milder abnormalities such as hypospadias and 
male factor infertility but all have normal adrenal function. In contrast overactivity or 
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overexpression of SF1 may also be a potential cause or modifier of human disease. 
Somatic duplications of 9q33 (SF1 locus) have been described in a cohort of children 
from Brazil with adrenocortical tumours [37]. Subsequently increased SF1 expression 
has been seen in adult adrenocortical tumours and has also been associated with a 
worse prognosis [38].  
 
Human mutations in DAX1 cause X-linked adrenal hypoplasia congenita which 
usually presents as primary adrenal failure at birth with hypogonadotrophic 
hypogonadism [39, 40]. DAX1 is one of the target genes for SF1 but it also inhibits 
SF1 mediated transcription; DAX-1 null mice do not present with adrenal hypoplasia 
or adrenal failure however the adrenal failure in the SF1 knockout mouse is partially 
rescued by knockout of DAX1 [41]. DAX1 human mutations give rise to hypoplasia 
of the human foetal adrenal with little or no evidence of a definitive zone and a poorly 
organised foetal zone. In the human foetal adrenal DAX-1 shows nuclear localisation 
in the definitive zone cells perhaps preventing SF1 expression and therefore inhibiting 
steroidogenesis in these cells. In contrast DAX-1 is less abundant and localises to the 
cytoplasm in foetal zone cells, possibly releasing the inhibition of SF1 and allowing 
steroidogenesis[42].  DAX-1 is also specifically enriched in the subcapsular region 
similar to sonic hedgehog (Shh) (see below). This data suggests that DAX-1 loss of 
function leads to depletion of steroidogenic progenitor cells with enhanced 
differentiation of definitive zone cells secondary to reduced inhibition on SF1 and 
therefore ultimately adrenal hypoplasia.  
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1.3.4: Hedgehog signalling 
Hedgehog (Hh) signalling is required for the growth and normal development of a 
number of tissues and has been identified as a regulator of both adult stem cell 
populations and embryonic stem cells [43, 44]. Sonic hedgehog (Shh) in the adrenal 
gland binds to its receptor (Patched-1) and releases inhibition of the Smoothened 
membrane protein allowing downstream activation of Gli transcription factors (Gli1-
3). Gli1 expression is absolutely dependent upon Hh signalling and is only seen in the 
capsule and a few subcapsular, non-steroidogenic, cells. Recently King et al. showed 
that Shh mRNA is expressed in the mouse adrenal cortex and also identified Gli-1 and 
Shh expressing cells as candidate adrenoprogenitor and stem cell populations [21]. 
They identified Shh signalling as the potential mechanism underlying the cell 
migration model (discussed above) of adrenal growth and maintenance in mice. In 
this model there are 2 populations that contain adrenocortical progenitors. Firstly, SF1 
positive cells derived from the adrenogonadal primordium delaminate and establish a 
primary adrenal lineage (the foetal zone/X zone). Some of these cells initiate Shh 
signalling and can differentiate into any steroidogenic lineage. These Shh positive, 
SF1 positive progenitors within the zona glomerulosa can populate the cortex 
throughout development and promote adrenal maintenance in later life. The Shh 
positive cells signal to the surrounding mesenchymal cells, acting possibly as a 
chemoattractant or mitogen for the coalescing capsule. These mesenchymal derived 
cells that are Gli1 positive (Sf1 negative, Shh negative) within the adrenal capsule or 
subcapsular mesenchyme can also give rise to Sf1 positive cells and these cells can 
also subsequently differentiate and contribute to all steroidogenic lineages, at least in 
part via a Shh expressing intermediate population. Huang et al. and King et al. 
showed that tissue specific knockout of Shh led to small adrenals but proper zonation 
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was maintained indicating that Shh has a role in the growth of the adrenal cortex but 
not its differentiation in mice [21, 45]. King et al. also showed that in the absence of 
Shh proliferation indices of the cortical cells are relatively normal but that the capsule 
is very thin, indicating that the conversion of capsule cells to cortical cells is disrupted 
accounting for the growth failure.  
 
Interestingly a recent paper examining the effects of eliminating SF1 sumoylation in 
vivo provided further evidence suggesting correct Shh signalling is required for 
normal adrenal and gonadal development [46]. Sumoylation is generally considered to 
repress transcriptional activation of its given substrate. However by creating a 
knockin mouse with a mutant unsumoylatable SF1 homozygous allele Lee et al.  
showed that disrupting the SF1 sumo cycle leads to increased activation of Shh and 
the Shh signalling pathway in the adrenal gland. Shh positive cells, which are usually 
restricted to the immediate subcapsular layer, were seen penetrating deep into the 
cortex. Additionally there was a notable expansion of Gli1 positive cells in the 
subcapsular layer and definitive zone suggesting that loss of SF1 sumoylation elevates 
Shh expression to amplify hedgehog signalling. This was in contrast to a number of 
known SF1 targets, for example CYP11A1, in which the expression levels remained 
unchanged. In addition the authors found the mutant adrenals expressed a number of 
testicular markers, for example SOX9, and also exhibited a persistent foetal X zone 
suggesting eliminating SF1 sumoylation interferes with normal adrenal maturation. 
Paradoxically they noted reduced Shh expression and a thinner subcapsular layer of 
Gli-1 cells in older mutant adrenals together with reduced adrenal weights. They 
proposed that the early expansion of Shh positive adrenal progenitors would interfere 
with the adrenal stem cell niche and potentially disrupt steroidogenic cell 
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differentiation by recruiting progenitors prematurely, consistent with the role of Shh 
in adrenal stem cell proliferation and maintenance discussed above.  
 
Mutations in Shh and other genes involved in the hedgehog signalling pathway can 
lead to holoprosencephaly, which is frequently associated with secondary adrenal 
insufficiency. Pallister-Hall syndrome, which has been associated with adrenal 
hypoplasia and insufficiency in humans, has been shown to be caused by a frame shift 
mutation in Gli-3, although the adrenal phenotype may also be secondary to pituitary 
defects [47]. 
 
1.3.5: Wnt/β-catenin 
Wnt/β-catenin signalling is essential for normal embryonic development and 
maintenance and differentiation of stem cell populations in many tissues including the 
adrenal. Among Wnt factors Wnt 4 is specifically required for adrenal development 
[15]. Wnt activation allows cytoplasmic and nuclear accumulation of β-catenin, 
leading to activation and transcription of downstream genes. Specific inactivation of 
B-catenin in a mouse model, using cre-lox techniques to target only SF-1 expressing 
cells, showed adrenal hypoplasia at birth with high SF-1 cre transgene expression [48]. 
In mice with lower levels of Cre expression the phenotype was delayed and the mice 
displayed increased cortical thinning and adrenal failure later in life. The cortical 
depletion is hypothesised to be secondary to a reduction in adrenocortical progenitor 
cells as B-catenin/Wnt signalling has been demonstrated to be essential in a number 
of progenitor cell systems. It is possible that hedgehog signalling and Wnt/B-catenin 
signalling regulate adrenocortical progenitor populations in concert as B-catenin has 
been shown to be required for SF1 positive cell proliferation and survival and 
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hedgehog and Wnt signals are frequently reciprocally regulated [49]. Overexpression 
of β catenin causes adrenal hyperplasia and a secondary zona glomerulosa situated 
next to the medulla. Wnt4 deletion causes absence of the zona glomerulosa [50].  
 
Many other transcription factors have been identified as being essential for normal 
adrenal development in mice including, SALL1, CITED2, FoxD2 and WT1. 
Knockout of any of these factors in mice leads to an adrenal phenotype however only 
mutations in Gli-3 have been associated with adrenal hypoplasia and insufficiency in 
humans (Pallister-Hall syndrome). 
 
1.3.6: Acd and chromosomal instability 
An interesting spontaneous autosomal recessive mutant with developmental defects in 
organs derived from the urogenital ridge was identified in an inbred mouse strain 
from the Jackson laboratory [51]. This mouse, named the Acd mouse, has 
adrenocortical dysplasia, with hypoplastic adrenals, skin hyperpigmentation, growth 
retardation, infertility and hydronephrosis. Biochemically female mice had lower 
baseline corticosterone levels and both sexes had elevated ACTH levels compared to 
wild type but interestingly aldosterone levels were normal indicating a normal 
functioning zona glomerulosa. Subsequently Keegan et al identified the cause of the 
Acd mutant phenotype, a novel splice mutation in the Acd gene which encodes the 
telomere protein Tpp1 [52]. This protein is a component of the shelterin complex that 
maintains telomere integrity and protects the telomere from telomerase activity. 
Therefore these mice had telomere dysfunction and genomic instability. They further 
characterised the adrenal defect showing that the mutant adrenals consisted of 
enlarged cortical cells with irregular nuclei, The adrenals lacked an X-zone at any age 
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indicating that the developmental program yielding a mature adrenal cortex was 
interrupted. However the fundamental defect leading to the adrenal phenotype 
remains unknown, it was presumed to be caused by a defect in cellular proliferation 
but this is unproven and so the role of Acd in adrenal cortical development is still to 
be established. No human mutations in Acd /Tpp1 have been identified. However 
other human syndromes caused by genomic instability including Werner syndrome 
(caused by mutations in the RecQ DNA helicase RECQL2) and dyskeratosis 
congenita (caused by mutations in the TERC gene) have similar features to the Acd 
mouse including germ cell failure, adrenal insufficiency and skin abnormalities [53, 
54]. Therefore genomic instability, through an as yet undiscovered mechanism, can 
lead to adrenal insufficiency both in mice and humans.  
 
1.3.7: GATA transcription factors 
GATA4 and GATA6 are expressed in both human and mouse adrenals [55]. GATA1-
6 are zinc finger transcription factors that bind to gene promoters and enhancers to 
regulate gene expression. GATA1-3 are primarily expressed in haematopoetic 
lineages whilst GATA4-6 regulate cellular proliferation, differentiation and apoptosis 
in mesoderm and endoderm derived tissues including the adrenal cortex. Null 
mutations for any of the GATA transcription factors (except GATA5) are embryonic 
lethal. GATA4 is only expressed in the foetal adrenal cortex, i.e in less differentiated 
proliferating cells whilst GATA6 is present in both foetal and adult adrenal cells. 
GATA6 acts with SF1 to upregulate StAR, CYP11A1, CYP17A1, HSD3B2 and 
SULT2A1 while GATA4 upregulates inhibin-α, CYP 17A1 and StAR [55]. In adult 
mouse gonads GATA4 expression is most readily detected during periods of active 
proliferation in ovarian granuloma cells and testicular sertoli cells [56, 57]. Up-
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regulation of GATA4 expression has been identified in a small number of 
adrenocortical tumours and has been linked to more aggressive tumour behaviour [58].  
 
1.3.8: Adrenal maintenance and zonation 
The adult adrenal cortex is a dynamic organ that is constantly remodelling to meet the 
steroidal requirements of the animal and thus maintain homeostasis. The zona 
glomerulosa is under the control of the renin-aldosterone system so that activation, by 
for example, placing animals on low sodium or high potassium diets leads to a rapid 
expansion of the zona glomerulosa whereas inhibition, by for example ACE inhibitors, 
leads to its rapid diminution. Similarly, the ZF, under the control of the HPA, can be 
expanded by ACTH treatment but reduced by chronic exposure to glucocorticoids 
[59]. It is proposed that remodelling occurs in a similar way to the growth and 
development of the foetal adrenal gland, by recruitment of differentiated 
steroidogenic cells into the zona fasciculata or zona glomerulosa from 
stem/progenitor populations within the adrenal capsule, although transdifferentiation 
between zona glomerulosa and zona fasciculata cells cannot be ruled out. It has been 
theorized that there may be progenitor cells within each zone but the most accepted 
concept as discussed above is that cells initially reside in the capsule or subcapsular 
region or the zona glomerulosa, then successively become zona fasciculata cells then 
zona reticularis cells through either centripetal migration or as the whole tissue is 
pushed down by pressure of cell division. Freedman et al. recently presented 
preliminary data suggesting zona fasciculata cells arise from the zona glomerulosa 
using fate mapping studies in which CYP11B2 –Cre mice were crossed with reporter 
lines to mark zona glomerulosa cells [60]. It is then presumed that the zona fasciculata 
cells eventually become zona reticularis cells in the human adrenal however 
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experiments to prove this have not been performed since the zona reticularis only 
develops in humans and some higher primates and so this cannot be explored using 
mouse or rodent models.  
 
The actual regulation controlling the zonation of the adrenal cortex remains poorly 
understood; there are a number of hypotheses to explain potential methods of 
zonation but no definitive method. The first hypothesis is that the development of the 
zona fasciculata and zona reticularis is related to the growth and development of the 
adrenal cortex so that differentiation of cells into zones is regulated by the gradient of 
a morphogen such as hedgehog, Wnt or Notch. This hypothesis is consistent with the 
observed cell migration model involved in adrenal development and maintenance. It 
is proposed that the morphogen would be at its highest concentration near the capsule 
and reducing to a low level adjacent to the medulla. This is most likely given the 
blood supply within the adrenal gland as the arterial supply reaches the capsule first 
before entering and supplying each layer from the zona glomerulosa to the zona 
reticularis, when the blood reaches the medulla it flows into the medullary vein. This 
is similar to that observed in the colon where the gradient of morphogens has been 
shown to influence cellular differentiation in the colonic crypts [61]. 
 
A second hypothesis, especially when considering development of the zona reticularis, 
proposes that a specific hormone may act on a precursor cell (either a stem cell or 
zona fasciculata cell) to cause development of the zona reticularis [62, 63]. A number 
of different hormones have been postulated including leptin, as adrenarche occurs 
with pre-adolescent increases in adiposity and leptin levels. Alternatively a pituitary 
hormone such as POMC or a Pit1/POU1F1 dependent factor, for example prolactin, 
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may be involved. The development of the adrenal reticularis, adrenarche and adrenal 
androgen synthesis is becoming more important as several recent research papers 
have indicated that children with premature adrenarche may be at increased risk of 
PCOS and metabolic syndrome in later life [64]. The factors controlling DHEAS 
secretion are especially intriguing given the function of DHEAS in children and 
adults remains elusive. Although DHEAS is the major precursor in sex steroid 
synthesis and its deficiency causes androgen deficiency in females, many additional 
functions distinct from its role in sex hormone production have been proposed. These 
include neurosteroid properties as DHEAS can cross the blood brain barrier and 
perhaps plays a role in human brain maturation [65]. Additional research, perhaps 
using novel pluripotent stem cell techniques, is required to further scrutinise 
adrenocortical zonation.  
 
1.4: Steroidogenesis 
1.4.1: Foetal cortisol synthesis 
Goto et al. suggest that human foetal adrenals secrete cortisol from as early as 8 
weeks gestation. Type 2 3β hydroxysteroid dehydrogenase (HSD3B2) expression can 
be identified in the foetal zone from about 6 to 14 weeks peaking at approximately 8-
9 weeks [66]. HSD3B2 expression is required for cortisol synthesis and to shift 
steroid synthesis away from the androgen-secreting pathway. This period is also the 
critical time for sexual differentiation. The ability of the foetus to synthesise cortisol 
at this time allows negative feedback on the HPA axis, reducing steroid production, 
but most importantly reducing androgen synthesis. This protects the female foetus 
from excess androgens allowing normal female genital development. From 14 weeks 
gestation onwards HSD3B2 expression is very low and therefore the foetal adrenal 
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gland predominantly secretes large quantities of the androgen precursors DHEAS and 
DHEA [66]. However at this time placental aromatase activity increases substantially 
and converts DHEA and DHEAS to oestrogens thereby protecting the female foetus 
from excess androgens and virilisation. From 24 weeks gestation HSD3B2 expression 
is present in the definitive zone and the transitional zone consistent with the ability of 
the foetus to make cortisol in the third trimester [67]. The spatiotemporal regulation 
of HSD3B2 expression is poorly understood.  
 
1.4.2: Post-natal steroidogenesis 
Steroidogenesis requires the concerted action of a number of different enzymes 
including cytochrome P450 (CYP) and hydroxysteroid dehydrogenase enzymes 
(Figure 1.3). The steroid produced depends on the stimulus, ACTH or angiotensin II 
and therefore whether the zona fasciculata or zona glomerulosa is stimulated and also 
the specificity of steroidogenic enzyme expression within each zone. Zona 
glomerulosa cells lack CYP17A1 and therefore cannot produce cortisol and 
conversely zona fasciculata and reticularis cells lack CYP11B2 and therefore cannot 
synthesise aldosterone. Specific cofactors are also required for the CYP enzymes. 
These are present either within the endoplasmic reticulum and depend on electron 
transfer from NADPH via the electron donor enzyme P450 oxidoreductase or are 
present in the mitochondria and require electrons donated from 
adrenodoxin/adrenodoxin reductase for normal activity (Figure 1.3).  
 
Cortisol is produced at an average production rate of 9-11mg/m2/day (approximately 
10-30mg daily) but aldosterone is produced in much smaller quantities of 
approximately 100-150 micrograms daily [11, 68]. The adrenal androgens are 
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produced in the highest quantities in adults; DHEAS is the most abundant steroid in 
the adult human circulation [69]. 
 
Figure 1.3 
 
Figure 1.3. Pathway of adrenal steroid synthesis. Enzymes required for a steroidogenesis are 
indicated in the shaded grey boxes, those outlined in red are CYP type I enzymes requiring 
electron transfer via adrenodoxin reductase and adrenodoxin. Those outlined in yellow are 
microsomal CYP type II enzymes receiving electrons from P450 oxidoreductase. The 17-20 
lyase reaction catalysed by CYP17A1 also requires cytochrome b5 (b5). Enzyme expression 
specific to each zone is indicated using the coloured boxes. Enzymes common to more than 
one zone are shown in the grey box. ZG, zona glomerulosa; ZF, zona fasciculata; ZR, zona 
reticularis; IMM, inner mitochondrial membrane.  
 
1.5: Adrenal Insufficiency 
Adrenal insufficiency can be classified as either primary or secondary adrenal failure. 
Secondary adrenal failure may be iatrogenic or can be caused by pituitary or 
hypothalamic disease. The latter is most commonly due to a space-occupying lesion 
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resulting in panhypopituitarism due to mass effect but may also occur following 
treatment with surgery or radiotherapy [70]. Iatrogenic adrenal insufficiency follows 
withdrawal of exogenous glucocorticoids but is usually transient. A number of rare 
genetic disorders may also lead to secondary adrenal insufficiency. These include 
defects in genes involved in pituitary and hypothalamic development including 
HESX1, LHX3, LHX4, PROP1 and SOX3 all of which can lead to combined pituitary 
hormone deficiency including ACTH deficiency [31]. Congenital isolated ACTH 
deficiency is due to mutations in Tpit or T-box 19 genes or POMC as discussed above. 
Pituitary destruction from infiltration, apoplexy (Sheehan’s syndrome) or trauma can 
also lead to ACTH deficiency. Secondary adrenal failure leads to isolated 
glucocorticoid deficiency due to ACTH deficiency; the mineralocorticoid axis is 
unaffected and aldosterone production is normal. 
 
The most common cause of primary adrenal failure in the developed world is 
autoimmune adrenalitis either as isolated adrenal failure or as part of an autoimmune 
polyendocrine syndrome (APS) [71]. APS type 1 also termed autoimmune 
polyendocrinopathy – candidiasis – ectodermal dystrophy (APECED) includes 
adrenal insufficiency, hypoparathyroidism and chronic mucocutaneous candidiasis. 
APS type 2 can also include chronic active hepatitis, type 1 diabetes mellitus, thyroid 
disease and malabsorption [71]. In the developing world tuberculous adrenalitis 
remains an important cause of primary adrenal failure; 5% of patients with active 
tuberculosis have adrenal involvement [72]. Destruction of the adrenal gland can also 
be due to other infectious agents for example fungi, HIV and associated CMV or 
adrenal haemorrhage (including Waterhouse-Friderichsen syndrome) or infiltration.  
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Table 1.1 
Diagnosis Clinical features in 
addition to AI 
Steroid 
deficiency 
Gene mutation 
Congenital adrenal hyperplasia 
 
21 hydroxylase deficiency 
11β-hydroxylase deficiency 
17α-hydroxylase deficiency 
 
3ß-HSD deficiency 
 
P450 oxidoreducatase deficiency 
 
P450 SCC deficiency 
46,XX DSD  
46,XX DSD & HTN 
46,XY DSD, HTN & no 
puberty in either sex 
46,XY DSD, postnatal 
virilisation in females 
46,XX DSD 46,XY DSD 
and skeletal anomalies 
46,XY DSD 
GD +/-MD 
GD 
GD, MD, SD 
 
GD, MD 
 
GD, MD, SD 
 
GD+/-MD/SD 
CYP21A2 
CYP11B1 
CYP17A1 
 
HSD3B2 
 
POR  
 
CYP11A1 
Congenital lipoid adrenal 
hyperplasia (CLAH) 
46,XY DSD GD+/-MR/SD STAR 
 
Familial Glucocorticoid Deficiency 
FGD type 1 
FGD type 2 
FGD type 3/Non-classical CLAH 
FGD type 4 
FGD 1: tall stature 
Isolated glucocorticoid 
deficiency with normal 
aldosterone secretion 
GD 
GD 
GD 
GD 
MC2R 
MRAP 
STAR 
NNT 
Triple A syndrome Alacrima, achalasia & 
neurological defects 
GD AAAS 
Adrenal hypoplasia congenital 
X linked AHC 
 
Xp21 contiguous gene syndrome 
 
SF1 linked AHC 
Hypogonadatrophic 
hypogonadism 
Duchenne Muscular 
Dystrophy + GK def 
46,XY DSD 
GD, MD 
 
GD, MD 
 
GD, MD+/-SD 
DAX 1 
 
Xp21 deletion; 
DAX1, GK & DMD 
SF-1 (NRB5A1) 
Adrenoleucodystrophy/ 
Adrenomeyloneuropathy 
CNS demyelination & 
neurological defecits  
GD +/-MD ABCD1  
 
IMAGe syndrome IUGR, metaphyseal 
dysplasia and genital 
anomalies 
GD, MD CDKN1C 
Smith-Lemli Opitz syndrome Growth failure, 
Craniofacial 
malformations 
developmental delay  
GD, MD DHCR7 
 
Table 1.1. Differential diagnosis of genetic defects leading to primary adrenal insufficiency. 
DSD; Disorder of sexual differentiation, HTN; hypertension, GD; glucocorticoid deficiency, 
MD; mineralocorticoid deficiency, SD; sex hormone deficiency 
 
The aetiologies of primary adrenal failure described above invariably lead to both 
glucocorticoid and mineralocorticoid deficiency. However there are a number of 
genetic defects that also lead to primary adrenal failure but these can present with 
either mineralocorticoid and glucocorticoid deficiency or isolated glucocorticoid 
deficiency (Table 1.1).  
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1.6: Familial Glucocorticoid Deficiency 
Familial Glucocorticoid Deficiency (FGD) also known as isolated glucocorticoid 
deficiency or hereditary unresponsiveness to adrenocorticotrophin (ACTH) is a rare, 
genetically heterogeneous autosomal recessive disorder.  It is characterised by 
resistance of the adrenal cortex to ACTH resulting in adrenal failure with isolated 
glucocorticoid deficiency. Mineralocorticoid production by the adrenal gland remains 
near normal. 
 
1.6.1: Aetiology and molecular genetics of FGD 
FGD is characterised by ACTH resistance due to defects in the early events of ACTH 
action leading to failure of cortisol synthesis. The resulting cortisol deficiency causes 
failure of the negative feedback loop to the pituitary and hypothalamus and hence 
grossly elevated ACTH levels. A number of autosomal recessive causes of FGD have 
been described and include FGD type 1 resulting from mutations in MC2R and FGD 
type 2 resulting from mutations in the melanocortin 2 receptor accessory protein 
(MRAP).  A third sub-group of patients presenting with FGD have been shown to 
have mutations in the steroidogenic acute regulatory protein (STAR), and recently 
Meimaridou et al. have identified mutations in nicotinamide nucleotide 
transhydrogenase (NNT) as a fourth cause of FGD [73]. 
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1.6.2: FGD Type 1 
MC2R was first cloned in 1992 by Mountjoy et al. [74].  Subsequently researchers 
have been able to identify more than 30 point mutations in MC2R in patients with 
FGD [75, 76]. The majority of these mutations are missense mutations occurring as 
either homozygous or compound heterozygous mutations.  Nonsense mutations are 
uncommon and are usually associated with a missense mutation on the other allele.  
Mutations in MC2R are distributed throughout the gene (see figure 1.4) and have been 
found in approximately 25% of patients with FGD. 
 
Figure 1.4 
 
Figure 1.4 Schematic diagram showing the locations of all MC2R mutations that are known to 
be associated with FGD type 1.  Those shown in orange are missense mutations, those in blue 
are probable benign polymorphisms and those in green are nonsense or frameshift mutations. 
Reprinted from [77] with permission. 
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The identification of homozygous mutations in affected individuals is highly 
suggestive of a causative role in the disease but does not provide conclusive proof. 
Functional analysis showing reduced function of mutant protein compared to wildtype 
is required for appropriate verification. However functional analysis of any MC2R 
mutation was problematic as it was difficult to achieve cell surface expression of the 
receptor in transfected cells [78].  This observation led to the hypothesis that a 
specific accessory factor, present in adrenal cell types is required to facilitate 
trafficking of MC2R to the cell surface. 
 
1.6.3: FGD type 2 
Metherell et al. carried out homozygosity mapping in 2 consanguineous families with 
FGD but without MC2R mutations. This identified a disease associated locus on 
chromosome 21q22.1.  Further studies identified 2 different mutations in the 2 
families in a candidate gene in this region which showed high adrenal expression. 
This gene was subsequently named the melanocortin 2 receptor accessory protein 
(MRAP) [79]. MRAP is a small single transmembrane domain protein. Functional 
analysis of MRAP revealed that it was essential for normal MC2R function [79].  
MRAP forms a unique antiparallel homodimer, which directly interacts with the 
MC2R at the endoplasmic reticulum and is required for correct folding or trafficking 
of the receptor to the cell surface.  Current evidence suggests that MRAP is also 
required at the plasma membrane for ACTH binding and signal transduction [80]. 
 
Since the discovery of MRAP it has been possible to prove using in vitro studies that 
mutations in MC2R are associated with loss of receptor function. The majority of 
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mutations lead to failure of the receptor to traffic to the cell surface, probably because 
the mutation leads to defective folding of the receptor at the time of its synthesis [81].   
  
Ten MRAP mutations causing FGD have been reported (see figure 1.5), all these 
result in either an absent or severely truncated protein. Mutations in MRAP account 
for approximately 20% of cases of FGD [82]. 
 
Figure 1.5  
 
Figure 1.5 Schematic diagram of human MRAP showing the location of all known mutations 
 
1.6.4: FGD type 3/ Non-classical Lipoid Congenital Adrenal Hyperplasia (LCAH) 
StAR is a mitochondrial phosphoprotein that mediates the acute response to 
steroidogenic stimuli by increasing cholesterol transport from the outer to the inner 
mitochondrial membrane. Defects in StAR usually result in Lipoid Congenital 
Adrenal Hyperplasia, a severe form of congenital adrenal hyperplasia.  However a 
small percentage of patients presenting with classical FGD were found to have 
mutations in STAR [83]. Review of history, examination, and biochemical data in the 
 32 
individuals diagnosed with FGD confirmed they had isolated glucocorticoid 
deficiency with normal or near normal renin and aldosterone levels.  However some 
patients did have mild reproductive anomalies including hypospadias and 
cryptorchidism, which had not previously been connected to their adrenal failure.  
The mutations found in STAR in FGD appear to lead to only partial impairment of the 
cholesterol uptake function of this protein. Thus classical LCAH is caused by 
mutations that completely abolish any functioning StAR while mutations that allow 
the protein to retain some function are associated with a non-classical LCAH or FGD 
[84]. 
 
Recently a case report described clinically isolated adrenal insufficiency in two 
brothers with a partially inactivating mutation in P450 Side Chain Cleavage Enyzme 
(CYP11A1). The younger brother had evidence of glucocorticoid deficiency but not 
mineralocorticoid deficiency as his electrolytes and plasma renin levels were normal 
[85]. This report together with the paper describing mutations in the STAR gene 
discussed above illustrates the need for genetic screening following careful clinical 
phenotyping. Determining the correct genetic diagnosis can be important for genetic 
counselling and providing families with the most appropriate screening and follow-up 
care.  
 
1.6.5: FGD type 4; Defects in antioxidant pathways 
Targeted exome sequencing in additional families identified mutations in 
nicotinamide nucleotide transhydrogenase (NNT) as another cause of isolated 
glucocorticoid deficiency [73]. These mutations were spread throughout the gene and 
included abolition of the initiating methionine, splice mutations and many mis- and 
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nonsense mutations. NNT is a highly conserved gene that encodes an integral protein 
of the inner mitochondrial membrane. Under most physiological conditions, this 
enzyme uses energy from the mitochondrial proton gradient to produce high 
concentrations of NADPH. Detoxification in mitochondria of reactive oxygen species 
(ROS) by glutathione peroxidases depends on this NADPH for regeneration of 
reduced glutathione (GSH) from oxidized glutathione (GSSG) to maintain a high 
GSH/GSSG ratio. The finding of NNT mutations in FGD suggests that, at least in 
humans, NNT is of primary importance for ROS detoxification in adrenocortical cells, 
highlighting the susceptibility of the adrenal cortex to this type of pathological 
damage [73].  
 
1.6.6: Clinical features of FGD 
Patients with FGD usually present during the neonatal period or early childhood with 
symptoms related to cortisol deficiency and ACTH excess.  The most common 
presenting features are those secondary to hypoglycaemia including jitteriness, 
tremors, hypotonia, lethargy, apnoea, poor feeding and hypoglycaemic seizures.  In a 
small number of patients undiagnosed hypoglycaemia in infancy may have been 
sufficiently severe to cause serious long-term neurological sequelae. Neonates may 
also present with jaundice, failure to thrive, collapse and very rarely transient neonatal 
hepatitis [86].   
 
Hyperpigmentation will usually develop by a few months of age due to the over 
stimulation of the melanocortin 1 receptor (MC1R) by high circulating ACTH levels, 
although there are exceptions to this [87]. Older children may present with a variety 
of features including increased pigmentation, recurrent infections, hypoglycaemia, 
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lethargy and shock. As this is an autosomal recessive disorder there is frequently a 
history of consanguinity and there may also be a history of unexplained neonatal or 
childhood deaths in FGD families.   
 A feature that has been observed in patients with FGD type 1 is tall stature [88].  The 
underlying mechanism is not clear but hydrocortisone replacement appears to stop 
this excessive growth [88]. This suggests that either the high ACTH levels or the 
cortisol deficiency itself may have a causative role. It has been proposed that ACTH 
at high concentrations may activate melanocortin receptors in bone and in the growth 
plate and stimulate growth [89]. Alternatively it has been reported that cortisol 
inhibits the synthesis of IGF binding protein 5 (IGFBP5) in the osteoblast suggesting 
that perhaps cortisol deficiency could result in a lack of inhibition and hence 
increased growth [90].  Tall stature is not a recognised feature of FGD type 2, which 
tends to present at an earlier age than FGD 1, meaning patients are treated earlier and 
do not have chronic exposure to high ACTH or low cortisol levels [91].   
 
ACTH also stimulates adrenal androgen synthesis from the zona reticularis and is 
required for normal adrenarche in children.  Children with FGD can have an absent 
adrenarche with delayed or absent pubic hair development [92]. However normal 
pubertal development controlled by the hypothalamic-pituitary-gonadal axis is 
unaffected and fertility is normal. 
 
1.6.7: Investigation and diagnosis of FGD 
The characteristic biochemical features of FGD are low or undetectable cortisol 
paired with high ACTH levels and normal electrolytes, renin and aldosterone levels.  
ACTH levels are often extremely high, often greater than 1000pg/ml (normal range < 
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80pg/ml). A standard ACTH stimulation test will confirm an impaired cortisol 
response (<550nmol/l) and verify adrenal insufficiency. 
 
The most important feature to distinguish FGD from other causes of adrenal 
insufficiency is the absence of mineralocorticoid deficiency.  However FGD patients 
frequently present with minor abnormalities of the renin-aldosterone axis for various 
reasons.  Firstly, at presentation, children with FGD are usually stressed and may be 
hypovolaemic, or pyrexial.  Alternatively they may be relatively water overloaded as 
a result of intravenous fluid replacement and because of reduced free water clearance 
associated with glucocorticoid deficiency. Usually, after introduction of appropriate 
hydrocortisone replacement any minor derangements in renin and aldosterone levels 
normalise and fludrocortisone replacement is not required. 
 
A conclusive diagnosis of FGD can be confirmed by identifying a mutation in MC2R, 
MRAP, STAR or NNT in these patients. However approximately 40% of patients have 
no mutation in any of the associated genes.   
 
1.6.8: Management of FGD 
The treatment is with physiological glucocorticoid replacement. This is usually given 
in the form of oral hydrocortisone 8-10 mg/m2/day in children and 20mg/day in adults. 
The total daily dose is given in 3-4 divided doses throughout the day. Prednisolone 
and rarely dexamethasone can also be used in certain circumstances.  In individuals 
with adequate replacement therapy ACTH levels often remain elevated and therefore 
cutaneous pigmentation can persist.  Attempting to suppress the ACTH levels must be 
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avoided as it will lead to over treatment, potentially iatrogenic Cushing’s syndrome 
and poor growth in children. 
 
Hydrocortisone dosing must be increased during times of stress to 2-3 times the 
maintenance dose.  It is important to ensure the patient and their family have adequate 
education and understand when and how to increase hydrocortisone doses and 
emergency management with intramuscular hydrocortisone or hydrocortisone 
suppositories.   
 
1.7: Aims of this research 
This research aims to investigate the genetic aetiology and pathogenetic mechanism 
of disease in patients with late-onset FGD. As described above FGD patients usually 
present with adrenal failure in infancy or early childhood, however there are a number 
of families in which affected individuals either have “mild” disease and present later 
in life or develop isolated glucocorticoid deficiency following a period of normal 
adrenal function.  
 
This project aims to study two such groups of patients; firstly two families of Turkish 
ethnicity who presented with late onset disease and secondly eight patients from the 
Irish travelling community, a genetically isolated population with high levels of 
consanguinity.  
 
Patients will first be screened for mutations in MC2R, MRAP, STAR and NNT. If 
sequencing is normal novel genetic loci for the disease will be sought by SNP 
genotyping. Once a significant locus is identified this can then be investigated for 
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likely disease causing genes.  Potential genes can be studied in silico and in vitro and 
subsequently sequenced in affected patients to identify disease causing mutations.  
 
These mutations will be functionally characterised in vitro to determine if the disease 
severity in these patients with FGD reflects the functional significance of the 
underlying mutation.  
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Chapter 2: Materials and Methods 
2.1 DNA extraction 
Genomic DNA was extracted from peripheral blood leucocytes following patient’s 
informed consent. Blood was collected in sodium EDTA tubes and DNA was 
extracted using the Illustra Nucleon Genomic DNA extraction kit (GE Healthcare), 
according to the manufacturer’s instructions. Briefly, this involves cell lysis using 
reagent A (10mM Tris-HCl, 0.32M Sucrose, 5 mM MgCl2, 1% (v/v) Triton x-100, pH 
8.0) and nucleic lysis with reagent B (detergent). Four times the volume of reagent A 
was added to the blood sample using aseptic techniques, mixed on a rotary wheel for 
4 minutes at room temperature and centrifuged at 1300g for 5 minutes. The 
supernatant was discarded and the pellet vortexed with 2ml reagent B, then 
transferred to a clean 15ml polypropylene centrifuge tube. Deproteinisation was 
carried out by adding 500µl sodium perchlorate solution and mixing by hand. 2ml of 
chloroform was subsequently added and the sample again mixed by hand to extract 
the DNA. 300µl Nucleon resin was then added and the sample centrifuged at 1300g 
for 3 minutes. The resin separates the chloroform and protein (lower phase) from the 
aqueous solution containing the DNA in the upper phase. This upper phase was 
removed to a clean tube with a minimum volume of 7.5ml. 2 volumes of cold absolute 
(100%) ethanol was added to precipitate the DNA. This can be removed by ‘fishing’ 
using a Pasteur pipette whose end has been sealed and shaped into a U by heating in a 
flame. The DNA was washed in 70% ethanol, allowed to dry and then dissolved in 
water. 
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2.2 PCR and sequencing  
2.2.1 Oligonucleotide design 
After establishing the gene sequence of interest using ENSEMBL, primer pairs were 
designed by following the guidelines below: 
• Primers should ideally be 17-25 bp in length 
• Sequences should be non-repetitive and non-palindromic 
• G/C content should be 40-60% 
• Forward and reverse primers should anneal at approximately the same 
temperature 
• Tm should be between 58-68oC and was calculated approximately as 
o Melting temperature (oC) = 4(number of C/G bases) + 2(number of A/T bases) 
• Primers should not form secondary structures 
 
2.2.2 PCR 
Each exon of genes of interest including intronic boundaries was amplified by PCR 
using specific primers (for these and all subsequent primer sequences see Table 2.2).  
The basic principle involves denaturing double stranded DNA at high temperatures, 
followed by annealing of sequence specific oligonucleotide primers typically at 
temperatures in the range of 50-60oC before synthesis of complementary DNA strands 
from 5’ to 3’ using a thermostable DNA polymerase. Repeated cycling allows 
exponential amplification of a specific portion of DNA. 
 
The reaction mixture contained 100ng of DNA template, 1  PCR buffer (Sigma, 
Poole, UK) (100nM Tris-HCl, pH 8.3, 500mM KCl, 15mM MgCl2, 0.01% gelatin) 
200µM each dNTP, 200nM each primer and 1U Thermus aquaticus (Taq DNA 
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polymerase (Sigma-Aldrich) with total volume typically 25µl. Cycling conditions 
were 95oC for 5 min (one cycle); 95oC for 30 sec, 55oC for 30 sec, and 72oC for 30 
sec (30 cycles); and 72oC for 5 min. Alternatively the cycling conditions were based 
on touchdown PCR, where the annealing temperature starts high and decreases by a 
single degree with every cycle, until a suitable annealing temperature is reached.  In 
this way non-specific binding of primers can be reduced. PCR products were 
separated and visualized using agarose gel electrophoresis. This technique applies an 
electric field across an agarose gel which induces the nucleic acids loaded into it to 
migrate towards the anode due to the net negative charge of the sugar-phosphate 
backbone of the nucleic acid chain. Different sized molecules move through the gel at 
different speeds with longer molecules moving more slowly as they experience more 
resistance. The PCR products were visualized on 1-2% agarose gel made in 1x TAE 
buffer (40mM Tris-acetate, 2mM disodium ethylenediaminetetraacetate (Na2EDTA), 
pH 8.3; National Diagnostics, UK) alongside DNA markers (GeneRulerTM DNA 
Ladder Mix, 0.5 mg DNA/ml, Fermentas) with ethidium bromide (0.2 µg/ml) or 
GelRed (Biotium) staining. Usually 5µl of each reaction was mixed with 1 µl of 
loading dye solution (40% w/v sucrose, 0.25% w/v bromophenol blue or Orange G, 
1mmol EDTA ph 8.0, prior to loading into the wells. Electrophoresis was carried out 
at approximately 100-120 V for 20-30 minutes or until clear separation of products 
was obtained. Ethidium bromide/GelRed intercalated into DNA will fluoresce under 
UV light at 300nm allowing the DNA and therefore the PCR product to be visualized. 
An Uvitec transluminator was used to visualize the bands and capture an image of the 
gel. The approximate size of the PCR product can then be determined by comparison 
with the DNA markers on the agarose gel. 
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2.2.3 Sequencing 
The PCR products were sequenced using the ABI Prism Big Dye sequencing kit and 
an ABI 3730 automated DNA sequencer (Applied Biosystems, Foster City, CA) by 
the Genome Centre in Bart’s and the London, QMUL. This is based on the Sanger 
dideoxy-mediated chain termination method [93]. This method requires a DNA 
template, a DNA primer, DNA polymerase, conventional deoxynucleotide-
triphosphates (dNTPs) and modified nucleotides that terminate DNA strand 
elongation (ddNTPs). In this method the double stranded DNA fragment is denatured 
into single DNA strands and a primer complementary to the known DNA sequence 
binds to the single stranded DNA template. DNA polymerase then binds to the primer 
and synthesizes a new strand of DNA incorporating free nucleotides that are 
complementary to the target fragment of DNA. The fluorescently labeled chain 
terminating nucleotides are modified to lack the 3’OH group required for the 
formation of the phosphodiester bond between two nucleotides thus terminating each 
DNA strand at the point of inclusion. This process is repeated many times generating 
many fragments of different lengths that all terminate in fluorescently labeled bases 
that correspond to A, T, G and C. The reaction is then transferred into thin glass 
capillaries where an electrical charge moves the negatively charged particles through 
a gel matrix. Similarly to electrophoresis described above the DNA fragments are 
then separated according to size and a laser used to excite the chain terminating 
fluorescent base, which is recorded as a coloured peak or band by the automated 
sequencer.  
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2.2.4 Sequence Analysis 
Analysis of sequence chromatograms was carried out using BioEdit URL: 
http://www.mbio.ncsu.edu/BioEdit/ (BioEdit is a biological sequence alignment 
editor and analysis program for Windows 95/98 NT. Nucleic Acids Symposium 
Series 41, 95-98). BioEdit is a freeware program that allows a DNA sequence to be 
compared to a reference sequence [94]. This allows the user to readily identify 
differences between 2 or more sequences by eye allowing the detection of potential 
mutations in the chromatograms generated from patient samples.  
 
2.3 Homozygosity mapping 
2.3.1 Genome wide mapping Array 
For the whole-genome scan, the GeneChip mapping 10 K array Xba131 (Affymetrix) 
was used in accordance with the manufacturer’s guidelines. These are described in 
detail in the GeneChip Mapping 10K 2.0 Assay manual 
(https://www.affymetrix.com/user/login.jsp?toURL=/support/file_download.affx?onl
oadforward=/support/downloads/manuals/10k2_manual.pdf). This version of the 
Mapping 10K array comprises a total of 11,555 single nucleotide polymorphisms 
(SNPs) with a mean intermarker distance of 210 kb, equivalent to 0.32 cM.  
 
High quality, double stranded, uncontaminated genomic DNA that is free from PCR 
inhibitors is required. The assay overview is described in Figure 2.1 and briefly 
outlined below. All reagents used in this assay are from New England Biolab (NEB) 
unless otherwise stated. 
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Figure 2.1 
 
 
Figure 2.1: Reprinted from Affymetrix Genechip Mapping 10K 2.0 Assay Manual. 
 
250ng of genomic DNA (50ng/µl) was digested using Xba1 restriction enzyme. The 
digested DNA fragments were ligated to adapters (Adaptor Xba) using T4 DNA 
ligase. Following thermal cycling the ligated DNA was diluted using molecular 
biology grade water. The diluted ligated DNA was then amplified using PCR. The 
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PCR master mix contains PCR primer Xba, which specifically targets the adapters on 
the ligated DNA fragments and PCR conditions are optimized to preferentially 
amplify fragments in the 250-1000 base-pair size range.  
 
The PCR reaction was prepared in a pre-PCR Clean Room but once the reaction was 
complete the PCR product should only be handled in a “post PCR” main lab to 
prevent contamination of future experiments. The PCR products were eluted and 
concentrated before fragmentation using DNase 1. The fragmented DNA was 
denatured and end-labeled using DNA GeneChip DNA labeling Reagent. The sample 
was hybridized onto a GeneChip Mapping probe array. The steps following 
hybridization were carried out by colleagues in the Genome Centre. Briefly, 
hybridized arrays were processed with an Affymetrix Fluidics Station 450 and 
fluorescence signals were detected using the Affeymetrix GeneChip Scanner 3000. 
Signal intensity data was analysed by the GeneChip DNA analysis software based on 
a model algorithm to generate SNP calls [95].  
 
SNP genotypes then scanned for regions of homozygosity using IBDFinder from the 
Centre for Autozygosity (http://autozygosity.org). This tool allows the identification 
of regions of homozygosity that are linked with or associated with a particular 
phenotype. IBDfinder does not calculate formal linkage probabilities but generates a 
graphical display of a numerical score that changes as the genotype data are scanned 
[96]. 
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2.4 Targeted Exome sequencing 
2.4.1 Sequence capture array and sequencing 
A custom sequence capture array targeting the exons, 50bp up- and downstream, plus 
1Kb upstream of the transcription start site for each REFSEQ gene within the areas of 
homozygosity (coordinates 4:96.3-100.3, 8:36.8-51.9 and 8:62.1-64.5) was designed 
and manufactured by Roche NimbleGen (Madison, WI) using a 385K custom 
sequence array. DNA (5µg) from one affected individual was subjected to target 
enrichment and sequencing. High quality DNA was required with a concentration 
between 50 -100ng/µl and OD260/OD280 ratio > 1.8, which was measured using a 
NanoDrop ND-1000 spectrophotometer at λ=260nm/280nm. The enrichment and 
sequencing was carried out by collaborators in Germany, briefly, the sequencing 
library was prepared using standard techniques including end repair, A-tailing, paired 
end adaptor ligation and amplification by PCR.  
 
A 472-fold enrichment of the targeted regions was achieved and the resultant library 
was subjected to massively parallel sequencing performed on a single lane of the 
Illumina GAII analyzer. Single Nucleotide Polymorphisms, with a threshold coverage 
of at least 10 reads on the respective nucleotide, were called with the MAQ alignment 
and downstream analysis tools [97]. Variants were checked against the Ensembl SNP 
database, release 54. Functional characteristics of the SNPs were checked with a 
pipeline based on an in-house variant database maintained by Dr. Hogler Theile. 
Novel SNPs that were non-synonymous coding variants, splice site mutations or 
coding insertions or deletions were prioritized for further analysis.  
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2.4.2 Genotyping of 200 control alleles 
PCR products (PCR method as above) for MCM4 exon 2 were digested by Alu1 
restriction digest. Alu1 cleaves the PCR product from a wild-type sequence once but 
does not cut the mutant sequence.  10µl of a PCR product was incubated with 10 U of 
Alu1 (1µl) (NE Biolabs), 3µl N4 10x Buffer, 0.3µl bovine serum albumin and 17.5µl 
double distilled (dd) water in a 30µl reaction at 37°C for 2 hours. Digestion products 
were resolved on a 2% agarose gel. Wild-type samples gave rise to 2 bands following 
digestion, PCR products from DNA with c.71-1insG were not digested and remained 
as 1 band, heterozygotes resulted in 3 bands.  
 
2.5 RNA extraction and cDNA sequencing 
2.5.1 RNA extraction from whole blood 
Total RNA was isolated and purified from patient and control leucocytes using the 
PAXgene Blood RNA system (Qiagen). 2.5 ml blood were collected into PAXgene 
Blood RNA tubes which allows storage, transport and stabilization of intracellular 
RNA in a closed tube.  
PAXgene Blood RNA Tubes contain a proprietary reagent composition based on a 
patented RNA stabilization technology (US Patents 6,602,718 and 6,617,170), this 
reagent composition protects RNA molecules from degradation by Rnases. This 
additive stabilizes the in vivo gene transcription profile by reducing in vitro RNA 
degradation and minimizing gene induction. A major challenge in analysing RNA is 
the instability of intracellular RNA, which rapidly degrades within hours after blood 
collection. Furthermore, certain RNA transcripts, through the process of gene 
induction, increase in vitro after blood collection. Both in vitro RNA degradation and 
gene induction can lead to an under- or overestimation of in vivo relative gene 
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transcript number. After blood is introduced into the tube, the intracellular RNA 
profile remains stable for 3 days at 18oC to 25oC, 5 days at 2oC to 8oC, or for a 
minimum of 50 months at -20oC or -70oC/-80oC (Paxgene protocol).  
After storage for 2-3 days at 4oC, the samples were processed as per the PAXgene 
Blood RNA Kit handbook to extract RNA. Briefly the blood sample was incubated in 
the PAXgene Blood RNA tube for a minimum of 2 hours at room temperature in 
order to achieve complete lysis of blood cells. The tube was then centrifuged for 10 
minutes and the resuspended pellet was incubated in optimized buffers (PAXgene) 
together with proteinase K to bring about protein digestion. An additional 
centrifugation through the PAXgene Shredder spin column was carried out to 
homogenize the cell lysate and remove residual cell debris, and the supernatant of the 
flow-through fraction was transferred to a fresh microcentrifuge tube. Ethanol was 
added to adjust binding conditions, and the lysate was applied to a PAXgene RNA 
spin column. During a brief centrifugation, RNA was selectively bound to the 
PAXgene silica membrane but contaminants passed through. Remaining contaminants 
were removed in several wash steps. Between the first and second wash steps, the 
membrane was treated with DNase I to remove trace amounts of bound DNA. After 
the wash steps, RNA was eluted in elution buffer and heat-denatured. RNA yields 
from 2.5ml healthy human blood are >3µg for over 95% of samples tested. 
 
2.5.2 cDNA synthesis and sequencing  
For cDNA production via reverse transcription, 2µl of 2mg/ml RNA in 15µl RNase 
free water was incubated with 2µl random primers (Promega, Southampton, UK) at 
70°C for 5 minutes, then incubated for 2 minutes on ice. 1µl of reverse transcriptase 
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enzyme was added, with 5µl 5x reverse transcriptase buffer (50mM Tris-HCl (pH8.3), 
75mM KCl, 3mM MgCl2 and 10mM DTT), 1.25µl dNTPs (deoxynucleotides; 
consisting of 10mM dATP, 10mM dCTP, 10mM dGTP, 10mM dTTP) and 0.75µl 
RNase inhibitor (RNasin, Promega, Southampton, UK), and the entire mixture was 
incubated at 37ºC for 60 minutes. The resulting cDNA was used as a template for 
PCR amplification and sequencing of MCM4 exons 2-4 (for primers see table 2.2) as 
described above.  
 
2.6 Leucocyte separation 
Fresh whole blood was collected into sample tubes containing EDTA. Mononuclear 
cells were extracted using a gradient density centrifugation method with Histopaque 
1077 as per the manufacturer’s protocol (Sigma, Poole, UK). Histopaque solution 
1077 has a density of 1.077. When blood is layered onto this solution and subjected to 
centrifugal forces, mononuclear cells are held at the plasma – histopaque interphase 
while erythrocytes gravitate to the bottom (figure 2.2). Briefly 6 ml histopaque-1077 
were added to a 15ml centrifuge tube and 6 ml blood carefully layered onto it. This 
was centrifuged at 700g for 30 minutes at room temperature (18-26ºC). The plasma 
was carefully aspirated and discarded to within 0.5cm of the mononuclear layer. The 
mononuclear layer was then removed into a clean tube. This was washed with 10ml 
isotonic phosphate buffered saline and centrifuged for 10 minutes at 200g. The 
supernatant was aspirated and discarded and the cells resuspended and washed again 
as above. 
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Figure 2.2 
 
 
 
Cells were lysed by addition of RIPA buffer (50mM Tris-HCl, pH 8.0, with 150mM 
sodium chloride, 1% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate and 0.1% 
sodium dodecyl sulphate), supplemented with Mini, EDTA-free Protease Inhibitor 
Cocktail Tablets (Roche) on ice for 30 minutes. Samples were then centrifuged at 17g 
for 12 minutes at 4°C and the supernatant added to an equal volume of 1 x Laemmli 
loading buffer [98] (Sigma, Poole, UK).  
 
2.7 Cloning MCM4 constructs 
Briefly, FLAG-MCM4 constructs were prepared using human MCM4 cDNA (Source 
Bioscience), which was cloned into a p3xFLAG-CMV10 expression vector (Sigma 
Aldrich) after PCR amplification. MCM4 cDNAs from the 2nd and 3rd in-frame ATGs 
were amplified using specific primers (for primer sequence see table 2.2) and cloned 
into the same p3xFLAG-CMV 10 expression vector (Sigma Aldrich). Alternatively, 
PCR amplification generated MCM4 with a C-terminal HA tag, which was then 
cloned into a pcDNA 3.1 expression vector (Invitrogen). The initiating methionine 
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was mutated using site directed mutagenesis.  The sequence of all constructs was 
verified by DNA sequencing. 
 
2.7.1 Purification of plasmid DNA 
MCM4 cDNA in a Bluescript vector was purchased from Source Bioscience. Clones 
were streaked onto LB Agar containing 100µg/ml ampicillin. p3xFLAG-CMV-14 
expression vector clones were also purchased and clones restreaked onto LB Agar 
plates with 100µg/ml ampicillin. Plates were left overnight at 37°C to obtain single 
colonies. To purify plasmid DNA a single bacterial colony was inoculated in 5ml LB 
broth containing ampicillin overnight at 37°C shaking at 220rpm.  After 14 hours the 
bacterial cells were centrifuged at 5400xg for 10 minutes at 4°C, and the supernatant 
was discarded.  The DNA was purified from the bacterial pellet using a modification 
of the alkaline lysis procedure [99]. Briefly, the cells were resuspended in buffer P1 
(50mM Tris-HCl ph 8.0, 10mM EDTA, 100µg /ml RnaseA) and lysed in an alkaline 
buffer (200mM NaOH with 1% SDS) before neutralisation with an acidic buffer (4.2 
M Gu-HCl, 0.9 M potassium acetate, pH 4.8).  The lysate was cleared via 
centrifugation before transfer to a silica DNA-binding column from the QIAprep 
Miniprep kit (Qiagen, Crawley, UK).  Endonucleases present were removed by 
washing and salt was also subsequently removed by a brief wash step.  DNA was 
eluted in distilled water and the concentration measured using a Nanodrop ND-1000 
spectrophotometer at λ=260nm.  
 
2.7.2 PCR of MCM4 
MCM4 cDNAs from the initiating methionine to the terminal stop codon (amino acids 
1-863), from the 2nd initiating in frame methionine (amino acid 51-863), 3rd initiating 
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in frame methionine (amino acid 75-863) or 4th initiating in frame methionine (amino 
acid 194-863) were amplified individually using specific primers incorporating 
EcoR1 and BamH1 restriction sites at the 5’ and 3’ ends of the cDNAs respectively 
(see table 2.2 for primers).  PCR was performed as described above and the products 
were visualised by agarose gel electrophoresis on a 1% gel.  
 
Additionally an MCM4 insert with a C-terminal HA tag was synthesised using PCR 
(for primers see table 2.2) to introduce an EcoR1 and BamH1 restriction site for 
cloning as above.   
 
2.7.3 Gel extraction  
The PCR bands were cut out of the gel and purified using the Qiagen QIAquick Gel 
extraction kit (Qiagen, Crawley, UK).  Briefly, the excised bands were incubated in a 
solubilisation buffer at 50°C until the agarose had melted, before the resolubilised 
DNA was applied to a silica DNA-binding membrane.  The membrane was washed 
once in solubilisation buffer and once in ethanol-containing buffer to remove salts.  
DNA was eluted in water before 1µl of sample was re-run on 1% agarose gel to 
confirm efficient purification. 
 
2.7.4 Restriction enzyme digestion of purified plasmid DNA 
10µl of PCR product was incubated with 10U of both BamH1 (1µl) and EcoR1 (1µl) 
(NE Biolabs), 3µl N2 10x Buffer, 1x (0.3µl) bovine serum albumin and 14.7µl ddH2O 
in a 30µl reaction at 37°C for 1 hour. Flag empty vector containing EcoR1 and 
BamH1 restriction sites was also digested; 500ng Flag vector (1.2µl) was incubated 
with 10U of both BamH1 (1µl) and EcoR1 (1µl) (NE Biolabs), 3µl N2 10x Buffer, 1x 
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(0.3µl) bovine serum albumin and 23.5ul ddH2O in a 30µl reaction at 37°C for 1 hour 
before being treated with 2µl alkaline phosphatase for 30 minutes at 37°C, to help 
prevent re-annealing of the vector. Both samples were run on a 1% agarose gel, 
visualised using GelRed and gel extracted as above. Purified insert (MCM4 cDNA) 
was then ligated into the digested Flag vector. 
 
2.7.5 Ligation into p3xFLAG-CMV-14 expression vector 
4µl purified MCM4 PCR product was incubated with 2µl p3xFLAG-CMV-14 
expression vector (Sigma Aldrich) and 1µl T4 DNA ligase in ligase buffer (300mM 
Tris-HCl (pH 7.8), 100mM MgCl2, 100mM DTT, 10mM ATP; Promega, 
Southampton, UK) made up to 10µl total with ddH2O overnight at 16°C before 
transformation into competent JM109 E.coli. 
 
2.7.6 Ligation into pGEMT-Easy 
If direct cloning was unsuccessful the insert was cloned into a pGEMT-Easy vector 
(Promega, Southampton, UK) before subcloning into p3xFLAG-CMV-14 expression 
vector. 5µl purified PCR product was incubated with 1µl pGEMT-Easy vector and 
1µl T4 DNA ligase in ligase buffer (300mM Tris-HCl (pH 7.8), 100mM MgCl2, 
100mM DTT, 10mM ATP; Promega, Southampton, UK) made up to 10µl total 
overnight at 4°C before transformation into competent JM109 E.coli. The DNA was 
purified, then digested, gel extracted and ligated into the p3xFLAG-CMV-14 
expression vector. 
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2.7.7 Transformation of DNA into competent bacteria 
E.coli strain JM109 highly competent cells (>108 cfu/µl) (Promega, Southampton, UK) 
were thawed on ice and mixed gently after thawing.  25µl of cells were transferred to 
a pre-chilled 1.5ml tube and 5µl of plasmid DNA was added to the cells.  The cell-
DNA mixture was incubated on ice for 10 minutes.  After incubation the cells were 
heat-shocked at exactly 42°C for 45 seconds before being returned to ice for 2 
minutes.  900µl of LB media was added to the cells and then the cells were incubated 
at 37°C with shaking (230-250rpm) for 45 minutes.  The cells were then centrifuged 
at 4000 g for 4 minutes.  The cells were resuspended in 100µl of LB media and spread 
onto LB agar plates containing 100µg/ml ampicillin overnight at 37°C.  For blue 
white selection of pGEMT-Easy containing clones, the LB agar was supplemented 
with 100µg/ml IPTG (Promega, Southampton, UK) and 50µg/ml X-Gal (Promega, 
Southampton, UK).  Correct insertion of the PCR product disrupts the lacZ operon 
and stops the bacteria synthesising the blue coloured substrate.  Therefore only white 
colonies were picked for inoculation. 
 
Plasmid DNA was purified as above (section 2.7.1) and 1µg digested using BamH1 
and EcoR1. The resulting fragments were run on 1% agarose gel and visualised using 
GelRed to confirm an insert was released. Colonies that released the correct size of 
insert were then sequenced to confirm the insert was both the correct sequence and in-
frame.  
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2.8 Site directed mutagenesis 
2.8.1 Abolition of initiating methionine of MCM4 with C-terminal HA tag in 
pcDNA 3.1 expression vector  
MCM4 with a C-terminal HA tag in a pcDNA 3.1 expression vector was synthesised 
as described above. The initiating methionine was then abolished using site directed 
mutagenesis using the QuikChange XL Site-Directed Mutagenesis Kit according to 
the manufacturer’s instructions (Stratagene) using primers “SDM MCM4” table 2.2. 
 
 
2.9 Cell culture  
The human kidney cell line HEK293 and the human cancer adrenal cell line H295R 
were purchased from the European Collection of Cell Cultures (ECACC) at the 
Health Protection Agency (HPA; Salisbury). HEK293T cells were maintained in 
Dulbecco’s Minimum Eagle Medium (DMEM) with 10% heat inactivated foetal calf 
serum (FCS; Invitrogen, Paisley, UK) and 50U/ml penicillin and 50µg/ml 
streptomycin (Pen/Strep; Invitrogen, Paisley, UK;). H295R cells were maintained in 
DMEM/F12 (Sigma, Poole, UK), (1:1) supplemented with 2% NU serum, ITS and 
penicillin/streptomycin. Cells were kept in a constant humidified atmosphere of 5% 
CO2 at 37ºC. 
 
Cells were harvested as follows: after growing in a 75cm3 (T75) cell culture flask to 
80-90% confluency, cells were washed twice with 10ml phosphate buffered saline 
(PBS).  Cells were incubated with 3ml Trypsin/Ethylenediaminetetraacetic acid 
(EDTA; Invitrogen, Paisley, UK) until detachment from the flask had occurred.  
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Trypsin/EDTA was neutralised with 7ml media and the cells were split into additional 
flasks or collected and spun gently at 100 g for 5 minutes until a pellet had formed. 
 
2.9.1 Transfections 
Cells were seeded either in 8 well chamber slides (Nunc, VWR, Leicester, UK), 12 
well plates, 6 well plates  or 25cm3 (T25) cell culture flasks (VWR, Leicester, UK) 
until 60% confluent. Cells were transfected using the Lipofectamine and Plus reagent 
system (Invitrogen, Paisley, UK) as per Table 2.1 and according to the manufacturer’s 
instructions.  
 
 
Table 2.1 
 Optimem Plus DNA/RNA Optimem Lipofectamine 
8 well slide 12.5 1 100ng 100 1 
12 well plate 50 2 500ng 200 2 
6 well plate 100 4 1µg 400 4 
T25 flask 250 10 2µg 1.5ml 10 
Table 2.1. Transfection mixtures for various cell culture vessels. Volumes (in µl) are shown 
for a single well of each vessel included.  
 
For example; for 8 well chamber slides, 100ng of siRNA or DNA was incubated at 
room temperature with 1µl Plus reagent in 12.5µl serum free media (Optimem; 
Invitrogen, Paisley, UK) for 20 minutes.  1µl Lipofectamine and 100µl Optimem were 
added to the mixture and incubated for 15 minutes.  Cells were washed twice with 
serum free media before the transfection mixture was added to the cells. Total 
plasmid DNA amounts were kept constant. Whole-cell lysates were prepared 24 or 48 
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hours after transfection.  
 
2.9.2 siRNA sequences and tranfection 
Small interfering RNAs (siRNAs) were purchased from Applied Biosciences, 
Warrington, UK.  Two siRNA molecules that target the MCM4 gene at exons 5 
(s69687) and exons 12 (s8592) or a scrambled control siRNA were transfected at 
concentrations of 50nM or 100nM for 24-48 hours, depending on the experimental 
design, and cells lysed as below. 
 
 
2.10 Western blotting 
2.10.1 Cell lysate preparation 
Cell lysates were prepared by washing cells 3 times with PBS. Cells from a 6 well 
plate were incubated in 150µl RIPA buffer (as above) supplemented with complete, 
Mini, EDTA-free Protease Inhibitor Cocktail Tablets (Roche) on ice for 30 minutes. 
Samples were then centrifuged at 17g for 12 minutes at 4°C and the supernatant 
added to the same volume of 1x Laemmli loading buffer [98] (Sigma, Poole, UK). 
The samples were heated at 100°C for 10 minutes and centrifuged at 17 g for 1 
minute before loading. 
 
2.10.2 SDS-PAGE 
The samples were run on precast 4-12% or 10% polyacrylamide NuPage BisTris gels 
(Invitrogen, Paisley, UK).  The gels were run in 1x 3-(N-morpholino)propanesulfonic 
acid (MOPS) running buffer (Invitrogen, Paisley, UK), consisting of 50mM MOPS, 
50mM Tris, 0.1% SDS, 1mM EDTA, pH 7.7.  A High Molecular Weight Marker 
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protein ladder (Invitrogen, Paisley, UK) was run alongside all samples. 10-40µl of 
sample per well (depending on sample, ie 20µl harvested cell lysate vs 30-40µl 
lymphocyte cell lysates) was loaded and the samples were run at 150V for 60 minutes. 
 
2.10.3 Immunoblotting 
After separation by electrophoresis, the samples were transferred to a nitrocellulose 
membrane by semi-dry transfer using a Trans-Blot SD semi-dry transfer cell (Bio-
Rad, Hemel Hempstead, UK).  The transfer buffer consisted of 20mM Tris, 120mM 
glycine and 10% methanol.  The semi-dry transfer of proteins was performed for 30 
minutes at 15V. After transfer the nitrocellulose membranes were blocked with 5% 
milk powder in PBS with 0.05% Tween20 (PBST) for 1 hour.  After blocking, 
membranes were incubated in 10ml 5% milk in PBST containing appropriate primary 
antibodies overnight at 4oC. The primary antibodies used included a polyclonal anti-
MCM4 antibody (Abcam, Cambridge, UK; targeting MCM4 exon 14, or Santa Cruz, 
CA, USA; targeting the N-terminal of MCM4, at 1:2000 and 1:500 dilution in 
milk/PBST respectively), anti-FLAG at 1:1000 (Sigma, Poole, UK) and β-actin or 
GAPDH at 1:10000 (Sigma Poole, UK) as a loading control. Following overnight 
incubation the membranes were washed in PBST three times for 10 minutes and then 
incubated in appropriate species-specific infra-red secondary antibodies (Licor, 
Cambridge, UK) at a dilution of 1:10000 for 1 hour.  After two washes in PBST and a 
single wash in PBS, the membranes were imaged using the Licor Odyssey infrared 
scanner. 
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2.11 Fluorescent cAMP reporter assay (dose response study)  
2.11.1 MRAP DNA constructs and site directed mutagenesis 
MRAP-3XFLAG vector had already been constructed in our laboratory by directional 
cloning of MRAPα into the HindIII and EcoR1 restriction sites of the p3xFLAG-
CMV-14 expression vector (Sigma, Poole, UK) after PCR amplification of human 
MRAPα (for primer sequences see table 2.2). 
 
Mutant MRAP vectors were then synthesised from this by site directed mutagenesis 
using the QuikChange XL Site-Directed Mutagenesis Kit according to the 
manufacturer’s instructions (Stratagene). A haemagglutinin-tagged human wild-type 
MC2R construct (HA-MC2R) was used for all experiments. 
 
2.11.2 cAMP Luciferase assay 
cAMP production can be assayed using Promega’s Dual-Luciferase Reporter Assay 
System which assays the activities of firefly (Photinus pyralis) and Renilla (Renilla 
reniformis/sea pansy) luciferases which are measured sequentially from the same 
sample. The 2 plasmids used in the assay are pRL-CMV Renilla Luciferase plasmid, 
this is driven by the CMV immediate-early enhancer/promoter. The second is a α 
GSU – 846 luciferase plasmid, containing luciferase driven by the cAMP responsive 
promoter α GSU -846. 
 
To measure the cAMP response in the presence of the mutant MRAP constructs, 
MC2R and the MRAP constructs were co-transfected with a cAMP-responsive 
luciferase reporter gene (-846αGSUluc, figure 2.3) along with pRL-CMV renilla.  
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Figure 2.3 
 
Figure 2.3 Schematic diagram of  cAMP activation of the Luciferase Reporter Construct. 
cAMP generates protein kinase A (PKA) which in turn leads to phosphorylation  of CREB 
(cAMP repsonse element binding protein) allowing it to bind to co-activators, leading to the 
recruitment of RNA polymerase II to the αGSU promoter and transcription of luciferase. 
 
Five to six hours after ACTH stimulation (allowing for transcription and translation of 
luciferase) the amount of luciferase is assayed.  This technique assumes luciferase 
production will be proportional to cAMP production. Luciferase is then measured via 
its ability to catalyse the formation of light (from ATP and luciferin according to the 
following reaction). 
        Luciferase 
ATP + Luciferin + O2         Oxyluciferin + AMP + PPi + CO2  + LIGHT 
    Mg2+ 
 
The intensity of light emission has a linear relationship to the concentration of 
luciferase and is measured using a luminometer.  Before Luciferase expression can be 
measured by bioluminescence, the enzyme must first be extracted from the cells. The 
Luciferase assay system facilitates the simultaneous extraction and measurement of 
luciferase from cells.   
CRE Luciferase 
CREB 
P P 
cAMP  PKA 
-850 
polymerase 
Luciferase 
promoter 
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Luciferase Assay Buffer II which contains luciferin is mixed with the experimental 
cell lysate. Firefly luciferase produces an initial burst of light that decays over about 
15 seconds to a low level of sustained luminescence, this is measured by the 
Luminometer.  Following this Stop and Glo solution is added, this simultaneously 
quenches the Firefly luciferase reaction and initiates the Renilla luciferase reaction. 
This produces a stabilized signal from the Renilla luciferase, which decays slowly 
over the course of the measurement.  The Renilla measurement acts as an internal 
control.  The luminometer then quantifies the luciferase and Renilla bioluminescent 
reactions which can be displayed in tables or graphically, allowing comparison 
between the degree of bioluminescence (and therefore cAMP production) in cells 
transfected with wild type or mutant MRAP.  
 
HEK293 cells grown in 6 well plates were co-transfected with HA-MC2R and either 
wild type MRAP, mutant MRAP or an empty vector (total plasmid per well - 1000ng) 
plus both α-GSU-846 luciferase (900ng) and pRL-CMV Renilla luciferase (100ng) 
reporter constructs. After 48 hours cells were stimulated with ACTH (concentration 
range 10-6 to 10-11) for 6 hours, lysates were harvested and cAMP production assayed 
as described previously [100]. 
 
2.11.3 Statistical Analysis 
Results are stated as mean +/- SEM of at least 4 independent experiments.  EC50 
values were obtained from Prism software.  Statistical analysis was performed using 
the Mann-Whitney Test (p<0.05 is significant).  
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2.11.4 Immunofluorescence 
HEK293 cells were transfected with wild type HA-MC2R and either FLAG-wild type, 
mutant Y59D or mutant V26A MRAP and grown on coverslips in 12 well plates or 
glass 8-well chamber slides ((Nunc, VWR, Leicester, UK) until 80% confluent or 48 
hours post-transfection, depending on the experiment.  Cells were washed twice in 
PBS, treated with either ice cold 100% methanol for 20 minutes at -20ºC to fix and 
permeabilise the cells, or 3.7% formaldehyde for 10 minutes to fix the cells. This was 
followed by PBS with 0.05% TritonX100 for 10 minutes to permeabilise the cell 
membranes. The cells were washed three times for 5 minutes in PBS, and then 
blocked in PBS containing 10% NDS and 0.3% bovine serum albumin (BSA), 
hereafter called Buffer A, for 1 hour.  After blocking the cells were incubated with 
primary antibodies, either AntiRabbit HA 1:500 or Anti Mouse Flag 1:500 (Sigma, 
Poole, UK) in Buffer A for 3 hours.  After incubation with primary antibodies the 
cells were washed three times in PBS and then incubated with species-specific 
secondary antibodies in Buffer A for 1 hour.  Cells were washed three times in PBS, 
briefly (1 minute) incubated with 2µg/ml 4’,6-diamidino-2-phenylindole 
dihydrochloride (DAPI, Sigma, Poole, UK) to counterstain nuclei and then washed 
again for 10 minutes in PBS.  The chamber or coverslip was removed from the slide 
and Fluorescent Mounting Medium (Dako, Ely, UK) was used to apply coverslips. 
 
Cells stained for MC2R and MRAP were visualised and imaged using the Zeiss 
LSM510 laser scanning confocal microscope. Images were taken using a 63x 
objective.  
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2.12 Mouse methods 
2.12.1 Generation and validation of mouse lines  
All mice used in these studies were obtained from our collaborators in Cornell 
University, New York and have been reported previously, along with genotyping 
protocols [101, 102]. 
 
2.12.2 Chaos mice 
Male C57/BL6J mice (Stock No. 000664) were treated with multidose N-ethyl-N-
nitrosourea (ENU) and then bred to C3HeB/FeJ (Stock No. 000658). The resulting 
male pups were then bred to C3HeB/FeJ females to obtain second generation mice, 
which were subsequently intercrossed to obtain third generation mice. A mutagenesis 
screen was then performed to select mice for chromosome instability (as assessed by 
micronucleus levels in erythrocytes). One of these mutants in which the tendency to 
form micronuclei segregated in a monogenic, autosomal recessive manner was termed 
Chaos3 (or chromosome aberrations occurring spontaneously 3). Further studies 
revealed that Chaos3 is a hypomorphic allele of Mcm4, containing a T to A 
transversion at nucleotide 1033 of the coding region that defines an amino acid 
change from phenylalanine to isoleucine at residue 345 (F345I). These mice have 
been backcrossed to C3HeB/FeJ for at least 8 generations prior to arrival at The 
Jackson Laboratory. 
 
2.12.3 MCM4 null mice 
Mice that carry a disruption allele of Mcm4 (referred to as Mcm4-) were generated. 
Mcm4- is derived from BayGenomics embryonic stem cell line RRE056 that contains 
a gene trap vector inserted between exons 12 and 13 of Mcm4, disrupting the highly 
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conserved MCM domain. Embryonic stem cell culture; Clone RRE056 cells (derived 
from the 129/Ola strain) were cultured in DMEM (GibcoBRL) supplemented with 
15% FBS (HyClone), 0.1 mM MEM nonessential amino acids, 2 mM GlutaMAX-1, 
penicillin-streptomycin (100 units/ml), β-mercaptoethanol (Sigma) and leukemia 
inhibitory factor (produced in-house). Cells were microinjected for chimera 
production into B6 blastocysts by standard methods. 
 
2.12.4 Mcm4+/- Mcm3+/- mice 
To generate the mice analyzed here, mice of the genotypes Mcm4Chaos3/Chaos3 
(chromosome aberrations occurring spontaneously 3) and Mcm4+/- Mcm3+/- were 
crossed to generate the control (Mcm4Chaos3/+ Mcm3+/-) and mutant (Mcm4Chaos3/- 
Mcm3+/) animals. 
 
2.12.5 Mouse histology   
Adult mouse adrenals were fixed in 4% paraformaldehyde (Sigma, Poole, UK) and 
embedded in paraffin. Sections were obtained using a microtome (Leitz 1512) at 6 µm 
thickness and mounted onto SuperFrost Plus slides (VWR). Sections were 
deparaffinised with 3 washes in xylene, followed by one wash in 100% ethanol. This 
was followed by incubation in 3% hydrogen peroxide in methanol (Fisher Scientific) 
to block endogenous peroxidase activity. Ethanol washes were then continued using 
100%, 90%, 70% and 50% solutions in H2O, followed by two washes in water to 
rehydrate. Haematoxylin and eosin staining was performed using standard procedures 
[103]. 
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2.12.6 GATA-4 immunohistochemistry 
Preliminary experiments showed that anti GATA-4 antibody (C-20, Santa Cruz 
Biotechnology) required antigen unmasking to give a clear and specific signal. To 
achieve that, the slides were boiled for 30 minutes in 10mM sodium citrate buffer 
pH6.   
 
After a 5 minute wash in PBS Triton X-100 0.1% (T-PBS), the slides were blocked 
for 30 minutes with 10% normal horse serum (Sigma Aldrich) and treated with biotin 
blocking reagent (Vector Laboratories) to prevent non-specific secondary antibody 
and tertiary reagent binding. They were then incubated overnight with goat anti 
GATA-4 diluted 1:250 in T-PBS. Any unbound antibody was removed by washing 
three times in T-PBS. This was followed by incubation with a biotinylated horse anti-
goat secondary (Vector Laboratories) diluted 1:500 in T-PBS, for 2 hours at room 
temperature. The slides were washed three times in T-PBS, treated with avidin-biotin 
complex (ABC Elite kit, Vector Laboratories) according to the manufacturer's 
instructions, rinsed again and incubated with 3-3’diaminobenzidine/nickel (Vector 
Laboratories). The reaction was stopped with H2O and slides were dehydrated and 
coverslipped using DPX mounting medium (Fisher). Images were acquired using a 
Leica DMR microscope (Leica), and digital images were captured using a Leica 
DC200 camera (Leica) and DCViewer software (Leica). 
 
2.12.7 CYP11A1 / YP11B1 immunofluorescence 
Sections were processed as above up to the blocking step, incubated with mouse anti-
CYP11B1 (1:20 in T-PBS) and rabbit anti-Side Chain Cleavage (Millipore, 1:1000 in 
T-PBS). After three washes with T-PBS, slides were incubated for 2 hr with goat anti-
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mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 568 (Invitrogen) diluted 
1:1000 in T-PBS and, after further washes, coverslipped. Images were acquired as 
above. CYP11B1 antibody was a kind gift of Dr C. Gomez-Sanchez (University of 
Mississippi Medical Center, Jackson, Mississippi).   
 
2.12.8 Non-radioactive in situ hybridisation (NR-ISH) 
Digoxigenin (DIG)-labeled antisense and sense Gli1 cRNA probes were available as 
they had been synthesized previously by in vitro transcription in the presence of DIG-
labeling mix (Roche) using ~1 µg of linearized template and T7 or SP6 RNA 
polymerase (New England Biolabs) [103]. All probes were used at a concentration of 
400-800ng/ml of hybridization buffer. Paraffin sections were dehydrated through an 
ascending alcohol series and NR-ISH performed as described previously [104]. 
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Table 2.2.  Primer sequences  
 
 Forward Primer Reverse primer 
gMCM4 AAAAGACAAATCCAGGAAGGC AACCTGAGCAGATAAAGCATCAG 
cMCM4 GAGCTACTCGCCAGGTGG GGAGTGCCGTATGTCAGTGG 
1st ATG 
MCM4 ATAGAATTCAATGTCGTCCCCGGCGTCGAC GAGGGATCCTTGCTCACAAGGC 
2nd ATG MCM4 ATAGAATTCAATGCCAACCTCG GAGGGATCCTTGCTCACAAGGC 
3rd ATG 
MCM4 ATAGAATTCAATGCATTCTTCA GAGGGATCCTTGCTCACAAGGC 
gANK1 CAGCCTCCCCTCTTCCC GGAGGCGGCTCGTACTG 
gADAM5P CGAAATGCATTGTAAAC CTTAAGAAGACAAAATTG 
Cloning MCM4-
HA GAGGGATCCTTGCTCACAAGGC 
GATGGATCCTCAAGCGTAATCTGGCACATCGTATG
GGTAGAGCAAGCGCACGGTCTTCC 
SDM 
MCM4 CGACGGAATTCAAAGTCGTCCCCGG CCGGGGACGACTTTGAATTCCGTCG 
MRAPα ACGCTGAAA GCTTAGTGCCACAGAGATG ACCAGTTGAATTCGCTATGGC CACGAT 
Y59D CTCATCTTGCTCGACATGTCCTGGT ACCAGGACATGTCGAGCAAGATGAG 
Y59F TCATCTTGCTCTTCATGTCCTGGTC GACCAGGACATGAAGAGCAAGATGA 
V26A ACCTCATTCCCGCGGACGAGAAGAA  TTCTTCTCGTCCGCGGGAATGAGGT 
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Chapter 3: Missense mutations in the Melanocortin 2 receptor accessory protein 
that lead to late onset Familial Glucocorticoid Deficiency type 2. 
 
3.1 Introduction 
Twenty percent of patients with Familial Glucocorticoid Deficiency (FGD) have 
mutations in the MC2R accessory protein (MRAP). The MRAP gene spans a 23 kb 
region on chromosome 21q22.1 and consists of 6 exons that are alternatively spliced 
to form two isoforms, MRAPα (exons 1-5) or MRAPβ (exons 1-4 &6) [79]. MRAPα 
encodes a 172 amino acid protein in contrast to MRAPβ encoding a 102 amino acid 
protein. The proteins have identical N terminal and transmembrane domains but differ 
at their C termini (Figure 3.1).  
 
Figure 3.1 
 
Figure 3.1. MRAP α and β isoforms. MRAP is alternatively spliced into either MRAPα or 
MRAPβ. Both proteins have identical N termini and transmembrane domains but diverse C 
termini.    
 
Previous work in our laboratory has shown that MRAP is essential for normal MC2R 
function. MRAP forms a unique antiparallel homodimer that colocalises and directly 
 68 
interacts with MC2R and is required for normal MC2R cell surface expression [79, 
105]. MRAP may also be involved in ligand interaction and signal transduction [106, 
107]. MRAP2 has been identified as a paralogue to MRAP, this gene encodes a 205 
amino acid protein with a single transmembrane domain and shows 27% homology to 
MRAPα. Like MRAP, MRAP2 is expressed in the adult adrenal gland, however it is 
also expressed in the ventromedial hypothalamus in the brain [108]. Similar to MRAP 
it has the ability to traffic MC2R to the cell surface leading to the formation of a 
functional ACTH receptor which responds to high levels of ACTH (10-6M) 
stimulation. 
 
Ten different MRAP mutations have been associated with FGD, all occurring in the N 
terminus or transmembrane domains. Interestingly, although MRAP2 may be able to 
replace MRAP function in vitro, MRAP2 clearly cannot replace MRAP function in 
vivo, as MRAP mutations present with FGD. This may be because of the relatively 
high concentration of ACTH required for MC2R signalling in the presence of 
MRAP2, which would exceed physiological circulating ACTH levels. Typically FGD 
patients with MRAP mutations present early with a severe phenotype, usually in the 
neonatal period (median 0.1 years) [91]. No patient reported to date has presented 
after 1.6 years. This most likely reflects the molecular basis of all MRAP mutations 
reported to date; all result in either an absent or severely truncated protein.  In contrast 
most MC2R mutations are missense mutations, nonsense mutations being uncommon 
and usually present in compound heterozygosity with a missense mutation.  
 
Two families with late onset FGD were referred to our group for genetic analyis 
(Figure 3.2). The proband in family 1 was diagnosed aged 4 years. Following family 
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review it was apparent that 2 older siblings had undiagnosed FGD. One sibling was 
well but the second had cerebral palsy likely secondary to hypoglycaemic seizures. 
The proband in family 2 was diagnosed aged 18 years with symptoms of fatigue, 
weight loss and depression.  
 
3.2 Patients 
3.2.1 Index Patient I 
Family 1 is a consanguineous Saudi-Arabian family with 6 children, 3 of whom have 
FGD (Figure 3.2).  The proband (II:6) was diagnosed aged 4 years following a severe 
exacerbation of asthma on the background of recurrent intermittent asthma requiring 
inhaled steroid treatment.  He was noted to be hypotensive, hypoglycaemic and 
hyperpigmented.  Electrolytes were normal (Na 134mmol/l, K 4.1mmol/l).  
Investigations revealed a grossly elevated ACTH level, 1050pg/ml (10-50) with a low 
paired cortisol level, < 25nmol/l (200-550).  Plasma renin (2.1 ng/ml/h [1.9–3.7]), 
VLCFA (C26:0 = 0.68, C24:0/C22:0 ratio = 0.85, C26:0/C22:0 = 0.011) and 17 
hydroxyprogesterone (6.1 nmol/l [0-10]) were all normal.  Adrenal autoantibodies 
were negative. 
 
A family review revealed a brother aged 15 years (II:2) and sister aged 20 years (II:1) 
who were both severely pigmented with high ACTH and low cortisol levels. The 
brother had no significant medical history and had never required hospitalisation, he 
was thriving and was developmentally normal. His sister suffered a hypoglycaemic 
seizure in infancy and subsequently developed cerebral palsy, however a causal 
relationship between the two cannot be assumed. Otherwise she had been relatively 
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well and had no history of further hypoglycaemic episodes later in childhood. Neither 
sibling had been treated for their FGD.  Another sister (II:3) who was reported to have 
been very pigmented, died during an intercurrent illness aged 11 years.  Both parents 
and 2 further siblings were unaffected.  
 
Figure 3.2 
 
Figure 3.2: Pedigree of family 1 indicating affected siblings. All affected individuals (black 
symbols) were homozygous for the Y59D mutation, unaffected parents and siblings (where 
characterised) were heterozygous (half-filled symbol) or wild type (open symbol). 
 
3.2.2. Index Patient II 
The index patient was a 38 year old male of Turkish origin, first diagnosed aged 18 
years after psychiatry review for symptoms of fatigue, weight loss and depression.  
On examination he was noted to have skin and mucosal hyperpigmentation, ACTH 
was grossly elevated at 1000 pg/ml with paired cortisol 345 nmol/l.  He was 
commenced on Prednisolone 7.5 mg/day but discontinued the medication after 6 
months.  He was relatively asymptomatic for the next 20 years suffering only 
prolonged minor infections. On second review hyperpigmentation remained and 
repeat ACTH was again markedly elevated at 3359 pg/ml with paired cortisol of 438 
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nmol/l.  Standard low dose ACTH stimulation test showed basal cortisol of 522 
nmol/l with no increase on stimulation. Plasma renin activity (1.32 ng/ml/h   [0.5-
1.9 ])/ h), aldosterone: 246 pmol/l  (30-420 pmol/l) and 17 OH- progesterone 
(3.4nmol/l [0-10 nmol/l]) were all within normal limits.  He remains untreated with 
glucocorticoids.  
 
3.3 Sequencing Results 
The coding exons of MC2R and MRAP were sequenced in these families. In both 
families the MC2R sequence was normal.  In family I MRAP sequencing in affected 
individuals (patients II:1 II:2 and II:6) revealed a novel homozygous missense 
mutation c.175T>G, predicted to cause the substitution of tyrosine with aspartic acid 
at position 59 (p.Y59D) (figure 3.3A and 3.4). The mother and one unaffected sibling 
(I:1 and II:4) were heterozygous at this position and one sibling (II:5) was 
homozygous for the wild type sequence.  Paternal DNA was unavailable for analysis.  
 
In family II, sequencing of MRAP identified a novel homozygous missense mutation 
c.76T>C, predicted to cause the substitution of valine with alanine at position 26 
(p.V26A) (figure 3.3B and 3.4).  Parental DNA was unavailable for analysis. 
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Figure 3.3 
 
Figure 3.3 A. Partial sequence chromatograms showing wild type, heterozygous and 
homozygous missense mutation c.175T>G; this is predicted to cause substitution of tyrosine 
with aspartic acid at position 59 (p.Y59D).  B. Partial sequence chromatograms showing wild 
type and novel homozygous missense mutation c.76T>C; this should cause substitution of 
valine with alanine at position 26 (p.V26A). 
 
 
Figure 3.4 
 
Figure 3.4 Schematic diagram of human MRAP illustrating the intracellular, extracellular and 
transmembrane domains. The locations of all known mutations including the novel mutations 
Y59D and V26A are shown.  
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3.4 cAMP luciferase reporter assay 
As discussed in the introduction, in the early stages of steroidogenesis ACTH binds to 
MC2R which induces intracellular production of cAMP, one of the major actions of 
which is to stimulate cAMP-dependent protein kinase (protein kinase A).  
Steroidogenic enzyme expression is stimulated via a number of mechanisms including 
activation of the cAMP response element binding protein (CREB), and ultimately 
results in an increased rate of cortisol synthesis. It has previously been shown that 
both MC2R and MRAP are essential for a normal cAMP response [79].  
 
HEK293 cells do not contain any endogenous MRAP or MC2R but do contain all 
other components necessary to allow a normal cAMP response to ACTH. Therefore 
when wildtype MC2R and MRAP constructs are transfected into HEK293 cells a 
normal cAMP response can be elicited [109].  By transfecting wild type MC2R in 
conjunction with either mutant or wildtype MRAP, cAMP production can be 
compared in the two cell systems and the difference in function between wild-type 
and mutant MRAP inferred.  By stimulating with varying doses of ACTH, dose 
response curves can then be generated for each construct. 
 
MRAP-3XFLAG vector had already been constructed in our laboratory by directional 
cloning of MRAPα into the HindIII and EcoR1 restriction sites of the p3xFLAG-
CMV-14 expression vector (Sigma, Poole, UK) after PCR amplification of human 
MRAPα [80].  The Y59D and V26A mutant MRAPα constructs were created by site 
directed mutagenesis of MRAP-3XFLAG vector as described in section 2.11.1.  
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HEK293 cells were seeded into 6 well plates and then transfected with HA-MC2R 
and either wild type MRAP, mutant MRAP or an empty vector. In addition each well 
was transfected with equal quantities of αGSU and Renilla. After 48 hours each well 
was stimulated with ACTH in concentrations ranging from 10-6 to 10-11M and one 
control well with MC2R and wildtype MRAP was left unstimulated. After 6 hours the 
cells were washed, lysed and cell lysate collected to be read in duplicate in a 
luminometer. Dose response curves were generated from the raw data and EC50 
measurements for all wildtype and mutant constructs were obtained using Prism 
(Prism Software Corp., Irvine, CA). The EC50 or half maximal effective concentration 
refers to the concentration of ACTH when 50% of its maximal effect is observed.  
 
In cells with either wild-type or mutant MRAP, ACTH stimulated the production of 
cAMP in a concentration dependent manner (Figure 3.5).  In cells with Y59D mutant 
MRAP there was a significantly lower cAMP response and the dose response curve 
was shifted to the right when compared to cells with wild type MRAP; wild-type EC50 
3.2x10-9M, Y59D mutant EC50 3.1x10-8M (p=0.0058) (Figure 3.5). In cells with 
V26A mutant MRAP there was a smaller but still significant shift in the dose 
response curve to the right; V26A mutant EC50 6.6x10-9M (p=0.0263) (Figure 3.5).   
 
These data reveal that the mutations have a deleterious effect on the ability of MRAP 
to facilitate ACTH signalling via MC2R. Phosphorylation of serine, threonine or 
tyrosine residues is a common post-translational mechanism by which mammalian 
cells regulate protein function. The substitution of aspartic acid, being a negatively 
charged amino acid, at position 59, may mimic a phosphorylated tyrosine and hence 
affect protein function. To investigate the possibility that the negative charge may be 
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responsible for the loss of function of the Y59D mutation, phenylalanine, which is a 
similar but non-polar aromatic amino acid to tyrosine, was substituted at this position 
by site-directed mutagenesis and the activity of these two mutants was compared. 
 
Figure 3.5 
 
Figure 3.5 Graph showing dose response curves (DRC) for all mutants compared to wild type. 
There was a significant shift in DRC for Y59D mutant MRAP (family I) (n=4), and a smaller 
but still significant shift in the DRC in V26A (family II) (n=8). There is no significant 
difference in function with Y59F (phenylalanine substitution) (n=4) compared to wild type, 
indicating that the negative charge associated with aspartic acid or the significant change in 
structure may be interfering with function.  
 
In cells with both wild type and Y59F mutant MRAP, ACTH again stimulated the 
production of cAMP in a concentration dependent manner, however there was no 
significant difference between wild type and mutant.  The dose response curve was 
similar in both cases; mean EC50 wild type 3.2x10-9M, mutant Y59F 3.9x10-9M 
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(p=0.9436) (figure 3.5), indicating that the negative charge of aspartic acid may be the 
cause of the reduced activity of the Y59D mutant. 
 
3.5 Immunofluorescence 
Confocal immunofluorescence studies were performed to try to establish whether this 
decreased function was caused by a trafficking or cell signalling defect.  Consistent 
with previous studies, wild type MC2R and MRAP are required for cell surface 
expression of MC2R (Figure 3.6 A-B).  However the mutant MRAP Y59D and V26A 
were also detected at the cell surface with MC2R suggesting that both MRAP mutants 
are trafficking competent (Figure 3.6 C-D). 
 
 77 
Figure 3.6 
 
Figure 3.6.  Immunofluorescent staining using both HA and FLAG antibodies detected HA-
MC2R at the cell surface of transiently transfected HEK293 cells when co-expressed with 
wild type, mutant Y59D and V26A FLAG-tagged MRAP. Wild type MRAP, mutant Y59D 
and mutant V26A MRAP interact with and promote trafficking of MC2R to the cell surface; 
in contrast, cells transfected with MC2R and empty vector (no MRAP) show intracellular 
accumulation of MC2R.  A: MC2R and Empty Vector (no MRAP).  B: Wild type MC2R and 
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wild type MRAP.  C: Wild type MC2R and mutant V26A MRAP.  D: Wild type MC2R and 
Mutant Y59D MRAP. 
 
3.6 Discussion 
This is the first report of missense mutations in MRAP. These mutations resulted in a 
much later onset phenotype compared to FGD2 due to truncation mutants.  In family I 
however there is a very wide range of clinical phenotypes with both a likely death 
secondary to adrenal insufficiency (sibling II:3) and survival to 15 years with no 
evident consequences (sibling II:2). This phenomenon has also been seen with MC2R 
mutations, in particular S74I [91]. The reasons for this remain unclear; however it 
seems likely that other genetic and environmental factors will influence the cortisol 
response to a suboptimal ACTH stimulus. We recently reported a child with FGD but 
without hyperpigmentation [87]. Excessive skin pigmentation related to elevated 
proopiomelancortin products acting on MC1R causes hyperpigmentation which is an 
important clinical finding suggestive of adrenal insufficiency. This child’s diagnosis 
was delayed because of the absence of hyperpigmentation due to coexistent MC2R 
and MC1R mutations, genes located on different chromosomes but belonging to the 
same family, the melanocortin receptors. This case illustrates how more than one 
genetic defect can modify the clinical phenotype. Similarly, the patient who died, 
presumably due to adrenal insufficiency, may have had genetic defects in other genes 
affecting adrenal function, for example the oxidative stress pathway (discussed further 
in chapter 7), rendering her more susceptible to adrenal crisis when stressed.  
 
The functional significance of the mutations identified in this study were investigated 
by transfecting MC2R in a heterologous cell line along with wild type or mutant 
forms of MRAP. These cells were then stimulated with ACTH and the cAMP 
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response was calculated using a cAMP-responsive luciferase reporter gene. Other 
assays are available which can also be used to evaluate MC2R function in vitro. 
ACTH binding to MC2R causes a conformational change in the receptor which leads 
to the exchange of GDP by GTP on the α-subunit. The GTP bound Gα-subunit 
stimulates adenylyl cyclase which stimulates conversion of ATP to cyclic AMP.  
cAMP subsequently activates Protein Kinase A (PKA) leading to phosphorylation of 
cAMP response element binding protein (CREB).  The ideal assay would measure the 
primary receptor response following stimulation with ACTH ie formation of the GTP 
bound Gα-subunit.  This can be assayed using a radioactive immunoassay. 
 
cAMP production can also be measured directly using the cAMP competitive binding 
assay.  This is based on the competition between cAMP in the samples and [3H] 
cAMP, for the binding protein extracted from bovine adrenal glands.  It is a sensitive 
assay that allows detection of cAMP over a broad range of concentrations.  The gold 
standard cAMP assay is the cAMP ELISA assay however this is very expensive 
which can prohibit its use in the laboratory for experiments which require analysis of 
multiple samples. 
 
cAMP imaging techniques have also been developed based on dissociation of PKA.  
Luciferase and YFP can be cloned to the regulatory and catalytic subunit of PKA.  In 
the absence of cAMP both subunits form a complex which gives a high BRET signal.  
When cAMP binds to the regulatory subunits the catalytic subunits dissociate which 
eliminates the BRET signal.  The change in the BRET signal allows cAMP 
concentrations via PKA dissociation to be measured [110]. 
 
 80 
However Luciferase is now the most widely used genetic reporter in studies on gene 
expression due to its high sensitivity and its absence from mammalian cells. Firefly 
luciferase is a 61kDa monomeric protein that does not require post-translational 
processing for enzymatic activity and therefore functions as a genetic reporter 
immediately upon translation [111]. Both reporters yield linear assays with sub 
attomole sensitivities; the linear range of luciferase detection for both firefly and 
Renilla luciferases extends over 7 logs of enzyme concentration [112]. Also, the 
absence of endogenous luciferase activity results in very low background activity.  
This leads to a higher sensitivity compared to other reporters eg CAT and beta-Gal 
assays. 
 
The dual luciferase assay is convenient as both firefly and Renilla luciferase activity 
can be measured sequentially from a single sample and the method requires no 
incubations or pre-treatment.  In contrast, the cAMP competitive binding assay 
requires radioactive buffers, generation of a standard curve, sample pre-treatment and 
lengthy incubations; generating dose response curves for multiple samples would be 
very time consuming. 
 
Experimental accuracy is improved by using an internal control.  In this case the 
"experimental" reporter, firefly luciferase, reflects the effect of the experimental 
conditions (mutant versus wild type MRAP) on the level of cAMP production.  The 
second "control" reporter, Renilla luciferase, is used to provide an internal control to 
which the activity of the experimental reporter is normalized. Normalizing the activity 
of the experimental reporter to the activity of the internal control eliminates inherent 
assay-to-assay variability, such as differences in the number and health of cultured 
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cells and the efficiencies of transfection and cell lysis, which can undermine 
experimental accuracy. 
 
Dose response curves were generated which showed ACTH stimulated the production 
of cAMP in a concentration dependent manner. Experiments were repeated a 
minumum of 3 times with most experiments repeated 6 times; a similar pattern was 
seen in all experiments.  Furthermore the functional characterisation of the 2 mutant 
MRAPs compared to wild type fits with the clinical picture in that the patients with 
the Y59D mutation were more severely affected than the patient with the V26A 
mutation. Two negative controls were employed, the first consisted of HEK293 cells 
transfected with wild type MC2R in conjunction with empty vector pcDNA 3.1. 
When stimulated with ACTH the luciferase activity was minimal (<1% of wildtype) 
indicating that MRAP is required together with MC2R for a normal response to 
ACTH. As the only difference in these cells compared to those transfected with 
MC2R and wild type MRAP was the absence of MRAP it can be assumed that the 
absence of luciferase activity is secondary to the absence of MRAP, therefore 
verifying the assay. As a second negative control cells were transfected with both 
wild type MC2R and wildtype MRAP but not stimulated with ACTH. These cells 
showed minimal luciferase activity (<1% wild type), again indicating the assay was 
robust.   
 
This assay, like all in vitro assays, can only give information about total cAMP 
concentrations rather than free cAMP concentrations ie second messenger pools that 
are not sequestered or bound to proteins.  Also the concept of cAMP 
compartmentalisation that assumes different cAMP concentrations in different 
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cellular compartments can not be tested in this assay [113]. In addition the luciferase 
assay measures cAMP production indirectly using the luciferase reporter assay, 
assuming luciferase transcription and translation is directly related to cAMP 
production. However the dose response curves do demonstrate increasing amounts of 
luciferase activity and finally bioluminescence detected by the luminometer.  This is 
almost certainly due to increasing cAMP responses as the negative controls 
demonstrate that cAMP production is not generated when cells are unstimulated or 
when MC2R or MRAP are absent, and indicate that the assay is a good way of 
characterising these mutants in vitro.  
 
Previous work has shown that the transmembrane domain of MRAP (amino acids 36-
62) is the domain that is required for MC2R–MRAP interaction and cell surface 
expression of MC2R. The substitution of the tyrosine residue for an aspartic acid in 
family I is therefore likely to interfere with MC2R interaction or trafficking. In 
addition, given that tyrosine has an uncharged polar structure but aspartic acid has a 
charged polar structure it is conceivable that this substitution would indeed affect 
MC2R interaction and trafficking to the cell surface. However confocal 
immunofluorescent studies did not support this. These studies indicated that the Y59D 
and V26A mutant were both able to successfully traffic MC2R to the cell surface 
suggesting that decreased function was secondary to a signaling defect at the cell 
surface. There is increasing evidence that MRAP has both a trafficking and a ligand 
binding/signal transduction function. A region between residues 19 and 21 seems to 
be specifically required for receptor signaling; deletion of this region results in a 
trafficking competent but signaling defective MRAP.  Binding data suggests that this 
region influences ACTH binding by MC2R [106-108].  
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When tyrosine is substituted with phenylalanine at position 59 there is no significant 
difference in function compared to wild type indicating that the negative charge 
associated with aspartic acid may be interfering with function, potentially because of 
the likely conformational change of the transmembrane domain resulting from the 
charged residue at this position. As tyrosine is a target for phosphorylation by certain 
intracellular kinases this observation raises the possibility that phosphorylation of this 
residue modulates the function of MRAP. Given aspartic acid is negatively charged 
this may mimic a continually phosphorylated tyrosine, potentially leading to continual 
downregulation of MRAP and reduced function in vitro as well as in vivo. 
Alternatively post translational modification of MRAP through this tyrosine residue 
may be affected by the aspartic acid substitution giving rise to reduced function. 
 
In Family II, the index patient had only a mild abnormality of adrenal function, 
leading to a suboptimal cortisol response to ACTH stimulation.  However he also had 
considerable elevations in ACTH levels up to 3359pg/ml leading to 
hyperpigmentation.  Adrenal failure secondary to autoimmune disease, tuberculosis or 
adrenoleucodystrophy was thought to be unlikely as it is probable that in this case 
mineralocorticoid deficiency would have evolved over time.  It is likely that his non-
specific symptoms including fatigue, weight loss and depression were secondary to 
his mild cortisol deficiency.  
 
Consistent with the observation of a mild phenotype in this patient the 
characterisation of V26A mutant MRAP demonstrates impaired rather than absent 
function evidenced by a right shift in the dose response curve.  Furthermore this shift 
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was very small for V26A and correlates with the patient’s mild clinical picture. This 
small reduction in function is unsurprising given that this is a very conservative 
change as both valine and alanine are nonpolar hydrophobic amino acids only 
differing in that valine has an additional carbon and methyl group.   
 
In summary, these missense mutations illustrate that MRAP mutations can present late 
in life leading to a variable phenotype of ACTH resistance.  Consistent with the 
phenotype, characterisation of these mutations confirms reduced rather than absent 
function.  These results, describing late onset disease resulting from missense MRAP 
mutations, further substantiate the hypothesis that disease severity in FGD patients 
reflects the functional significance of the underlying mutation.  Furthermore, these 
results have significant clinical implications as it is clearly important to screen late 
presenting patients with unexplained glucocorticoid deficiency for mutations in 
MRAP. 
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Chapter 4: Identification of the gene causing FGD in the Irish traveller 
population 
4.1 Patients 
4.1.1 The Irish travelling community 
The Irish travelling community was estimated to have a population of 36,224 at the 
2008 Republic of Ireland traveller census and a further 3,905 were estimated to live in 
Northern Ireland [114]. Irish travellers are an indigenous nomadic minority who have 
been documented as being part of Irish society for centuries. Although they have 
much in common with European travellers and Roma gypsies they are ethnically and 
genetically distinct. Irish travellers have a long shared history, identity, language and 
value system and are recognised as a cultural minority in Ireland. 
 
Travellers experience considerably higher mortality than the general Irish population 
across all age ranges; overall traveller mortality is 3.5 times higher [115].  This is due 
to all cause mortality, both external causes of death (including accidents, suicides and 
poisonings) and also illness, with respiratory illness and heart disease considerably 
higher than expected. Cancer deaths are also increased; 21.9 observed deaths in males 
(compared to 9.0 expected deaths) and 14 observed deaths in females (compared to 
8.0 expected deaths). Infant mortality is 3.6 times higher than the general population; 
traveller infant mortality rate is 14.1 per 1000 live births comparing to 3.9 per 1000 
live births in the general population.  Infant mortality rates are strongly associated 
with the socio-economic status of the mother which is clearly a contributing factor to 
the Irish traveller infant mortality rate [116].  However additionally there is a genetic 
contribution which is harder to define. Irish travellers nearly always marry within the 
community and often marry a relative which has created a genetically isolated 
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population with high levels of consanguinity. There is a significantly increased 
incidence of autosomal recessive disorders within this population, one of which is 
Familial Glucocorticoid Deficiency. A recent paper describing the phenotype of nine 
Irish travellers with FGD estimated the disease prevalence to be one in 2506 
compared to an overall prevalence of one in 201,898 in the general Irish population 
[4].  
 
4.1.2 Clinical Presentation 
I studied 7 children with adrenal failure from 3 kindreds within the Irish travelling 
population; all children are the product of first cousin marriages (Figure 4.1). Patients 
had been referred to the tertiary paediatric endocrine clinic in Our Lady’s Children’s 
Hospital in Dublin with typical clinical and biochemical features of Familial 
Glucocorticoid deficiency (FGD). They had isolated glucocorticoid deficiency, raised 
ACTH and normal renin and aldosterone levels. Patient 1, 3 and 7 presented with 
failure to thrive and hyperpigmentation; ACTH, cortisol levels and ACTH stimulation 
testing confirmed cortisol deficiency (Table 4.1). Patients 5 and 6 presented with 
hypoglycaemia, patient 5 with a hypoglycaemic seizure, both during an intercurrent 
illness. Hypoglycaemia together with hyperpigmentation on clinical examination led 
to positive screening for adrenal insufficiency. Patients 2 and 4 were screened due to 
positive family history; initially they had normal biochemistry but subsequently 
developed adrenal insufficiency. Unlike other forms of FGD, cortisol deficiency is 
often not as severe and onset is usually in childhood following a period of normal 
adrenal function, verifying development of disease during childhood. This potentially 
suggests a degenerative process that is in contrast to FGD 1 and 2, which can usually 
be detected from birth. All children were maintained on replacement hydrocortisone 
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10-12mg/m2/day. Age of presentation of adrenal failure, presenting complaints and 
biochemical data supporting adrenal insufficiency are presented in Table 4.1. Patient 
8 has not yet developed adrenal failure but does show evidence of other features 
(described in detail below) including short stature, increased chromosomal fragility 
and Natural Killer (NK) cell deficiency.  
 
Figure 4.1 
 
Figure 4.1 Pedigree of 3 affected kindreds. Shaded black, affected; shaded half black and half 
white, unaffected and heterozygous genotype; shaded white, unaffected and wild sequence 
type; shaded grey, unknown genotype and disease state. 
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Table 4.1 
Patient 
Age at 
diagnosis of 
adrenal 
insufficiency 
(yrs) 
9am 
cortisol 
(nmol/L) 
NR>200 
ACTH at 
diagnosis 
(ng/l) 
NR 9-52 
 
Maximum 
cortisol with 
ACTH 
stimulation  
NR>550 
Renin 
nmol/l/h 
NR 0.5-3.5 
Aldosterone 
pmol/l 
NR 100-850 
1 2.5 112 265 314 3.5 130 
2 12 167 50 356 3.3 435 
3 7.9 114 259 - 0.8 75 
4 0.5* 244 156 325 3.2 165 
5 5 <20 439 - 2.5 <55 / 126 
6 4.5 308 195 308 2.6 105 
7 0.5* 229 126 364 8.2 1125 
8 -* 210 27 577 4.3 285 
 
Table 4.1 Adrenal phenotype of patients included in the study. Patient 8 (aged 4 years) was 
included because she has short stature, increased chromosomal fragility and NK cell 
deficiency however she has not yet developed adrenal insufficiency. FTT: failure to thrive * 
Screened due to positive family history 
 
Adrenal imaging in one child was available and showed small atrophic adrenal glands 
on CT. Known causes of adrenal insufficiency were excluded including 
adrenoleucodystrophy, congenital adrenal hyperplasia, Triple A syndrome and 
Addison’s disease. Patients had normal long chain fatty acids, normal 17-hydroxy-
progesterone levels and adrenal autoantibodies were negative. Patients also had 
normal tear formation, normal swallow and no evidence of neurological disease, 
clinically excluding Triple A syndrome.  
 
Children had a low birth weight and are currently notably short compared to their 
mid-parental height standard deviation score (SDS) despite a normal growth 
hormone/insulin-like growth factor 1 (IGF-1) axis (Table 4.2 and Figure 4.2). Boys 
had a persistently delayed bone age throughout childhood but most girls (except 
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patient 8) had a normal bone age. Due to their failure to thrive in infancy, failure to 
show any catch up growth in childhood, and resultant short stature, many of these 
children were screened for additional pathologies. Cystic fibrosis screening, coeliac 
antibodies and inflammatory markers were all negative and thyroid function tests 
were normal in all patients.  
 
Table 4.2 
Patient 
Gestation 
(weeks) 
Birth 
Weight 
SDS 
Current 
Height 
SDS 
Bone age 
IGF1 
nmol/l 
IGFBP3 
mg/l 
NR 1.3-5 
1 36 -3.0 -3.3 Delayed 40 (20-85) 2.9/4.2 
2 39 -1.8 -2.1 Delayed 58 (20-85) - 
3 40 -2.1 -1.4 Normal 53 (20-85) 3.8 
4 39 -2.3 -2.3 Delayed 38 (20-85) - 
5 - - -1.1 Normal 24 (7-40) 4.3 
6 37 -2.2 -1.3 Normal 23 (4-37) 4.1/5.4/4.3  
7 38 -2.0 -3.4 Delayed 13 (4-20) - 
8 39 -1.9 -2.6 Delayed 6 (4-20) 1.7 
 
Table 4.2. Growth phenotype of all patients. SDS, standard deviation score; IGF1, Insulin 
growth factor 1; IGFBP3, Insulin growth factor binding protein 3; NR; normal range. 
 
Four children, patients 1 (male), 3, 5 and 6 (female) were of pubertal age. The boy 
had evidence of delayed puberty with no clinical signs of puberty or adrenarche. 
Biochemistry showed low gonadotrophins (eg LH 0.1 IU/l, FSH 0.4 IU/l) and 
undetectable testosterone levels consistent with hypogonadotrophic hypogonadism or 
constitutional delay of growth and puberty. Aged 14 years his pubertal staging was 
G1, P1, A1 with testes 3ml and no pubertal growth spurt. He was commenced on 
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testosterone injections for 6 months. These were subsequently stopped and over the 
following 5 years his puberty advanced to A2 P5 G5 but his testes remained only 12 
ml bilaterally aged 20 years. At this time his gonadotrophins are normal (LH 2.2IU/l, 
FSH 4.1 IU/l) with 9am testosterone 13.3nmol/l. Clinically he has evidence of absent 
adrenarche, this is confirmed biochemically; DHEAS 1.6 µmol/l (2.1-15.2) and 
androstendione 3.1 nmol/l (2.8-10.5), indicating poor adrenal androgen synthesis. 
 
Figure 4.2 
 
Figure 4.2 Graph showing patient and paired mid-parental height standard deviation scores.  
 
The 3 girls progressed into puberty at a normal age with menarche at ages 12.5 years, 
14 years and 14.1 years. All girls currently report regular monthly menses. All girls 
also clinically demonstrate lack of adrenarche, and although they had normal breast 
development, pubic hair and axillary hair development was delayed and pubertal 
staging continues to remain abnormal with staging B5, P3, A1, M1. Lack of adrenal 
androgens was also confirmed biochemically in the girls with androstendione (A4) 
and especially DHEAS levels low or undetectable (Table 4.3). 
 
 91 
Table 4.3 
Patient 
Current age 
(years) 
Puberty 
A4  
nmol/l 
2.8-10.5 
DHEAS 
µmol/l 
2.1-15.2 
1 (male) 20  Delayed 3.1 1.6 
3 (female) 18 Normal 3.6 <0.4 
5 (female) 17 Normal 1.9 <0.4 
6 (female) 22 Normal 2.3 <0.4 
 
Table 4.3 Pubertal status and adrenal androgen levels in those children who have reached 
puberty. A4, androstendione. 
 
Fanconi’s anaemia is another autosomal recessive disorder common in the Irish 
travelling community due to the high levels of consanguinity [117]. It is a genetically 
heterogeneous disorder, however a common homozygous deletion of exons 11-14 in 
the FANCA gene has been identified in the Irish traveling population. Fanconi’s 
anaemia has three cardinal features; elevated chromosomal breakage, pancytopaenia 
and congenital anomalies, including dysmorphic features such as radial ray 
abnormalities, micropthalmia (usually unilateral) and growth retardation. The children 
reported here had failure to thrive and growth retardation but did not have any of the 
other congenital abnormalities and did not develop pancytopaenia or bone marrow 
failure. However, given the family history, a number of children were screened for 
Fanconi’s anaemia using a chromosomal breakage screen. This is a screening test that 
involves culturing peripheral lymphocytes with an alkylating agent such as 
diepoxybutane or mitomycin C and looking for chromosomal breakage, for example 
abnormal chromosomal exchanges. Fanconi anaemia cells show increased 
chromosomal breakage compared to normal cells. These tests were carried out in a 
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laboratory in Bristol that is accredited to perform these investigations and to provide 
results for clinical care. Four children (patients 4, 5, 7, 8) had evidence of increased 
chromosomal breakage on screening with diepoxybutane (Table 4.4) but not always at 
levels high enough to be consistent with Fanconi’s anaemia (patients 4, 5 and 7). All 
children screened negative for the known genetic defect in the FANCA gene and 
displayed no other clinical characteristics suggestive of any other DNA repair 
disorder, and so the chromosomal fragility remained unexplained. 
 
Table 4.4 
Patient 
Normal cells out of 80 
screened 
Chromosomal breakage Chromosomal exchanges 
1 70 7 breaks 1 exchange 
2 69 3 breaks 2 exchanges 
3 73  8 breaks none 
4 56 13 breaks 4 exchanges 
5 64 22 breaks 8 exchanges 
6 pending pending pending 
7 20 21 breaks 5 exchanges 
8 69 152 breaks 54 exchanges 
 
Table 4.4 Chromosomal breakage. Lymphocytes treated with 0.1µg/ml diepoxybutane for the 
duration of culture, normal background < 8 breaks/2 exchanges per test (80 cells quantified) 
 
In 2006 Eidenschenk et al. reported four children from the Irish travelling community 
with a primary immunodeficiency consisting of a specific natural killer (NK) cell 
deficiency and susceptibility to viral infections [118]. One child had developed an 
Epstein Barr virus-driven lymphoproliferative disorder and two others developed 
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severe respiratory illness of probable viral etiology.  The fourth child was well with 
no history of recurrent infections or lung disease but was screened for NK cell 
deficiency due to the family history. The group identified a single 12 Mb region on 
chromosome 8p11.23-q11.21 that was linked to the immunodeficiency but were 
unable to identify the causative gene within this region. None of the children were 
described as having adrenal insufficiency or increased chromosomal fragility. 
However, two of my patient cohort (patients 7 and 8) are related to the kindred 
described and had had immunological investigations performed that identified a 
similar degree of NK cell deficiency (Table 4.5). On screening of the remainder of the 
cohort all children showed low but not absent NK cells with normal T and B cell 
lymphocyte subsets (Table 4.5).  
 
Table 4.5 
 Total 
lymphs 
T cells 
CD3+ 
T helper 
CD3/CD4 
T supp 
CD3/8 
B cells 
CD19 
NK cells  
NR 200-300 
/9-16% 
1 3586 75/2892 41/1478 34/1252 20/808 210/5%  
2 Unavailable 
3 2278 85/1934 57/1205 24/515 10/245 60/2%  
4 2597 81.2/2110 40.1/1043 34.6/898 14.1/365 78/3%  
5 2151 84.9/1825 47.3/1016 36.6/787 12.8/274 29/1.4% 
6 1719 76/1309 51/861 23/389 19/327 27/2% 
7 2515 60/1512 49/1206 10/239 33/842 18/1.1% 
8 1816 73.9/1337 55.1/1001 17.9/325 17.5/319 141/3%  
 
Table 4.5. Percentage and absolute numbers of T and B cell subsets in the first whole-blood 
sample analyzed are indicated for each individual tested. The absolute NK cell count 
(measured in cells/ml of whole blood) and the percentage of lymphocytes that were NK cells 
are also indicated. 
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NK cells are circulating cytotoxic lymphocytes that lack antigen specific T-cell and 
B-cell receptors. They belong to the innate immune system and are derived from 
CD34+ haematopoietic progenitor cells. They are defined by the expression of the cell 
surface marker CD56 and the lack of CD3 (thereby excluding T cells). NK cells are 
thought to mature in both bone marrow and secondary lymphoid tissue such as lymph 
nodes and tonsils. Although the maturation pathway has not been fully elucidated, it 
has been postulated that CD56 bright NK cells terminally differentiate into active 
CD56 dim NK cells. CD56 bright NK cells are named for their high-density surface 
expression of CD56 compared to CD56 dim NK cells which have a low density CD56 
cell surface expression. It has been postulated that the CD56 dim NK cell population 
is more mature than the CD56 bright population, and is derived directly from this 
population. Interestingly the CD56 molecule itself has been found to be important in 
promoting this terminal maturation step [119]. The function of NK cells remains 
unclear, however a few very rare cases of complete NK cell deficiency in humans 
have been reported and result in overwhelming fatal infection during childhood [120, 
121]. NK cells can secrete cytokines and chemokines that influence the host’s 
immune response. They can also kill certain infected or transformed cells and have 
anti-proliferative effects on viral and malignant transformed cells. CD56 dim NK 
cells can efficiently lyse target cells in the absence of prior stimulation and without 
the need for antibody recognition [122]. The lack of well defined inherited disorders 
associated with a deficiency in NK cell development has led to lack of understanding 
regarding definitive NK cell function in humans. 
 
Only one patient in our cohort clearly demonstrated increased susceptibility to 
infection; patient 6 had recurrent pneumonitis and had evidence of bronchiectasis on 
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CT chest. However on closer questioning it was apparent that patient 1, 3 and 7 also 
complained of recurrent chest infections requiring multiple courses of antibiotics and 
also required regular steroid and Ventolin inhalers. On routine examination, patients 1 
and 3 had abnormal chest X-rays with evidence of pneumonia but no evidence of 
bronchiectasis or interstitial lung disease, however this would usually require CT 
examination for diagnosis. Otherwise the patients did not display any increased 
susceptibility to infection and specifically did not have increased rates of viral 
infections eg. Herpes virus 1 and 2, Epstein Barr virus or molluscum contagiosum 
infection. 
 
It was apparent that these features (adrenal insufficiency, chromosomal fragility and 
NK cell deficiency) co-segregated in many individuals, and as inheritance patterns 
were suggestive of autosomal recessive mechanisms, it was hypothesized that a single 
genetic disorder might underlie all features. Ethics approval was obtained in April 
2008 (application number SAC-110-08) from Our Lady’s Children’s Hospital, Dublin 
Ethics Committee to investigate this group of patients to try to identify the genetic 
basis for their disease. This involved completing an Ethics Approval form together 
with providing an information sheet to provide details on the study for patients and 
parents (Appendix 1). Parental consent and an assent for children forms were drawn 
up. Once these were in place homozygosity mapping was used to identify common 
areas of homozygosity between affected patients in order to subsequently interrogate 
these areas in an attempt to identify the causative gene.  
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Patients had already been screened for mutations in MC2R and MRAP. In addition I 
sequenced STAR and P450 Side Chain Cleavage Enyzme (CYP11A1) and found 
normal gene sequences. 
 
4.2 Gene identification  
The technique of homozygosity mapping in consanguineous families utilises the 
concept that affected individuals will be homozygous by descent for a mutation and 
polymorphic markers nearby. The disease locus is therefore identified by seeking 
regions of homozygosity that are common between affected members of a 
consanguineous family and not seen in the unaffected ones. This technique has 
already proven very successful in identifying new genes in highly consanguineous 
families [79]. However the clinical presentation of FGD in these kindreds was 
variable, as discussed previously a number of patients have been shown to have 
entirely normal adrenal biochemistry before later presenting with adrenal 
insufficiency. In addition chromosomal fragility and NK cell deficiency are not 
always present. It is therefore difficult to confidently assign a relative as unaffected. 
For that reason only affected individuals were genotyped and regions of 
homozygosity common to all affected patients were identified.  
 
SNP array genotyping was performed with the GeneChip® mapping 10K microarray 
containing approximately 11,500 SNPs from The SNP Consortium database. The 
median physical distance between SNPs was approximately 105 kb, the average 
distance between SNPs was 210 kb and the mean genetic gap difference was 0.32cM. 
Briefly total genomic DNA was digested using a specific restriction enzyme, XbaI, 
and ligated to adapters. A generic primer that recognised the adapter sequence was 
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used to preferentially amplify fragments of DNA from 250 to 1000 base pairs long. 
Each SNP was located within one of these amplified fragments. The amplified DNA 
was then fragmented, labeled and hybridized to the GeneChip Mapping 10K Array. 
Allele specific hybridization was performed by synthesizing two 25 base-pair 
oligonucleotide probes each with the two possible alleles in the centre of the probe, 
one probe a perfect match for the “A” allele and one probe a perfect match for the “B” 
allele. The DNA was hybridized to the array and it could then be determined whether 
the SNP was AA AB or BB by analyzing the resulting signal from the allele specific 
probes.  
 
Hybridized arrays were processed with an Affymetrix Fluidics station 450 and 
fluorescence signals were detected using the Affymetrix GeneChip Scanner 3000 by 
colleagues in the Genome Centre at Barts and the London. Signal intensity data was 
analysed by the GeneChip DNA analysis software based on a model algorithm to 
generate SNP calls [95]. 
 
Formal linkage analysis requires high quality genotyping, correct pedigree structure 
and accurate computational analysis [96]. Within an inbred population, when there are 
multiple loops of consanguinity it is recommended practice to simplify the pedigree 
structure for LOD score calculations. However this then raises the concern regarding 
the actual significance of the LOD score [96]. Furthermore, formal linkage analysis 
assumes the pedigree structure is correct but in inbred populations, including the Irish 
traveller population, there are often unknown or undisclosed inbreeding loops. These 
will have an unpredictable effect on the formal LOD score and IBD analysis. In 
addition, the limited number of individuals available for analysis (4 patients) reduced 
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the potential power, therefore formal linkage analysis was not performed. Instead, the 
IBDfinder program was used to identify regions of autozygosity [96]. This program 
takes a qualitative approach to the identification of regions of identity by descent 
(IBD) in affected individuals from consanguineous unions. It ignores linkage 
disequilibrium and pedigree structure, thereby allowing the analysis of singletons and 
groups of related or unrelated individuals. Formal linkage probabilities were not 
calculated but a graphical user interface was used to identify regions of 
homozygosity. IBD finder generates a graphical display of a numerical score that 
changes as the genotype data are scanned. The program uses the presence of rare SNP 
alleles as well as heterozygous markers to identify regions. Each homozygous SNP is 
scored by counting the number of homozygous SNPs between it and the nearest 
heterozygous SNP, and the average number of homozygous SNPs between it and the 
nearest centromeric and teleromeric heterozygous SNPs. These scores are plotted 
against the chromosome map coordinates to give a read out of the size of the region of 
homozygosity and also the number of SNPs that lie in that region. An allowance can 
be made for genotyping errors.   Significant regions were therefore determined by 
including all regions where >10 consecutive SNPs were identical in all patients and 
allowing for a genotyping error of 1 in 50.  
 
This led to the discovery of 3 IBD regions common to all 4 genotyped affected 
patients; 4:96.3-100.3, 8:36.8-51.9 and 8:62.1-64.5 (table 2), totaling 21.5Mb (Table 
4.6).   
 
Examination of ENSEMBL and similar databases (eg UCSC) revealed 319 known 
and predicted genes at these loci. Ideally, genes would have been prioritised for 
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sequencing based on known function and by determining their expression patterns in 
human tissues either in silico or in vitro. Expression patterns could be investigated in 
silico, using databases based on EST and RT-PCR data such as the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and the GNF SymAtlas 
(http://symatlas.gnf.org/SymAtlas/) as well as mouse in situ hybridization maps such 
as Genepaint (http://www.genepaint.org/). Genes with little or no evidence of adrenal 
expression using any of these tools would be considered less likely to be candidates 
for FGD genes.  Genes showing highly adrenal-specific expression would be 
considered good candidates for further study by sequencing and/or knockdown 
analysis.   
 
However, given the number of potential candidate genes discovered it was decided to 
prioritise genes for sequencing on the basis of their known functions. Based on known 
function and expression patterns only 2 genes appeared to be good candidates for 
FGD. These included the Steroidogenic Acute Regulatory Protein (StAR) and also 
Voltage Dependent Anion Channel 3 (VDAC3). The 7 exons in StAR together with 
the intron/exon junctions in 3 patients (from 3 different families) had previously been 
analysed and no potential disease causing mutation was identified. Therefore although 
it was possible that an intronic mutation or a mutation in the promoter region of StAR 
could be present leading to the FGD phenotype, this was considered to be unlikely 
and StAR was therefore excluded as a potential disease-causing gene. 
 
VDAC3 on chromosome 8:42,249142-42263415 has 2 annotated transcripts which 
are known to be protein coding, VDAC3-002 (ENST00000521158) and VDAC3-003 
(ENST00000022615). VDAC3 is an outer mitochondrial membrane protein porin that 
 100 
forms a channel through the mitochondrial outer membrane and allows diffusion of 
small hydrophilic molecules through the mitochondrial membrane. 
 
VDAC3 is thought to be specifically involved in translocation of adenine nucleotides 
through the outer membrane. Although VDAC3 is ubquitously expressed it shows 
relatively high expression in the adrenal gland and testes (www.proteinatlas.org) and 
therefore may play a role in steroidogenesis. Primers were designed to amplify all the 
protein coding exons in this gene and these were sequenced. This revealed wild type 
sequences with no potential disease-causing mutations indentified.  
 
4.2.2 Targeted Exome Sequencing 
Homozygosity mapping identified 21.5 Megabases (Mb) of genome in which the 
disease-causing gene was most likely located. The remainder of the genes in these 
intervals were not obvious candidates based on their known or suspected functions.  
Targeted massively parallel sequencing was then used to sequence all the protein 
coding regions within this 21.5 Mb region, which totaled approximately 1.1 Mb. The 
coordinates of the regions of homozygosity (Table 4.6) were supplied as well as the 
co-ordinates of the total genomic sequence of MC2R, MRAP and StAR to ensure no 
variants in these genes, known to be associated with FGD, had been missed. First, a 
custom sequence capture array targeting the exons, 50bp up- and downstream, plus 
1Kb upstream of the transcription start site for each REFSEQ gene within these 
regions, was designed and manufactured by Roche NimbleGen. This was a Titanium 
Optimized Sequence 385K Capture Array that allows capture and enrichment of 
contiguous or non-contiguous genomic regions. Briefly, 5µg of genomic DNA was 
required, this was fragmented and hybridized to the custom designed capture array.  
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Unbound fragments were removed and the target-enriched pool was eluted and 
amplified. The enriched sample was then ready for high-throughput sequencing.   
 
A 472-fold enrichment of the targeted regions was achieved and sequencing was 
performed for one patient sample on one lane of an Ilumina platform using Solexa 
technology. SNPs, with a threshold coverage of at least 10 reads, were called and the 
results were checked against the Ensembl SNP database, release 54.  
 
This identified 680 variants from the 2009 human reference sequence (GRCh37/hg19) 
within the disease-linked loci only. It was hypothesized that the disease causing 
mutation would be novel so all variants with a minor allele frequency (MAF) > 0.01  
in any SNP database were removed. This reduced the number of potential variants to 
41 (Table 4.7). The mechanism of inheritance is almost certainly autosomal recessive 
given the inheritance pattern illustrated in the family tree (Figure 4.1). In addition, 
these patients are born within a genetically isolated population from highly 
consanguineous marriages. Therefore, heterozygous variants were excluded, leaving 9 
homozygous variants for further analysis (Table 4.8). This included 3 variants in 
MRAP; 1 in the 5’ untranslated region (UTR) in exon 2 (variant 7, Table 4.8), 1 
intronic variant (variant 9, Table 4.8) and 1 intergenic variant (variant 8, Table 4.8). 
Variant 9 was subsequently identified as a SNP (rs67001164) and variant 8 was 
located 3145 bases before exon 3, not near any putative promoter site of MRAP, and 
therefore both were deprioritised. Variant 7 in the 5’ UTR was sequenced but this 
variant did not segregate with disease in the families. 
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Table 4.6 Regions of homozygosity according to SNP genotyping.  
SNP name Position Patient 4 Patient 3 Patient 5 Patient 7 
Chrm 8      
rs725680 36800000 AB AB AB AA 
rs1455362 40200000 AB AB AB AA 
rs724322 40200000 AB AB AB AA 
rs726922 40200000 AB AB AB BB 
rs725401 40400000 AB AB AB AA 
rs721176 40500000 BB BB BB BB 
rs1073640 40600000 AA AA AA AA 
rs2127705 43200000 AA AA AA AA 
rs1603681 47400000 AA AA AA AA 
rs1384217 49700000 AA AA AA AA 
rs1383279 50300000 AA AA AA AA 
rs723497 50500000 BB BB BB BB 
rs2385545 50900000 AA AA AA AA 
rs1385982 50900000 AA AA AA AA 
rs1074385 50900000 AA AA AA AA 
rs1450127 51300000 AA AA AA AA 
rs310575 51600000 BB BB BB BB 
rs723597 51900000 AA AA AA BB 
rs723595 51900000 AA AA AA BB 
      
rs663747 61700000 AB AB BB AA 
rs1808634 62100000 AA AA AA AA 
rs745101 62100000 AA AA AA AA 
rs1367972 62200000 AB AB BB AA 
rs344288 63000000 BB BB BB BB 
rs344285 63000000 BB BB BB BB 
rs684872 63000000 AA AA AA AA 
rs622576 63000000 BB BB BB BB 
rs344214 63100000 BB BB BB BB 
rs1825310 63200000 BB  BB BB 
rs931130 63800000 AA AA AA AA 
rs2127561 63800000 BB BB BB BB 
rs965894 63800000 BB BB BB BB 
rs725329 63900000 AB AB AB BB 
rs1431587 64500000 AA AA AA BB 
rs1452488 64600000 AB AB AB AA 
      
chrm 4      
rs1073308 96200000 BB BB BB BB 
rs723367 96200000 AA AB AA  
rs965823 96300000 AA AB AA AB 
rs5003029 96400000     
rs1986598 96400000 AA AA AA AA 
rs1118570 96800000 AA AA AA AA 
rs1369980 97000000 BB BB BB BB 
rs1436532 97000000 BB BB BB BB 
rs1073690 97000000 BB BB BB BB 
rs997076 97200000 BB BB BB BB 
rs1911792 98700000 BB BB BB AB 
rs1111541 99300000 BB ? BB BB 
rs1881450 99700000 AA AA AA AA 
rs951299 99800000 BB BB BB BB 
rs1230151 100000000 AA AA AA AA 
rs1540053 100301200 AB AA BB AA 
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There were 6 additional variants in 6 different genes, with 3 of these variants in 
intergenic regions and 3 in intronic regions. There was no obvious coding variant that 
was most likely to cause disease, for example, a non-synonymous coding variant, 
coding insertion or deletion. 
 
Table 4.7 
 
Table 4.7 All novel variants identified using targeted exome sequencing. Variant ID (Var ID), 
Chromosome number (chrm), location of variant (var from), reference and variant nucleotide 
(ref nuc and var nuc) are detailed. Variant depth (var depth) describes the number of times the 
variant was sequenced and variant frequency (var freq) is the number of times the variant 
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nucleotide was called, determining if the variant is homozygous or heterozygous. The gene 
and consequence of the variant is also described. Those variants shaded in gray are 
homozygous variants.  
 
Table 4.8 
 Chrm Location Ref 
base 
Variant 
base 
Total 
depth 
Variant 
freq 
Gene Variant 
type 
1 8 39369387 A G 93 93 ADAM5P Intronic 
2 8 39560326 C A 58 58 ADAM19 Intergenic 
3 8 41873633 T G 31 31 ANK1 Intergenic 
4 8 42997668 T C 255 255 HOOK3 Intergenic 
5 8 42014233 G T 223 223 HGSNAT Intronic 
6 8 49036627 A G 255 255 MCM4 Splice 
site 
7 21 32587235 G A 199 199 MRAP UTR 
8 21 32590002 A G 24 24 MRAP Intergenic 
9 21 32595042 C T 255 255 MRAP Intronic 
 
Table 4.8 Novel homozygous variants identified in patient 4 by targeted exome sequencing. 
Chrm – chromosome; Ref base – reference base; Variant freq – variant frequence. 
 
However when the 3 intronic variants were analysed, 1 variant in mini chromosome 
maintenance-deficient 4 homologue (MCM4) was in the consensus splice site of exon 
2 of MCM4. Of the other intronic variants, 1 in ADAM5P at nucleotide 39369387 
(variant 1, Table 4.8) lies 50 bases downstream of exon 10 and was subsequently 
identified as a SNP (rs73612404); MAF 0.456), and the variant (variant 5, Table 4.8) 
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in HGSNAT was 45 bases 5’ to exon 4 and was also subsequently identified as a SNP 
(rs72647302;MAF 0.02) when the 1000 genome project database was examined. 
 
Therefore the only potential variant to be further examined was variant 6, c.71-1insG, 
a homozygous splice site mutation in the acceptor splice site of exon 2 of MCM4. 
This variant was within the region of homozygosity, in the pericentric region of 
chromosome 8 (Figure 4.3). 
 
Exon 2 of MCM4 including the intron/exon regions, was amplified by PCR and 
sequenced (Figure 4.4). This variant was also sequenced in the other 8 affected 
patients from the Irish Travelling community, their parents and unaffected siblings 
and demonstrated to segregate with disease (Figure 4.1). In kindreds A and C parents 
were heterozygous for the MCM4 variant and all siblings tested had either 
heterozygous or homozygous wildtype sequences, (parental and sibling samples were 
not available for kindred B). This variant was not present in SNP databases and was 
not seen in The 1000 Genomes Project (www.1000genomes.org) the NHLBI Exome 
sequencing Project (>10700 alleles sequenced; http://evs.gs.washington.edu/EVS/). 
300 Caucasian control chromosomes were also screened using a genotyping approach. 
PCR products for MCM4 exon 2 were digested by Alu1 restriction digest. Alu1 
cleaves the PCR product from a wild-type sequence once but does not cut the mutant 
sequence. Control samples gave rise to 2 bands following digestion, PCR products 
from DNA with c.71-1insG were not digested and remained as 1 band, and 
heterozygotes resulted in 3 bands. All control samples had homozygous wild type 
sequences. 
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Figure 4.3 
 
 
Figure 4.3 SNP genotyping of chromosome 8p12.2-q12.3 locus surrounding MCM4 
 
 
Figure 4.4 
A 
 
B  
 
 
Figure 4.3 A. Partial sequence chromatograms showing; the intron2/exon2 junction in 
genomic DNA from control, parent and patient samples (intronic bases in lowercase, exonic 
in uppercase). An arrow indicates the start of exon 2 of MCM4. B. The location of the 
mutation, c.71-1insG, prior to exon 2 (red arrow).  
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4.2.3 cDNA Sequencing 
This mutation was present in the 3’ splice site of intron 1, altering the consensus 
sequence, and would thus be predicted to disrupt splicing of exon 2, potentially by 
shifting the splice acceptor site upstream by 1 nucleotide and leading to a frameshift 
and a foreshortened open reading frame encoding a prematurely terminated 
translation product (p.Pro24ArgfsX4). However, the true significance of the mutation 
cannot be established from DNA sequencing or prediction websites. To identify the 
consequences of this mutation, blood was taken from patient 1, patient 2, and an 
unaffected sibling control in kindred 3 (Figure 4.1) and RNA was extracted. Briefly, 
total RNA from patient and control leucocytes was purified and cDNA synthesised 
using reverse transcription as described in Methods, Section 2.5. The cDNA was used 
as a template for PCR amplification and sequencing of MCM4 exons 2-4. 
 
Sequencing confirmed that this mutation did affect splicing by shifting the splice 
acceptor site by one base and incorporating an extra guanine into the mRNA 
transcript (Figure 4.5A). This results in a foreshortened open reading frame and a 
predicted prematurely terminated translation product (p.Pro24ArgfsX4) (Figure 4.5 B, 
C and D) of only 27 amino acids. Parents had a mixed cDNA sequence with evidence 
of both wild type and mutant sequences present. This verified that the splice site 
mutation identified in MCM4 was pathological, leading to a truncated protein and 
confirming this variant in MCM4 as the disease-causing mutation. 
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Figure 4.4 
A 
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Figure 4.4 A. Partial sequence chromatograms showing; the intron2/exon2 junction in 
genomic DNA from control, parent and patient samples (as above). Arrows indicate the base 
change from A to G and (right) cDNA from control, parent and patient indicating wild-type, 
mixed and mutant cDNA sequences respectively, the latter resulting in a premature stop 
codon.  B. The location of the mutation, c.71-1insG, prior to exon 2 (red arrow) which leads 
to a shift in the consensus splice site (nucleotides ag in red) and the introduction of an extra G 
into patient mRNA/cDNA is indicated.  C. Protein structure of MCM4 indicating (top) the 
positions of the two CDK (cyclin dependent kinase) binding domains, zinc finger (turquoise), 
Walker A&B motifs (purple) and an arginine ring finger (dark blue), these motifs are 
conserved across all MCMs and are essential for MCM4 functionality. Also indicated are 4 
in-frame methionines (M).  D. The predicted consequence of the c.71-1insG mutation leading 
to premature truncation of the protein at amino acid 27 (p.Pro24ArgfsX4) is shown. 
 
4.3 Discussion 
Homozygosity mapping identified three regions of homozygosity common to all 
genotyped patients totalling 21.5 Mb. Genes were prioritised for sequencing by 
selecting those that appeared to be good candidates for FGD based on known gene 
function. These criteria identified only two potential genes, STAR and VDAC3, which 
both had normal sequences. The original plan was then to select those genes that 
showed highly adrenal specific expression and use a novel screening approach based 
on siRNA knockdown of candidates in adrenal cells. However candidates could not 
be filtered further as no genes showed adrenal specificity. This approach was 
therefore not feasible given the large number of potential candidate genes identified 
within the loci.  In addition it was possible that some candidate genes may not 
influence the immediate ACTH signaling response and would therefore resist 
identification using the proposed knockdown screen.   
 
In 2009 massively parallel sequencing was being successfully applied to discover 
genes for rare Mendelian disorders. In a milestone proof-of-concept paper, Ng et al. 
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showed that targeted whole exome sequencing, followed by a filtering approach 
(Figure 4.6), correctly identified the known disease gene involved in Freeman 
Sheldon syndrome  [123]. The same group then went on to show that exome 
sequencing could identify the gene underlying an uncharacterised Mendelian disorder, 
Miller syndrome, using the same strategy [124]. 
 
This approach uses targeted exome capture through enrichment by array hydridization 
to 164,000 targets used to define the exome followed by sequencing using massively 
parallel platforms. There are a number of different technologies available including 
454, Solexa and SOLiD technology [125, 126].  
 
454 technology with pyrosequencing utilizes adapters which are ligated to fragments 
of DNA and facilitate their capture on a bead (one fragment per bead). A water-in-oil 
emulsion is created to amplify each fragment individually in its droplet, after 
amplification the emulsion is broken, the DNA denatured and the beads containing 
one amplified DNA fragment each are distributed into the wells of a fiber optic slide. 
The wells are loaded with sequencing enzymes and primer (complementary to the 
adapter on the fragment ends), then exposed to a flow of one unlabeled nucleotide at a 
time, allowing synthesis of the complementary strand of DNA. When a nucleotide is 
incorporated pyrophosphate is released and converted to ATP, which drives a 
luciferase-based reporter. The read length is between 100-150 nucleotides long.  
 
Solid technology (ABI) also involves ligation of adapters to fragments of DNA 
followed by amplification on beads by emulsion PCR. The DNA is denatured and 
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beads deposited onto a glass slide. A sequencing primer is hybridized to the adapter 
and reads of 30-35 nucleotides are created using a sequencing-by-ligation technique. 
 
Figure 4.5 
 
Figure 4.5 Filtering strategy applied in exome sequencing. (Taken from Nature Genetics 
Biesecker, January 2010 [126]) 
 
For our sequencing Solexa technology from Ilumina was employed. For this 
fragments of DNA are ligated to end adapters, denatured and bound at one end to a 
solid surface that has been coated in a dense layer of adapters. Each single stranded 
fragment is immobilized at one end while its free end hybridizes to a complementary 
adapter on the surface. This adapter initiates synthesis of the complementary strand in 
the presence of amplification reagents. Multiple cycles of this solid phase 
amplification followed by denaturation create clusters of approximately 1000 copies 
of single stranded DNA molecules on the surface. Synthesis reagents, primers, DNA 
polymerase and four differently labeled reversible terminator nucleotides are added to 
the flow cell. Synthesis of the complementary strands involves incorporation of each 
nucleotide in sequence and identification by its colour before the 3’ terminator and 
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fluorophore are removed. The cycle is continually repeated giving a read length of 
approximately 30-35 bases [125, 127]  
 
This technology allowed us to sequence all the protein coding regions in the 
associated areas of homozygosity and identified a splice site mutation in MCM4 as the 
only potential disease causing mutation. This mutation segregated with disease within 
three kindreds and was not present in over 11,000 control chromosomes sequenced. I 
confirmed that this splice site mutation was pathological giving rise to an abnormal 
mRNA sequence that is predicted to be translated into a truncated protein with 
potentially significant functional effects.   
  
MCM4 is one part of the MCM2-7 complex that is essential for normal DNA 
replication and genome stability (Figure 4.7). It has recently been confirmed as the 
replicative helicase and therefore plays an essential role in cell division. The MCM 
(mini chromosome maintenance) proteins were originally identified and subsequently 
named from a screen for Saccharomyces cerevisiae (budding yeast) mutants that led 
to defects in maintaining a simple minichromosome. The MCM genes MCM2, 
MCM3 and MCM5 were first identified as causing defective plasmid segregation. 
MCM4 (originally CDC54), along with MCM7, were isolated as cell cycle division 
mutants and MCM6 was isolated as a chromosome segregation mutant in 
Schizosaccharomyces pombe (fission yeast) [128, 129]. Each MCM gene is essential 
for viability and many experiments have demonstrated the key involvement each 
protein plays in DNA replication. MCMs are found in both eukaryotes and archea but 
have not been identified in bacteria, although many bacteriophage genomes do 
contain MCM orthologues [130].  
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MCMs are a distinct subgroup of the large AAA ATPase family, these generally form 
large ATP-dependent complexes, often heterohexamers, and have many cellular 
functions. MCM2-7 are defined by a characteristic version of the ATPase domain 
which spans approximately 200 residues and is named the MCM box. This MCM box 
is highly conserved throughout the MCM family and includes 2 ATPase consensus 
motifs, the Walker A and Walker B motifs (Figure 4.5C). The Walker A motif 
GDPxx(S/A)KS, is involved in ATP binding. The Walker B motif, D(D/E), is part of 
the sequence IDEFDKM which is conserved throughout all MCMs and is required for 
ATP hydrolysis. All MCMs also contain an “arginine finger” (SRFD) and a “zinc 
finger” which is thought to contribute to complex assembly and ATPase activity 
[131]. MCM2-7 show less homology outside this MCM box; MCM4 from humans is 
more similar to MCM4 in yeast than MCM2 in humans [132]  
 
The heterohexameric complex of minichromosome maintenance proteins MCM2-7 
plays an essential role in origin licensing in all eukaryotes. Origin licensing builds a 
fundamental basis for genome stability in DNA replication. MCM2-7 is recruited to 
replication origins by Cdt1 as an essential component of the pre-replication complex, 
which is assembled from late M to early G1 phase of the cell cycle (Figure 4.7). This 
complex also includes the origin recognition complex (Orc1-6) and Cdc6, additional 
AAA ATPase proteins. These origins are then licensed for DNA synthesis, ensuring a 
single initiation of DNA synthesis from MCM bound origins in the subsequent S 
phase thus restricting genome replication to once per cell cycle. Once the MCM 
proteins are loaded onto the DNA, Orc1-6 and Cdc6 are no longer required and are 
released for subsequent cycles of DNA replication [130]. 
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DNA unwinding is an active process that requires coupling the conformational 
changes caused by nucleotide binding and hydrolysis to the physical manipulation of 
nucleic acids. In the event of DNA damage, insufficient dNTPs or an unusual DNA 
sequence, DNA replication forks can be damaged leading to DNA double strand 
breaks and chromosome rearrangements. This activates checkpoints that block further 
DNA replication, cause cell cycle arrest which leads to stabilisation of DNA – protein 
interactions until the problem is rectified. This stabilisation of the replication fork 
requires interaction with Mrc1, Tof1 and Csm3 (the M/T/C complex) [130].  
 
MCM2-7 has also recently been identified as the replicative helicase activated by S 
phase promoting kinases such as cyclin dependent kinases (CDKs) and Dbf4-
dependent kinase (DDK) (Figure 4.7 C). CDK and DDK both control origin firing but 
CDK appears to provide the link to the cell cycle. Following activation additional 
proteins are loaded onto DNA at the sites of replication, these include Cdc45, the 
GINS complex and MCM10 [133-135]. The function of these replication factors 
remains unknown. Finally DNA polymerase is loaded and bidirectional DNA 
synthesis can commence. All 6 MCMs colocalise with DNA polymerase during 
elongation. Inactivation of any of the MCMs during S phase rapidly blocks DNA 
replication [136]. 
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Figure 4.6 
 
 
Figure 4.6 (Taken from Bochman et al. Microbiology and molecular biology reviews dec 
2009) MCM involvement in eukaryotic DNA replication initiation and elongation.  
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The eukaryotic helicase MCM2-7 is a heterohexamer containing 6 distinct and 
essential subunits. The heterohexameric complex is completely conserved among all 
eukaryotes implying the 6 subunits are all of functional importance. There are 
different hypotheses to explain this, firstly that the active AAA ATPase sites are 
biochemically equivalent but the divergent N and C termini in each subunit have 
different functions. Alternatively the 6 subunits may be catalytically distinct and 
contribute differentially to the DNA unwinding. This latter hypothesis is currently 
favoured as the same mutation within the active site in different subunits leads to 
different phenotypes [130]. However it is now apparent that MCMs do have many 
functions beyond replication. There is an abundance of MCMs over and above the 
quantity required to licence DNA replication origins and function as the replicative 
helicase. They are also widely distributed in regions outside of replicating DNA. This 
has lead to the suggestion that MCMs may affect transcription and influence the 
epigenetic code by modifying chromatin remodeling. 
 
Although the heterohexamer MCM2-7 has been identified as the replicative helicase, 
the dimeric heterotrimer MCM4/6/7 has been shown to exist as a subcomplex that 
exhibits helicase activity in vitro which is inhibited by the addition of MCM2 or the 
MCM5/3 dimer. This suggests that MCM4, MCM6 and MCM7 are needed for 
helicase activity but MCM2, MCM3 and MCM5 act as negative regulators in vitro. 
However in vivo it appears that active sites contributed by MCM4, MCM6 and 
MCM7 are largely required for ATP hydrolysis, ssDNA binding and helicase activity 
while MCM2, MCM3 and MCM5 play a secondary role possibly involving the 
coordination of ATP hydrolysis with DNA unwinding [131].  
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MCM4 has been shown to have a number of independent functions within the 
MCM2-7 complex. DDK phosphorylation of MCM4 has been shown to assist Cdc45 
loading [137]. Consensus sites for CDKs are found in most MCM4 families and CDK 
phosphorylation of MCM4 is required for S-phase initiation however MCM4 
phosphorylation appears to have many different functions and effects. 
Phosphorylation of human MCM4 occurs at numerous N-terminal serines and 
threonines including Ser-3, -32, -54 and -88 and Thr-7, -19 and -110. Phosphorylation 
by CDK1 and CDK2 at these sites in HeLa cells has been shown to vary with the cell 
cycle [138]. Phosphorylation is greatly enhanced in the G2 and M phases at sites Thr-
7, -19, Ser-32, -54, -88 and Thr-110 whereas phosphorylation of Ser-3 is detected 
only during the interphase. Phosphorylated MCM4 exhibits different affinities for 
chromatin; MCM4 phosphorylated at sites 3 and 32 was not generally colocalized 
with replicating DNA; MCM4 phosphorylated at site 32 was enriched in the nucleolus 
throughout the cell cycle. In general, hypophosphorylation of MCM2, MCM3 and 
MCM4 correlates with MCM chromatin binding, however mutation of CDK sites in a 
single MCM, at least in yeasts, is not sufficient to disrupt replication control, 
indicating the presence of multiple levels of redundant control [131]. In vitro studies 
indicate that CDK-dependent phosphorylation of MCM4 also disrupts the helicase 
activity of the MCM2-7 complex. MCM4 has also been postulated to be the target of 
the checkpoint kinase pathway in response to replication arrest [139]. Taken together 
these data suggest that phosphorylation of MCM4 may have several distinct and site-
specific roles in the function of DNA replication during the mammalian cell cycle.   
 
A viable mutant allele of Mcm4, Chaos 3 (chromosome aberrations occurring 
spontaneously 3), was identified in a forward genetic screen used to discover potential 
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novel genes involved in chromosomal instability and therefore potentially associated 
with cancer risk. This screen utilizes chemical mutagenesis using N-ethyl-N-
nitrosourea (ENU), an alkylating agent that acts by transferring the ethyl group of 
ENU to nucleobases (usually thymine) in nucleic acids. This agent is a highly potent 
mutagen and can produce a mutation rate as high as 1.5x10-3 in mouse spermatagonial 
cells [140]. ENU produces point mutations and can be used to isolate both dominant 
and recessive mutations that lead to chromosomal instability. Micronuclei can arise 
from acentric chromosome fragments or whole chromosomes that have not been 
incorporated in the main nuclei at cell division and therefore act as a measure of in 
vivo chromosomal damage [101]. Flow cytometry is a high-throughput assay that 
measures micronucleus formation by exposing cells to anti-CD71, which specifically 
labels micronucleated reticulocytes allowing their detection, and therefore is a proxy 
measure of chromosomal instability induced by potential mutagens. This screen 
identified Chaos 3 as a mouse chromosome instability mutation [101] 
 
Mcm4 Chaos 3 encodes a mutation in an evolutionarily invariant amino acid (F345I). 
Heterozygote mice show mildly elevated (2 - 5 fold) micronucleus frequencies 
compared to wild type animals. Homozygotes show a significant increase with over 
7% of erythrocytes containing micronuclei. The authors created the corresponding 
allele in budding yeast and showed a minichromosome loss phenotype. Mcm4 null 
mutations are lethal; homozygosity for a disrupted Mcm4 allele (MCM4-) results in 
pre-implantation lethality. However, Mcm4Chaos3/- embryos died late in gestation 
indicating Mcm4Chaos 3 is hypomorphic. Initially, Mcm4Chaos3/Chaos3 mice were fertile 
and overtly indistinguishable from wild type littermates apart from the increased 
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micronucleus formation. However, more than 80% of females subsequently died due 
to mammary adenocarcinomas, with a mean latency of 12 months [141].  
 
It is clear that any mutation in MCM4 is likely to have significant phenotypic 
consequences given its essential role in DNA replication and genome stability. The 
mutation identified in the patient cohort was predicted to give rise to a foreshortened 
open reading frame and a prematurely terminated protein of only 27 amino acids, 
effectively abolishing all MCM4 function. Loss of function MCM4 mutations been 
shown to be incompatabile with survival in eukaryotes and therefore if the MCM4 
mutation identified here is indeed the causative mutation then the patients must be 
able to adapt in some way, possibly utilising an alternative transcriptional or 
translational start site down stream of the mutation. The results from experiments 
designed to investigate this are described in Chapter 5.   
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Chapter 5: Investigation of MCM4 protein production in patients 
 
5.1 Introduction  
MCM4, as part of the heterohexameric complex MCM2-7, is a fundamental 
contributor to the integrity of the eukaryotic genome. A mutation that effectively 
abolishes MCM4 function would be predicted to be lethal in every eukaryotic system, 
therefore raising the intriguing question as to how these patients are able to survive.  
 
5.2 MCM4 transcripts 
Ensembl and UCSC were examined for alternative transcripts that may be unaffected 
by this mutation. There are 9 protein coding transcripts but only 3 MCM transcripts 
that include all functional domains of MCM4, MCM4-004 (ENST00000523944), -
001 (ENST00000262105) and -003 (ENST00000396826) (Figure 5.1). Two of these 
transcripts are merged Ensembl/Havana (Sanger) transcripts that are also consensus 
coding sequences (CCDS); MCM4-004 (CCDS6143) and -001 (CCDS6143). This 
database is a collaborative effort to identify a core set of human and mouse protein 
coding regions that are consistently annotated and of high quality.  
 
All three transcripts would be similarly affected by the splice site mutation identified, 
producing a prematurely terminated protein (illustrated in Figure 4.5). Transcripts 
MCM4-004 and -001 have slightly different N-terminal untranslated regions but start 
from the same initiating methionine and have the same protein sequence. Transcript 
MCM4-003 has a different mRNA sequence with 39 bases noted as intronic rather 
than exonic giving rise to an in-frame deletion of 13 amino acids (Figure 5.2 A and 
B). However this protein would be affected similarly to transcript -004 and -003 with 
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the mutation leading to a prematurely terminated protein. I could not detect any 
cDNA sequence consistent with MCM4-003 in patient or control samples (Figure 
5.2C) 
 
Figure 5.1 
 
 
Figure 5.1 Schematic diagram showing all annotated MCM4 transcripts from the Ensembl 
database (www.ensembl.org). Red; protein coding, yellow; merged Ensembl/Havana, Blue; 
processed transcript. 
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Figure 5.2 
A. MCM4-001/MCM4-004 
  
...GTACTCCGAGCACTATGTCGTCCCCGGCGTCGACCCCGAGCCGCCGCGGCAGCCGGCGTG 
GAAGGGCCACCCCCGCCCAGACGC                                                             
gtgagtcccccgagccgggcccactacagcccccggcgccgccccgtctgccctctcgcc 
..............................aatccaggaaggccggccctgaaagttaat 
ggctgtcttttctgttttgtgtgacacaag                                                           
CTCGGAGTGAGGATGCCAGGTCATCTCCCTCTCAGAGACGTAGAGGCGAGGATTCCACCT 
CCACGGGGGAGTTGCAGCCGATGCCAACCTCGCCTGGAGTGGACCTGCAGAGCCCTGCTG 
CGCAGGACGTGCTGTTTTCCAGCCCTCCCCAAATGCATTCTTCAG                                                            
gtgcgtgtctgaagatcttggttttgctgtgcttgatacacagctgatgctttatctgct 
..............................caacatgctgtaatttcaggtttgatatgc 
caccagaatttcctaattttgtttttatag                                                            
CTATCCCTCTTGACTTTGATGTTAGTTCACCACTGACATACGGCACTCCCAGCTCTCGGG 
TAGAGGGAACCCCAAGAAGTGGTGTTAGGGGCACACCTGTGAGACAGAGGCCTGACCTGG 
GCTCTGCACAGAAGGGCCTGCAAGTGGATCTGCAGTCTGACGGG                                                            
gtgagtatgcagtctcctgaaaccatcttatggcgggtatcatgtgggtaactctgtttt 
catgattctgtcatgtttttctgtgtag 
 
B. MCM4-003 
...GTACTCCGAGCACTATGTCGTCCCCGGCGTCGACCCCGAGCCGCCGCGGCAGCCGGCGTG 
GAAGGGCCACCCCCGCCCAGACGC                                                            
gtgagtcccccgagccgggcccactacagcccccggcgccgccccgtctgccctctcgcc 
..............................aatccaggaaggccggccctgaaagttaat 
ggctgtcttttctgttttgtgtgacacaag                                                        
CTCGGAGTGAGGATGCCAGGTCATCTCCCTCTCAGAGACGTAGAGGCGAGGATTCCACCT 
CCACGGGGGAGTTGCAGCCGATGCCAACCTCGCCTGGAGTGGACCTGCAGAGCCCTGCTG 
CGCAGGACGTGCTGTTTTCCAGCCCTCCCCAAATGCATTCTTCAG                                                           
gtgcgtgtctgaagatcttggttttgctgtgcttgatacacagctgatgctttatctgct 
..............................caacatgctgtaatttcaggtttgatatgc 
caccagaatttcctaattttgtttttatag                                                            
CTATCCCTCTTGACTTTGATGTTAgttcaccactgacatacggcactcccagctctcgggtag                                                            
AGGGAACCCCAAGAAGTGGTGTTAGGGGCACACCTGTGAGACAGAGGCCTGACCTGGGCT 
CTGCACAGAAGGGCCTGCAAGTGGATCTGCAGTCTGACGGG                                                            
gtgagtatgcagtctcctgaaaccatcttatggcgggtatcatgtgggtaactctgtttt 
catgattctgtcatgtttttctgtgtag 
 
C. 
 
Figure 5.2 A. Transcript MCM4-001/-004. B. Transcript MCM4-003. Bases noted as intronic 
in MCM4-003 but exonic in MCM4-004 and -001 are highlighted in yellow. Upper case; 
exons, lower case; introns, purple; untranslated. C. Sequencing of patient cDNA confirming 
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transcript -001 /-004 is identified in patient sample – exonic region not present in transcript 
003 highlighted. 
 
5.3 MCM4 protein in patient and control lymphocytes and human cell lines 
Cell lysates from control and patient populations were then examined to try to identify 
if MCM4 protein was absent from patient cells. Peripheral mononuclear cells were 
extracted from whole blood using a gradient density centrifugation technique as 
described in detail (section 2.6 materials and methods). These cells, including 
lymphocytes (T cells, B cells and NK cells), monocytes and macrophages, were 
washed, lysed and the supernatant added to an equal volume of loading buffer.  
 
Cell lysates from patients and unaffected human controls were immunoblotted for 
MCM4, using a polyclonal C-terminal anti-MCM4 antibody (Abcam) that was raised 
against the exon 14 peptide sequence. This identified two major proteins migrating at 
approximately 96kDa and 90kDa, the smaller 90 kDA protein appearing to run as a 
doublet in some samples (Figure 5.3). Patient samples showed only one major MCM4 
species at 90kDa (Figure 5.3A and B). Cell lysates from the human cell lines, 
HEK293 (human kidney cell line), H295R (human cancer adrenal cell line) and 
SHSY5Y (human neuroblastoma cell line) were also immunoblotted using the same 
MCM4 antibody. In these images it is easier to visualise the 2 separate smaller 
MCM4 isoforms present (Figure 5.3C). 
 
To confirm that the faster migrating bands seen on immunoblotting with MCM4 
antibody were MCM4 isoforms and not non-specific bands a different MCM4 
antibody was used but unfortunately this gave rise to multiple non-specific bands and 
so was not helpful. Therefore small interfering RNAs (siRNAs) designed against 
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MCM4 were used in an effort to cause depletion of both wild type full length MCM4 
and also the smaller putative MCM4 isoforms. siRNAs s69687 and s8592 (Applied 
Biosystems) that specifically target MCM4 at exon 5 and exon 12 respectively were 
transfected at concentrations of 50nM into HEK293T cells, as a control a scrambled 
siRNA was transfected into HEK293T cells.  After 48 hours the cells were harvested 
and cell lysates were immunoblotted for MCM4. The MCM4 specific siRNA leads to 
reduced expression of both full length wild type MCM4 and also the smaller MCM4 
isoforms suggesting that this band is indeed MCM4 and not a non-specific artefact 
(Figure 5.4). Cell lysates were also immunoblotted for β-Actin as a loading control. 
 
Figure 5.3 
 
C 
 
Figure 5.3 Cell lysates from both control and patient lymphocytes show evidence of MCM4 
protein. A and B. Lysates from patient and control human lymphocytes were immunoblotted 
with an anti- MCM4 antibody. Whilst control subjects have two main protein species of 
approximately 96 and 90kDa, the predicted full-length 96kD product is missing in the 
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patients. There is also a faster migrating band present in some control and patient samples that 
is approximately 75kDa. C. Lysates from human cell lines show evidence of 3 MCM4 
species, with 2 smaller MCM4 isoforms present. 
 
Figure 5.4 
 
Figure 5.4 siRNA targeted to exon 12 of MCM4 shows depletion of both 96kDa isoform and 
the smaller MCM4 isoforms at approximately 90kDa. 
 
5.4 Translation of MCM4 can occur from an alternative downstream methionine 
As discussed above there is no alternative splice variant reported that would explain 
these smaller MCM4 species. I hypothesized that alternative translational start sites 
may be present to explain the 2 smaller isoforms of MCM4 present in patient samples.   
Expression vectors for C-terminally HA-tagged full length MCM4 and MCM4 in 
which the initiating methionine codon was abolished by site-directed mutagenesis 
(M1X) were transiently transfected into HEK293 cells and the cell lysates were 
immunoblotted with both HA and MCM4 antibodies. M1X expression resulted in a 
smaller MCM4 species of approximately 90kDa that also appeared to be a doublet 
and that corresponded in size to that seen in control samples indicating that the shorter 
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forms seen could arise by alternative initiation of translation from a downstream 
initiating methionine codon (Figure 5.5). 
 
Figure 5.5 
 
Figure 5.5 HEK293 cells were transfected with full length MCM4 or MCM4 with the first 
methionine mutated, both of which were tagged with a C-terminal HA tag. The lysates were 
then blotted with both MCM4 antibody (left panel) and HA antibody (right panel). Abolition 
of the initiating methionine of MCM4 leads to expression of a smaller MCM4 species of 
approximately 90kDa detected using the HA antibody (right panel). In the left panel please 
note the full length MCM4 at 96kDa detected in cells that have been transfected with MCM4 
with the first methionine mutated (M1X) is endogenous MCM4. 
 
There are multiple in-frame methionines down stream of the initiating methionine 
(M1); the first 2 down stream methionines would produce 2 proteins of approximately 
the correct size. The protein from the second methionine (M2) at amino acid position 
51 (exon 2) has a predicted molecular weight of 91 kDa, the protein from the third 
methionine (M3) at amino acid position 75 (exon 2) has a predicted molecular weight 
of 89 kDa. This small difference in size correlates to the small difference in size seen 
in all blots. Both M2 and M3 are also C-terminal to the mutation and would therefore 
be unaffected by the insertion (Figure 4.5). The third downstream in-frame 
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methionine at position 194 (exon 5) produces a protein of approximately 75 kDa, 
which is too small to be either of the isoforms seen consistently in patient and control 
samples but may explain the smaller MCM4 protein seen intermittently in patient and 
control lymphocytes (Figure 5.3B). 
 
5.5 MCM4 isoforms identified in cell lysates correspond in size to MCM4 
constructs beginning from the 1st, 2nd, 3rd and 4th in-frame methionines. 
cDNAs encoding MCM4 isoforms beginning at the 1st (described above), 2nd, 3rd and 
4th in-frame methionines were generated by PCR and then inserted into the triple 
FLAG expression vector. These constructs were transiently expressed in HEK293 
cells, the cell lysates collected and immunoblotted. The 1st 2nd and 3rd in-frame 
methionines produced proteins corresponding in size to those seen in vivo suggesting 
that the faster migrating proteins observed in patients may result from internal 
initiation from the second and third in frame ATG (Figure 5.6A). The 4th in-frame 
methionine gives rise to a much smaller protein of approximately 75kDa as expected, 
however this isoform may be present in some patient and control samples (Figure 
5.3B and 5.6B).  
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Figure 5.6 
A. 
 
B 
 
Figure 5.6 A. Flag-tagged full length MCM4 and constructs beginning at the second and third 
in frame ATGs were expressed in HEK293 cells. Lysates from each were run individually 
(lanes1-3), altogether (lane 4) or in combination with the full length and 3rd ATG (lane 5) 
and immunoblotted using an anti-FLAG antibody. The relative mobility of the different 
species indicates that the smaller MCM4 species may be produced by translation from the 2nd 
and 3rd in frame ATG.    
B. Flag-tagged full length MCM4 and constructs beginning at the 4th in frame ATG were 
expressed in HEK293 cells. Lysates from wild type cells, cells with FLAG-full length MCM4 
and FLAG-4th ATG MCM4 were each run individually (lanes1-3), and immunoblotted using 
an anti-FLAG and anti-MCM4 antibody. The relative mobility of the different species 
indicates that the smaller MCM4 species is too small to be due to internal initiation from the 
4th in-frame ATG. Similarly to Figure 5.5, the right hand panel immunoblotted with MCM4 
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identifies endogenous MCM4 in cells that are transfected with an MCM4 construct beginning 
at the 4th in frame ATG but this is not identified when immunoblotting with the FLAG 
antibody. 
 
5.6 Smaller MCM4 isoforms lack the N-terminus 
The smaller protein isoforms were also seen in a number of human cell lines (Figure 
5.3B) but was not detected by immunoblotting with an N-terminal antibody for 
MCM4 suggesting this smaller MCM4 protein lacks the N-terminus (Figure 5.7). The 
N–terminal antibody (Santa Cruz) is targeted to the first 300 amino acids of MCM4.  
 
Figure 5.7 
 
Figure 5.7 Different cell lysates show evidence of both the major full length and smaller 
MCM4 isoforms when immunoblotted with the MCM4 C-terminal antibody.  However when 
the same lysates are immunoblotted with the N-terminal antibody the smaller MCM4 
isoforms are no longer seen suggesting that the smaller isoforms lack the N-terminus of 
MCM4. 
 
5.7 Discussion 
These experiments demonstrate the loss of the 96kDa MCM4 isoform in patients 
confirming the loss of translation of full length, wild type MCM4 protein. This is 
likely to be due to the frameshift introduced by the extra guanine incorporated into the 
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mutant mRNA (c.71-1insG).  As predicted, given the essential requirement of MCM4 
in DNA replication, the patients show evidence of alternative translation and slightly 
smaller MCM4 isoforms are present in cell lysates. Additional smaller isoforms have 
been reported in some previous work on MCM4 [142] but in other MCM4 papers the 
western blots are cropped to show only the full length MCM4. In one paper by 
Chuang et al. it is apparent there are additional bands below the wild type (Figure 1 A 
of their paper) but this is not completely clear as again the blot is cut just at this point 
[102]. Although I could not use alternative MCM4 antibodies to confirm these 
proteins were MCM4 specific, siRNA targeted to exon 12 of MCM4 shows depletion 
of wild type 96 kDa isoforms as well as the smaller isoforms indicating that these are 
indeed MCM4 and not nonspecific artefacts. 
 
There are no alternative cDNA transcripts present that could explain these proteins 
and so alternative translational start sites downstream of the mutation were examined.  
When the initiating methionine in MCM4 is mutated alternative translation can occur 
giving rise to two slightly smaller MCM4 isoforms of approximately the same size as 
those seen in patients and control cell lines. This suggests that these smaller isoforms 
are indeed from internal initiation from downstream methionines. 
 
Initially it was felt that the MCM4 doublet observed in the immunoblot of patient and 
control leukocytes may be due to a post translational modification of one MCM4 
isoform, for example phosphorylation, as there is evidence for multiple 
phosphorylation sites on MCM4 [131, 142]. However the FLAG-tag experiment 
illustrates that the difference in size between MCM4 from the first methionine and 
MCM4 from the 2nd and 3rd methionine is similar to the difference in size between 
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the 3 isoforms seen in control samples therefore suggesting that the MCM4 isoforms 
seen in patient samples may be due to internal initiation from the second and third in-
frame methionines. Furthermore an N-terminal MCM4 monoclonal antibody that was 
raised against the first 300 amino acids of MCM4 does not detect the smaller isoforms 
indicating that they are missing this N-terminal epitope of MCM4. This is consistent 
with the location of the mutation and the alternative translational start site 
downstream, producing proteins missing the N-terminus. Taken together, these 
studies strongly suggest that the smaller MCM4 species arise from internal initiation.  
 
As Mcm4 knockout in animals is lethal it is likely that the smaller MCM4 isoform 
rescues the patients from a lethal phenotype, ie the full length isoform is required for 
adrenal cortisol production but alternative isoforms are sufficient for alternate 
functions and to be compatible with life. In this regard it is important to note that both 
proposed proteins starting from amino acids 51 and 75 contain all the essential 
conserved C-terminal domains required for canonical MCM4 function including the 
200 residue “MCM box” which includes the Walker A and B domains and the zinc 
and arginine fingers.  
 
Single missense mutations in MCM4, eg Chaos 3 homozygous mice, in eukaryotic 
systems can lead to a severe phenotype. It is therefore surprising that a protein 
missing 51 or 71 amino acids is compatible with survival. However the mutations 
studied are generally in conserved areas that are functionally essential. The N-
terminus of MCM4 is not well conserved. It is defined as the first 198 amino acids 
and studies have revealed that deletion of the first 130 amino acids is not lethal in 
eukaryotic cells [143]. Masai et al. investigated the function of N-terminally truncated 
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MCM4 mutants. They generated truncation mutants lacking the first 67, 130, 150 or 
200 amino acids of MCM4 protein in fission yeast cells. The -67 and -130 truncated 
mutants were able to function normally but the -150 mutant showed a reduced growth 
rate and the -200 mutant was not viable. The residues conserved in MCM4 start at 
position 158 suggesting that the -200 mutant is lacking some essential conserved 
residues required for MCM4 function.   
 
This group also investigated the function of the N-terminal domain of MCM4. The 
initiation of DNA replication is strictly controlled by G1 cell cycle signals that are 
activated or suppressed by extracellular growth or differentiation signals respectively. 
The G1 cell cycle signals regulate Cdk-cyclins and ultimately protein kinases. Cdc7-
Dbf4 is among those activated by G1 signals and is known to play a critical role in the 
activation of DNA replication origins. The N-terminal region of MCM4 is highly 
enriched for serine/threonine residues including specific (S/T)(S/T)P clusters. Masai 
et al. showed that specific residues in the MCM4 N-terminal segment can be 
phosphorylated by Cdc7 kinase in vivo and in vitro. They showed that both Cdc7 and 
Cdk phosphorylate MCM4 and that Cdc7 stimulates loading of Cdc45 onto the 
chromatin through phosphorylation of the N-terminus of MCM4. Although the N-
terminus is not well conserved throughout species, multiple (S/T)(S/T)P clusters are 
found in many species suggesting that Cdc7-phosphorylation of the MCM4 N- 
terminal domain and its role in recruitment of Cdc45 may be conserved throughout 
evolution. Cdc45 plays a crucial role in the initiation of DNA replication suggesting 
that phosphorylation of MCM4 is a key event for activation of replication origins. 
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MCM2 and MCM6 also contain putative phosphorylation sites in their N-terminal 
domains. Mutation or deletion of these sites in just one MCM has no effect, but 
deletion in all 3 MCMs results in loss of viability. Taken together this suggests that 
phosphorylation of MCM2, MCM4 or MCM6 plays functionally important but 
potentially redundant roles in recruitment of replication factors including Cdc45 onto 
the chromatin. In contrast it has been reported that Cdc2 phosphorylates the chromatin 
free forms of MCM4 through its N-terminus during the G2/M stages of the cell cycle 
to prevent re-association with chromatin [144]. This role, which has not been shown 
to be replicated by MCM2 or MCM6, is a potentially important method of regulation, 
limiting DNA replication to once per cell cycle and preventing abnormal re-
replication.  
 
This provides a hypothesis that patients expressing only N-terminally truncated 
MCM4 isoforms lacking either the first 51 or 75 amino acids may be able to survive 
by utilising usually redundant phosphorylation sites on MCM2 and MCM6. However, 
the loss of the optimum phosphorylation sites on MCM4 would clearly have an effect 
on cell cycle regulation and most likely initiation of DNA replication. Patients could 
also have potentially lost an important mechanism of regulation that helps to limit 
initiation of DNA replication to once per cell cycle. Together these defects are likely 
to have substantial effects on patient cells including interfering with origin licensing, 
causing cell cycle defects and chromosomal damage such as breaks and gaps, all 
simultaneously leading to replication stress and genomic instability. This is evident in 
patients; lymphocytes treated with diepoxybutane show increased levels of 
chromosomal fragility compared to wild type controls. This is clearly of concern for 
the patients future health as genomic instability has been shown to lead to increased 
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incidence of cancer both in animal models with MCM4 defects and in humans who 
have other disorders of DNA replication [141, 145, 146]. 
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Chapter 6: Adrenal histology in a MCM4 depleted mouse model, Mcm4Chaos3/- 
Mcm3-/+ 
6.1 Introduction 
MCM4 is a ubiquitously expressed protein that forms the pre-replication complex 
together with MCM2-7, the origin recognition complex proteins ORC 1-6, CDT1 and 
CDC6.  It is surprising that a mutation in MCM4 would give rise to specific 
developmental defects such as adrenal failure although this phenomenon has been 
previously reported with defects in other subunits of the replication complex, for 
example Meier Gorlin Syndrome [147]. This syndrome is caused by mutations in 
ORC1-6 and is associated with distinct defects including absent or hypoplastic patella 
and markedly small ears as well as pre- and postnatal growth failure and 
microcephaly.  
 
Adrenal glands from affected patients were not available for study.  In an attempt to 
elucidate the mechanism of adrenal failure caused by a defect in MCM4 a 
collaboration was established with a group from Cornell University, Ithaca, New 
York, USA who had already reported a Mcm4 depleted mouse model. The mice have 
previously been reported in detail and are described in the methods section [101, 102, 
141]. Briefly, to generate the mice analyzed here, mice of the genotypes 
Mcm4Chaos3/Chaos3 (chromosome aberrations occurring spontaneously 3) and Mcm4+/- 
Mcm3+/- were crossed to generate the control (Mcm4Chaos3/+ Mcm3+/-) and test 
(Mcm4Chaos3/- Mcm3+/-) animals. 
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6.2 Test Mcm4Chaos3/- Mcm3+/- animals 
A mutant hypomorphic allele of Mcm4, Chaos3, leads to genomic instability and 
cancer in mice [141]. Chaos 3 is a point mutation changing phenyalanine to isoleucine 
at residue 345, an amino acid conserved across diverse eukaryotes and important for 
interaction between MCM4 and other MCMs. As previously discussed in chapter 4 
(section 4.3) micronucleus frequencies act as a measure of in vivo chromosomal 
damage and Mcm4Chaos3/+ heterozygote mice show mildly increased micronuclei 
frequency compared to wild type (2 to 5 fold) whereas homozygotes show a marked 
(approximately 20 fold) increase over wild type. Young Chaos 3 heterozygotes and 
homozygote mice are overtly indistinguishable from wild type littermates but greater 
than 80% of female homozygotes die with mammary adenocarcinomas within 12 
months [141].  
 
The same group generated Mcm4+/- heterozygote mice using a gene trap vector 
inserted between exons 12 and 13 of Mcm4 disrupting the highly conserved MCM 
domain (Figure 6.1). Mcm4+/- heterozygote mice appeared normal and did not have 
higher levels of spontaneous micronuclei. Homozygosity for a disrupted Mcm4 allele 
(Mcm4-/-) caused pre-implantation lethality. Mcm4Chaos3/- embryos died late in 
gestation at approximately 14.5 days post coitum and most were growth retarded 
[141].  
 
Mouse embryonic fibroblasts from Mcm4+/- heterozygote mice show normal levels of 
MCM4 but Mcm4Chaos3/Chaos3 mice have reduced levels of MCM4. Mcm4Chaos3/- have 
markedly reduced levels MCM4 indicating the F345I mutation appears to destabilise 
the MCM4 protein [141]. Genetic reduction of MCM3 (Mcm3 heterozygosity) 
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surprisingly rescued the near 100% lethality of Mcm4Chaos3/- mice giving nearly 6 fold 
increased viability [102]. MCM3 mediates nuclear export of MCM2-7 suggesting that 
it is the reduced export and therefore increased levels of chromatin bound MCM that 
rescues the embryos. Mcm4Chaos3/- Mcm3+/- mice also have high levels of genomic 
instability, indicated by elevated micronuclei in red blood cells. Furthermore they 
exhibit severe growth failure and increased susceptibility to the development of, 
primarily, mammary tumours, histiocytic sarcomas, and lymphomas, depending on 
genetic background. These animals provide the closest viable animal model to our 
patient cohort, in that MCM4 levels were reduced to the lowest levels compatible 
with life.   
 
Figure 6.1 
 
 
Figure 6.1 (Taken from Shima et al.[141]; supplementary Figure 1) “Structure of the Mcm4 
gene-trap allele. Mcm4 exons are shown with filled rectangles (5’ and 3’ YTR regions are left 
blank). The highly conserved MCM box is shown spanning exons 10-14. The gene trap vector 
contains En2 (engrailed 2) intron and subsequent splice acceptor (SA), and beta-geo (B-geo) 
reporter gene along with SV40 polyadenylation signal (pA). B-geo is a fusion gene of beta-
galactosidase and neomycin resistant gene. The pGT21xf vector is inserted right after exon 
12, thus efficient splicing of transcripts from exon 12 to the splice acceptor in the gene trap 
vector disrupts the MCM box. Both 5’ and 3’ ends of the insertion were confirmed by 
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genomic PCR as shown with the sequence traces. There were insertions of some ambiguous 
sequences at both ends of the insertion site. However there was no evidence for deletions that 
may be caused by the insertion. The F345I mutation is also indicated.”   
 
6.3 Analysis of adrenals from Mcm4 mutant mouse models 
Adrenals from 3.5 month old wild type littermates and also Mcm4Chaos3/+Mcm3-/+ 
mice were of normal size. Haematoxylin and eosin (H and E) staining revealed a 
normal morphology in both control animals, illustrated in figure 6.2 A, a’, a’’ and D, 
E, e’. In contrast H and E staining of adrenals from 2 different Mcm4Chaos3/- Mcm3-/+ 
3.5 month old animals revealed an abnormal adrenal histology characterised by small, 
tightly packed, intensely stained spindle-shaped cells in the cortex just beneath the 
capsule which appeared to be migrating into the cortex  (figure 6.2 B, b’, b’’ and C, 
c’,c’’).  
 
By 12 months of age these cells were abundant and in some areas spanned the cortex 
from the capsule to the medulla (Figure 6.3). Such changes were not observed in wild 
type littermate controls (not shown). The normal adrenal morphology in 
Mcm4Chaos3/+Mcm3-/+ control mice demonstrates that it is neither the Mcm3 
heterozygosity nor the single Chaos 3 allele that leads to an abnormal adrenal 
morphology but the additional reduction in Mcm4 levels that leads to adrenal disease.   
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Figure 6.2 
 
Figure 6.2 Analysis of adrenals from Mcm4 mutant mouse models. A, D and E. Adrenal 
cortices of wild type and Mcm4Chaos3/+Mcm3-/+ mice have a normal morphology. B, C. H/E 
staining of mutant Mcm4Chaos3/- Mcm3-/+ mouse adrenals (B and C) shows they have an 
abnormal morphology with atypical spindle-shaped cells observed within the cortex. 
Abbreviations: ZG, Zona Glomerulosa; ZF, Zona Fasciculata; M, Medulla. Scale bar; 100 
microns (numbers eg 21282 relate to individual mice identification numbers) 
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Figure 6.3 
 
 
Figure 6.3 H/E staining of adrenals from Mcm4Chaos3/- Mcm3-/+ mice show a more severe 
phenotype at 12 months. Image representative of findings in n=2 mice studied 
 
Figure 6.4 
 
Figure 6.4 Atypical cells in the cortex are not steroidogenic. 3.5 month old wild type (A) and 
Mcm4Chaos3/- Mcm3-/+ mice adrenals (B) were stained for CYP11A1 (A, a’, B, b’), CYP11B1 
(a’’) and merged CYP11A1-B1 (b’’). The atypical cells populating the ZF in Mcm4Chaos3/- 
Mcm3-/+ adrenals are negative for both CYP11A1 and CYP11B1 (b’’). 
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The expression of steroidogenic enzymes CYP11A1 and CYP11B1 was analysed in 
both control and mutant Mcm4Chaos3/- Mcm3-/+ mice. This indicated that many cells in 
the mutants were negative for CYP11A1 (P450 side chain cleavage) (Figure 6.4B), in 
contrast to the wildtype (Figure 6.4A). Co-staining with the zona fasciculata marker 
CYP11B1 (P450 11β-hydroxylase) showed that these CYP11A1 negative cells were 
also CYP11B1 negative (Figure 6.4b’’) implying they were not capable of producing 
glucocorticoid. Sections were also stained with the nuclear stain DAPI. This 
demonstrated that the cells not expressing CYP11A1 were morphologically identical 
to the spindle shaped cells seen in H and E staining confirming that the spindle-
shaped cells are non-steroidogenic cells (Figure 6.2 and 6.5b’). 
 
Figure 6.5 
 
Figure 6.5 Spindle shaped cells are non-steroidogenic. 3.5 month wild type (A, a’ and a’) and 
mutant Mcm4Chaos3/- Mcm3-/+ adrenals were stained for CYP11A1 (SCC). Mutant Mcm4Chaos3/- 
Mcm3-/+  adrenals were also stained with DAPI showing that the cells that stained negative for 
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CYP11A1 had the same morphology as the spindle shaped cells seen in previous H and E 
staining. Abbreviations: ZG, Zona Glomerulosa; ZF, Zona Fasciculata; M, Medulla; C. 
Capsule. 
 
The adrenal capsule adjacent to these abnormal cells appeared to be much thinner in 
the adrenals from mutant Mcm4Chaos3/- Mcm3-/+ mice compared to the adrenal capsule 
from wild type mice. This is particularly obvious in the higher power H and E images 
in Figure 6.6 where the wild type adrenals (A-H) have capsules showing the usual 
architecture, being two to three cell layers thick with thin, elongated nuclei arranged 
in the plane of the capsule, but the mutant adrenals have either a very thin capsule (P) 
or appear to have completely lost it (J, K) adjacent to the abnormal cells. 
Interestingly, the capsule adjacent to regions lacking the spindle cell phenotype 
appears to be relatively normal (O, Q). The juxtaposition of the thinning capsule and 
the non-steroidogenic cells in the mutant adrenals suggested that these cells might be 
capsular in origin.  
 
To explore this further, expression of the mesenchymal capsule marker Gli1 was 
analysed by in situ hybridisation and indicated that the abnormal cells were Gli1 
positive (Figure 6.7 provided by Dr Leo Guasti). Gli1 expression is dependent on 
hedgehog signaling and should only be seen in the capsule and a few subcapsular 
cells [21, 45]. No steroidogenic cells in wild type adrenals stain positive for Gli1 
expression and the presence of many Gli1 positive cells within the adrenal cortex in 
the Mcm4Chaos3/- Mcm3-/+ mutant mice is very abnormal. 
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Figure 6.6 
 
Figure 6.6 H/E staining of adrenals from normal and mutant mice. The normal capsule 
architecture in the wild type (A-H) is lost adjacent to the abnormal cells in Mcm4Chaos3/- Mcm3-
/+ mice adrenals (J-Q).  
 
GATA-4 and GATA-6 are zinc finger transcription factors that are expressed in 
human and mouse adrenals and regulate cellular proliferation, differentiation and 
apoptosis within the adrenal cortex, with null mutations for GATA-4 and GATA-6 
being embryonic lethal in mice. GATA-4 is expressed in the foetal adrenal but not the 
adult adrenal and up-regulates inhibin-α, CYP17 and StAR expression predominantly 
in less differentiated proliferating cells [55]. Up-regulation of GATA-4 expression has 
been seen pathologically in adult adrenals in some adrenocortical tumours and has 
been associated with more aggressive behavior. Immunohistochemistry showed that 
the abnormal spindle shaped cells also stained positive for GATA-4 expression 
(Figure 6.7) in contrast to the wild type adrenal cortex which showed typically very 
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few GATA-4 positive cells. As GATA-4 stains the nucleus it is clear that the 
morphology of the nuclei in these cells is identical to that seen in the spindle shaped 
cells and those cells identified as non-steroidogenic in figure 6.5b’’. In addition the 
distribution is very similar to the spindle shaped cells identified in Figure 6.2 and 6.3. 
Taken together this strongly suggests that the GATA-4 staining is marking the spindle 
shaped, non-steroidogenic cells.  
 
Figure 6.7 
 
Figure 6.7  A-D. In situ hybridisation on 12 month old adrenals showed that Gli1 expression 
is restricted to the capsule in the wild type (A) but detected in the cortex in the atypical cells 
in Mcm4Chaos3/- Mcm3-/+ mice (B). C and D are sense probe controls. E-F. GATA-4 
immunoreactivity was rarely observed in the wild type adrenals and always in cells close to 
the capsule; a few darkly stained cells are visible in E. In Mcm4Chaos3/- Mcm3-/+ mice, the 
atypical cells are GATA-4 positive (darkly stained cells in F). Scale bars; a’-d’ 100 microns, 
E-F 40 microns. 
 
It is thought that hedgehog and Wnt /β-catenin signaling may regulate adrenocortical 
progenitor populations in concert as β-catenin expression has been shown to be 
required for SF1 positive cell proliferation and survival [48]. β-catenin expression 
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was therefore analysed in wild type and mutant Mcm4Chaos3/- Mcm3-/+ mice. This 
revealed a very abnormal morphology with evidence of increased β-catenin 
expression throughout the zona fasciculata in contrast to wild type when only a small 
number of cells in the zona glomerulosa stain positive (Figure 6.8B). 
 
Figure 6.8 
 
Figure 6.8 Abnormally increased β-catenin in mutant mice. 3.5 month old wild type (A and 
B) and Mcm4Chaos3/- Mcm3-/+ mice adrenals (C and D) were stained for P450 side chain 
cleavage (SCC) and β-catenin (BETA-CAT). There is significantly increased expression of β-
catenin in the mutant mice throughout the zona fasciculata (D) compared to wildtype (B). 
 
6.4 Discussion 
This chapter has analysed a mouse model in which MCM4 levels have been reduced 
to the lowest levels compatible with life, in order to study the effect this has on 
adrenal development and histology.  
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Adrenals from 3.5 month old Mcm4Chaos3/- Mcm3-/+ mice revealed an abnormal 
morphology characterised by small, tightly packed, spindle-shaped cells infiltrating 
the cortex from just beneath the capsule. By 12 months of age these cells were 
abundant throughout the cortex and in some areas spanned the cortex from the capsule 
to the medulla indicating that this is a progressive phenotype. They were not observed 
in the wild type or in Mcm4Chaos3/+Mcm3-/+ adrenals. Analysis of the expression of 
steroidogenic enzymes indicated many cells in the mutants were negative for 
Cyp11a1 (P450 side chain cleavage) in contrast to the wild type. Co-staining with the 
zona fasciculata marker Cyp11b1 (P450 11-beta-hydroxylase) showed that these 
Cyp11a1 negative cells were also Cyp11b1 negative indicating they were not 
steroidogenic. These cells were also GATA-4 and Gli1 positive. Taken together these 
data indicate that the adrenal morphology in this MCM4 depletion mouse model is 
grossly abnormal with steroidogenic cells displaced by non-steroidogenic, GATA-4 
and Gli1 positive cells that are likely to compromise steroidogenic output. 
 
A similar morphological picture has been seen in certain in-bred mouse strains post 
gonadectomy [148, 149]. Both female and male mice of the DBA/2J strain develop 
spindle shaped cells, termed A cells, with limited steroidogenic capacity, post 
gonadectomy. Similarly to the mutant Mcm4Chaos3/- Mcm3-/+ mice these cells appear 
initially in the subcapsular region of the adrenal gland and were shown to stain 
positive for GATA-4 both by immunohistochemistry and in situ hybridisation. As the 
mice age these animals also develop sex steroid producing cells known as B cells 
presumably in response to unopposed gonadotrophin production by the pituitary gland 
[149]. These are large lipid laden cells and were not identified in adrenal glands from 
the MCM4 depleted mice. In addition, luteinizing hormone receptor (LHR) mRNA 
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was detected in both A and B cells. Although antibodies to test for LH receptor 
positivity in the mutant Mcm4Chaos3/- Mcm3-/+ mice were not available it is unlikely 
this would have been positive as there is presumably no additional stimulus in the 
MCM4 depleted animals to push the undifferentiated spindle shaped cells towards a 
gonadal phenotype in contast to the gonadectomised animals. The gonadectomized 
mice subsequently develop adrenocortical tumours and the severity of tumorigenesis 
correlated with the level of GATA-4 and LHR expression. In addition to these mouse 
studies, GATA-4 has also been shown to be associated with adrenal tumourogenesis 
in human studies [58]. Wooley et al. have also demonstrated that gonadectomy in 
female mice causes undifferentiated cells in the subcapsular region of the adrenal 
gland to differentiate into sex steroid producing cells that are histologically and 
functionally similar to ovarian tissue. 
 
GATA-4 and GATA-6 are thought to have important but distinct roles in 
adrenocortical and gonadal cell differentiation and function. Both have been 
implicated in the regulation of gene expression and differentiation in steroidogenic 
cells in the testes and ovary [56, 57]. GATA-4 expression is high during periods of 
active cell proliferation in sertoli and granulosa cells. GATA-4 expression is 
expressed transiently in the foetal mouse and foetal human adrenal gland but not the 
adult adrenal. In the foetal human adrenal GATA-4 expression was patchy and not 
isolated to any specific adrenal zone at gestational week 19, however it was mainly 
localized to the foetal zone. In contrast GATA-6 is expressed in both foetal and adult 
adrenal. In the foetal adrenal GATA-6 was abundant and localized to both foetal and 
definitive zones but was more prominent in the definitive zone [55]. 
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In the mutant Mcm4Chaos3/- Mcm3-/+ mice there was no evidence of sex hormone 
producing cells and no evidence of either adrenocortical adenomas or adrenocortical 
tumours. However the appearance of the spindle shaped cells in the MCM4 deficient 
animals suggests that these cells are potentially undifferentiated subcapsular cells that 
are unable to differentiate into steroidogenic cells. These cells are positive for the 
capsular marker Gli1, and at least during embryogenesis these cells appear to be a 
stem cell population for growth of the cortex [21]. The juxtaposition of these Gli1 
positive spindle cells with the capsule would suggest that they are inappropriately 
proliferating stem/progenitor cells that are unable to convert to a steroidogenic 
phenotype. The depletion of the capsule adjacent to these regions further suggests that 
the normal control of this niche has been perturbed with the balance between self-
renewal and division disrupted, leading to a loss of these cells.  Instead they 
abnormally activate GATA-4 expression, perhaps in a response to try to force 
differentiation or in an attempt to recapitulate foetal adrenal conditions again to try to 
promote differentiation. Alternatively these cells may originate from the foetal 
adrenal and are unable to extinguish GATA-4 expression as normal in post-natal life 
leading to an abnormal accumulation of GATA-4 positive cells.  
  
This hypothesis does not explain why cortisol production in humans is specifically 
affected by an MCM4 defect whereas there appears to be no deficit in aldosterone 
production. Perhaps the absolute volumes produced (cortisol approximately 
15mg/m2/day versus aldosterone 150 micrograms/day) means that cortisol production 
is primarily affected and patients may go on to develop mineralocorticoid deficiency 
with further degeneration of the adrenal cortex. Figure 6.5b’’ indicates that the 
spindle shaped cells are infiltrating the cortex at 3.5 months by growing between the 
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glomeruli which can be observed expressing CYP11A1, suggesting that, at least at 
that age, aldosterone production is not compromised. Alternatively, progenitor cells 
may be able to differentiate into glomerulosa cells but are unable to further 
differentiate into fasciculata cells, supporting the cell migration model of adrenal 
development/regeneration [21].  
 
Many cells in the mutant Mcm4Chaos3/- Mcm3-/+ mice express abnormally high levels of 
β-catenin compared to wild type. Interestingly, transgenic mice with constitutive 
activation of β-catenin in the adrenal cortex also show evidence of subcapsular 
adrenal spindle cells [150]. However, as well as spindle cell hyperplasia these animals 
also developed steroidogenic cell hyperplasia and dysplasia of the cortex and medulla. 
In addition they developed adrenocortical tumours with ectopic differentiation of the 
zona glomerulosa at the expense of the fasciculata cells leading to primary 
hyperaldosteronism. This group showed centripetal invasion of the adrenal cortex by 
spindle shaped cells originating from outer cortical areas, and similarly to the mutant 
Mcm4Chaos3/- Mcm3-/+ mice, these spindle cells expressed GATA-4 but no 
steroidogenic enzymes. In addition rats placed on a low sodium diet show evidence of 
increased β-catenin expression, increased CYP11B2 expression and expansion of the 
zona glomerulosa ([21] personal communication). Indeed if the increased β-catenin 
expression seen in the MCM4 depleted animals is replicated in human patients and 
similarly cells are preferentially differentiated into zona glomerulosa cells rather than 
zona fasciculata cells, this is a possible explanation for the patients aldosterone 
sufficiency.  
 
 150 
β-catenin is required for progenitor cell renewal and differentiation in numerous cell 
lines [23] and adrenocortical cell renewal is impaired in mice with reduced β-catenin 
levels [48]. However the putative progenitor cells do not express β-catenin and 
therefore the authors speculate that hedgehog signaling, which is known to frequently 
cooperate with Wnt signaling, is implicated in the accumulation of spindle shaped 
cells in the mutant adrenals. King et al. also suggested that progenitor cell 
proliferation and differentiation may be regulated by both β-catenin and hedgehog 
signaling as these are frequently regulated reciprocally [21]. This suggests that 
MCM4 regulation of hedgehog and β-catenin signaling may act to control adrenal 
stem cell differentiation. However the mechanism by which MCM4 regulates β-
catenin expression requires additional study.  
 
In contrast, it is interesting to note that a spontaneous autosomal recessive mutation in 
Tpp1, a component of the shelterin complex that maintains telomere integrity, causes 
telomere dysfunction and genomic instability but also a disordered morphogenesis of 
the adrenal cortex in mice (the acd mouse) [151]. This suggests that chromosomal 
instability per se can cause adrenal disease. However the mechanism of adrenal 
disease has not been fully elucidated in these animals and is thought to be due to a 
fundamental defect in cellular proliferation within the adrenal cortex. In contrast to 
the Mcm4Chaos3/- Mcm3-/+ mice acd mutant mice had markedly increased cortical cells, 
with up to a sevenfold increase in volume, and with nuclei often showing a variety of 
inclusions. These changes were not seen in Mcm4Chaos3/- Mcm3-/+ mice. Given the 
morphological differences between the two mutant mice it seems unlikely that the 
chromosomal instability that is undoubtedly present in the Mcm4Chaos3/- Mcm3-/+ mice 
is the sole cause of the adrenal failure.   
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The significant morphological changes seen in the Mcm4Chaos3/- Mcm3-/+ mouse 
adrenals demonstrate that MCM4 deficiency causes adrenal defects in mice as well as 
humans. However, it would be important to demonstrate that these changes cause 
biochemical abnormalities such as low corticosterone levels or elevated ACTH levels. 
Unfortunately as we did not have direct access to the mice it proved difficult to carry 
out these experiments, but this is something that should be investigated in the future.  
 
Replacement of steroidogenic cells with spindle cells cannot be demonstrated in 
patients with MCM4 deficiency as there are no human adrenal glands to study. 
However the adrenal phenotype seen in mice suggests that MCM4 may have a role in 
adrenal development, possibly in the control of adrenal stem cell differentiation, and 
it is likely that this is recapitulated in humans.  
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Chapter 7: Discussion 
 
7.1 Introduction 
FGD is a rare autosomal recessive disorder that is characterized by isolated 
glucocorticoid deficiency. A number of genetic causes have been described including 
mutations in the Melanocortin 2 receptor (MC2R), the Melanocortin 2 receptor 
accessory protein (MRAP), the steroidogenic acute regulatory protein (StAR) and 
most recently nicotinamide nucleotide transhydrogenase (NNT) [73, 75, 79, 153]. 
Patients typically present in infancy or early childhood however there is significant 
variability in the age of presentation with age of onset reported from birth to late 
childhood. There is variability in onset within patients with mutations in the same 
gene, for example, MC2R, and even within patients with the same mutation, for 
example the S74I mutation in MC2R [91]. In contrast patients with mutations in 
MRAP usually present in the neonatal period [79]. It was postulated that this 
difference was due to the nature of the mutations as most MC2R mutations are 
missense mutations but all MRAP mutations result in either an absent or severely 
truncated protein.  
 
I identified two populations who presented with late onset FGD. Firstly two families 
of Turkish ethnicity who presented with delayed onset FGD and secondly eight 
patients from the Irish travelling community. This second cohort demonstrated late 
onset glucocorticoid deficiency that was associated with a number of additional 
features including chromosomal fragility, NK cell deficiency and short stature. 
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I investigated these patients and discovered firstly that missense mutations in MRAP 
can lead to later onset FGD and secondly I discovered a novel pathogenetic 
mechanism in Irish traveller patients with FGD.  
 
7.2 Missense MRAP mutations 
I identified the first two missense mutations in MRAP; Y59D and V26A in the 
Turkish families. I generated ACTH dose response curves for MC2R when 
transfected with wild-type or mutant MRAP and showed that both mutant MRAPs 
demonstrate impaired rather than absent function evidenced by a right shift in the 
dose response curve. Immunocytochemistry showed normal trafficking indicating a 
probable signaling defect. The characterisation of these mutations confirming reduced 
rather than absent function is consistent with the phenotype and further substantiates 
the hypothesis that disease severity in FGD patients reflects the functional 
significance of the underlying mutation. 
 
 
7.3 Novel pathogenetic mechanism of adrenal failure – MCM4 mutations 
I studied eight children from a genetically isolated Irish population who had an 
interesting variant of adrenal failure. Patients had typical biochemical features of 
FGD with isolated glucocorticoid deficiency, raised ACTH and normal renin and 
aldosterone levels. Unlike other forms of FGD, cortisol deficiency was often not as 
severe and onset was usually in childhood following a period of normal adrenal 
function. Affected children develop hypocortisolaemia but also growth failure, 
increased chromosomal breakage and natural killer (NK) cell deficiency.   
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Targeted exome sequencing in patients identified a variant (c.71-1insG) in mini 
chromosome maintenance-deficient 4 homologue (MCM4) that is predicted to result 
in a severely truncated protein (p.Pro24ArgfsX4). Given the essential role MCM4 
plays in cell division it is surprising that this mutation, causing early termination of 
the reading frame, should produce such a mild phenotype when gene knockout in 
mice is embryonic lethal. However although I confirmed patient lymphocytes show 
loss of the full-length 96kDa MCM4 protein as predicted from RNA analysis, they do 
show evidence of two smaller MCM4 isoforms that likely rescue the patients from a 
lethal phenotype.  
 
Given the location of the mutation and the fact that the antibody I used detects the C-
terminus of MCM4, it is probable that this smaller isoform has a disrupted N-terminal 
domain in these patients, but the essential conserved C-terminal domains remain 
intact. This protein was not detected by immunoblotting with an N-terminal antibody 
for MCM4 providing further evidence this smaller MCM4 protein lacks the N-
terminus. The N-terminus is not well conserved, and studies have revealed that 
deletion of the first 130 amino acids is not deleterious in eukaryotic cells [144]. 
Further work has also suggested that although the eukaryotic N-terminal domain is 
non-essential it is involved in protein kinase regulation of cell cycle progression 
[154].  
 
Given the known function of MCM4 together with the ubiquitous requirement of this 
protein it is not surprising that patients would have chromosomal instability or growth 
failure. However it could not have been predicted that defects in this gene could 
specifically lead to adrenal failure and NK cell deficiency. Nevertheless I believe that 
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I have identified the correct disease causing mutation for a number of reasons. First I 
performed homozygosity mapping on 4 individuals from 3 different families and all 
individuals had adrenal failure and NK cell deficiency. Because of the variability 
especially in timing of onset of the disease ‘unaffected’ family members were not 
included in the analysis and therefore formal linkage studies were not carried out. All 
areas of homozygosity common to these three individuals were included in the areas 
for targeted exome sequencing. Candidate gene sequencing proved inconclusive and I 
therefore used exome sequencing to sequence all protein coding regions within these 
areas of homozygosity to ensure no coding sequence variants were missed.  I cannot 
however rule out the possibility that a variant outside the coding regions could be 
contributing to the phenotype.  
 
It is also possible that the disease causing mutation lies in a small area of 
homozygosity that was not identified by genome wide scanning using 10K Arrays. To 
help prove that the MCM4 mutation I identified was causing adrenal disease I 
examined a Mcm4 depletion mouse model. I found that these mice have grossly 
abnormal adrenal morphology, characterized by non-steroidogenic GATA-4 and Gli1 
positive cells within the steroidogenic cortex significantly reducing the number of 
steroidogenic cells in the zona fasciculata. Some features similar to this mutant 
adrenal histology have been described in murine adrenal hyperplasia [149, 151, 155]. 
The hyperplastic cells in these mouse models are morphologically very similar to 
those I observed, and are also GATA-4 positive and non-steroidogenic. The presence 
of these non-steroidogenic cells in the cortex reduces the number of steroidogenic 
CYP11B1 expressing cells and hence presumably the glucocorticoid output of the 
zona fasciculata. The adrenal cortex is a dynamic organ that is constantly remodeling 
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to maintain homeostasis. It is proposed that it does this by recruiting differentiated 
steroidogenic cells into the zona fasciculata or zona glomerulosa from 
stem/progenitor cell populations [21, 156]. One such population has been 
characterised in the mesenchymal adrenal capsule with, at least during development, 
Gli1 expressing cells delaminating from the capsule and entering the cortex, 
concomitantly extinguishing Gli1 expression and activating SF-1 and CYP11A1 
expression to become steroidogenic [21]. In light of this it is interesting to note that 
the GATA-4 positive, non-steroidogenic, cells also express Gli1, suggesting that they 
may be capsule cells that enter the cortex but fail to differentiate into a steroidogenic 
identity, instead activating GATA-4 expression. This is supported by the observation 
that the capsule appears to be thin adjacent to the regions of infiltration, further 
suggesting that over time the rate of infiltration exceeds the ability of the capsule to 
self renew. Depletion of MCMs has been proposed to lead to stem cell defects in mice 
[102, 157], with lower MCM2 levels associated with reduced numbers of stem cells in 
the subventricular zone, skeletal muscle and intestinal crypts in adult mice. Similarly, 
the relatively specific impingement of the MCM4 defect on adrenal function may be a 
consequence of its effect on the growth of these mesenchymal stem/progenitor cells 
and their differentiation into steroidogenic cells. This suggests MCM4 may have 
additional functionality beyond DNA replication. 
 
This study did not, as expected, provide further information on the essential 
components of the ACTH signaling pathway however it has identified a surprising 
and novel mechanism of adrenal failure that had not previously been recognised. 
Exome sequencing has also identified mutations in nicotinamide nucleotide 
transhydrogenase as another cause of FGD, highlighting another novel unexpected 
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mechanism of adrenal failure [73]. Further exome sequencing projects are likely to 
identify more novel genes involved in adrenal development and function in the near 
future. 
 
Complete NK cell deficiency in humans is very rare, with the few cases reported 
resulting in overwhelming and fatal infection during childhood [122].  The children in 
our cohort clearly have low but not absent NK cell levels and only one patient 
demonstrates increased susceptibility to infection. I have not characterised the NK 
defect however a second group also investigated children from the Irish travelling 
community with primarily NK cell deficiency and increased susceptibility to viral 
infections. This group used linkage analysis and fine mapping to identify the same 
mutation that I identified in MCM4 as the disease causing mutation in these patients 
[158]. On further examination these patients also had evidence of adrenal 
insufficiency and intrauterine and postnatal growth failure. The patients had more 
severe immune defects than the patients I studied; one patient developed an Epstein 
Barr virus-driven lymphoproliferative disorder and two others developed severe 
respiratory illnesses that were probably of viral origin. One patient died from 
progressive lung disease. This group further characterized this mutation by creating 
EBV-transformed B-cell lines from patients and controls. In agreement with my 
results they showed that the patient cell lines had no evidence of full length MCM4 
protein but did have evidence of two smaller MCM4 isoforms, both missing the N-
terminus. In addition they showed that the mutation did not destabilize the mRNA and 
that the smaller MCM4 isoforms formed a normal MCM2-7 complex with the other 
MCM proteins and this complex was able to bind DNA normally. However they also 
showed that the smaller MCM4 isoforms led to a cell cycle defect by affecting DNA 
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replication and disrupting the normal control of the prevention of re-replication 
therefore impacting the mitotic phase of the cell cycle. They confirmed that the 
MCM4 mutation causes genomic instability specifically in response to aphidicolin 
treatment but not diepoxybutane (DEB). This may explain the differences in 
chromosomal instability seen in our patients as we used lymphocyte culture in DEB to 
look for chromatid breaks and chromosomal exchanges.  
 
Gineau and colleagues further investigated the impact of MCM4 deficiency on NK 
cell terminal differentiation. NK cell classification in humans is based on the surface 
density of CD56, an N-CAM isoform. It has been shown that CD56bright cells account 
for 10% of peripheral blood NK cells and can proliferate and produce IFN-γ in 
response to stimulation with cytokines such as IL-2 and IL-18. CD56bright NK cells 
differentiate into CD56dim NK cells; these account for 90% of peripheral blood NK 
cells and are cytolytic and produce cytokines when they encounter target cells. They 
showed that the patients had very small numbers of NK cells due to selective loss of 
the CD56dim NK cell subset and that the CD56bright NK cells did not proliferate in 
response to IL-2 or IL-15. They concluded that the MCM4 deficit selectively affects 
the ability of CD56bright NK cells to terminally differentiate into CD56dim NK cells 
[158]. This further corroborates my hypothesis that MCM4 may have additional 
functionality beyond DNA replication for example in differentiation of adrenal stem 
cells into steroidogenic cells.  
 
MCM4, as part of the MCM 2-7 complex, is part of the pre-replicative complex, 
which licenses origins for DNA synthesis in the S phase [132, 159].  Recently 5 genes 
that encode different components of the pre-replicative complex have been implicated 
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in Meier-Gorlin syndrome [148], which includes pre- and post-natal growth failure. 
The growth phenotype illustrated by our patients is also recapitulated in Mcm4Chaos3/- 
Mcm3+/- mice [142]. It is possible that this growth failure is explained by the 
ubiquitous requirement of the MCM complex for DNA replication and cell 
proliferation. Taken together this indicates that defects in replication licensing might 
lead to disorders with similar growth retardation phenotypes but distinct 
developmental abnormalities.  
 
In addition to the abnormal adrenal and growth phenotype Mcm4Chaos3/- Mcm3+/- mice 
also have high levels of genomic instability, indicated by elevated micronuclei in red 
blood cells, which correlates with the chromosomal fragility seen in our patients. 
Furthermore they exhibit increased susceptibility to the development of, primarily, 
mammary tumours, histiocytic sarcomas, and lymphomas, depending on genetic 
background [102]. None of the patients have as yet developed any form of cancer but 
given the protein is essential for normal DNA replication and the phenotype observed 
in the mice, the patients may have an increased risk of neoplastic change. Increased 
cancer risk is associated with many other chromosomal instability syndromes for 
example Bloom syndrome, Fanconi anaemia, ataxia telangiectasia and Nijmegen 
breakage syndrome [146]. It is possible that impaired DNA replication in this 
syndrome due to dysregulation of the MCM2-7 complex and intrinsic genome 
instability may overwhelm DNA damage, repair and response systems allowing the 
occurrence of mutations in critical housekeeping genes, for example p53. Our patient 
cohort will have to be followed carefully but a formal screening process to identify 
malignancy early has not yet been put in place.  
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In conclusion I have identified a mutation in MCM4 characterising a new DNA 
replication disorder. Patients demonstrate many similarities to other DNA repair and 
replication disorders including increased chromosomal fragility, pre- and post-natal 
growth retardation and variable immune deficiency, and in addition this disorder 
includes adrenal insufficiency. Patients exhibit variability not only in disease 
susceptibility but also in the other features of the syndrome including age of onset of 
adrenal insufficiency, NK deficiency and levels of chromosome breakage. The other 
components of the MCM complex therefore represent prime potential candidates for 
other undiagnosed cases of chromosomal instability or adrenal failure. 
 
7.4 Future work 
In collaboration with our colleagues in Cornell I plan to perform ACTH stimulation 
tests on Mcm4Chaos3/- Mcm3+/- and wild type mice using a similar protocol to that 
published previously by Coll et al. [160]. I will assay basal and stimulated 
corticosterone levels using a corticosterone radioimmunoassay to reveal whether these 
mice have reduced corticosterone output as Nnt mutant mice do [73]. 
 
Also in collaboration with Cornell I plan to study ovarian and testicular tissue from 
Mcm4Chaos3/- Mcm3+/- mice compared to wild type. It is possible that these tissues may 
share some of the same abnormal features seen in adrenal cortex given both are 
steroidogenic and are derived from the same mesenchymal origins. This may be 
clinically relevant to the patients and if appropriate their ovarian or testicular reserve 
can be monitored using anti-mullerian hormone and inhibin B levels. I plan to 
investigate adrenal expression of MCM4 in wild type mouse and human embryos at 
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different ages of development to try to further characterise the role of MCM4 in 
adrenal development. 
 
I believe the interpatient variability in chromosomal fragility is potentially attributable 
to the use of a sub optimal screening method, i.e. culturing lymphocytes in 
diepoxybutane. I propose to screen our patient cohort for evidence of chromosomal 
fragility by identifying micronucleus frequencies using flow cytometry. Shima et al. 
clearly showed that chromosomal instability in mice can be assessed by using 
micronucleus levels in erythrocytes [101]. Dertinger et al. subsequently designed a 
flow cytometry based system that identifies the incidence of peripheral blood 
micronucleated reticulocytes in humans [161]. The analysis of micronucleus 
formation in newly formed red blood cells is essential for all studies involving species 
whose spleen effectively sequesters and destroys micronucleus containing 
erythrocytes. Dertinger used a fluorescent immunological reagent, anti-CD71, to 
identify newly formed erythrocytes together with an additional fluorescent label to 
exclude platelets from the micronucleated reticulocytes. I propose to investigate 
micronucleus frequencies in our patient cohort in collaboration with Professor Owen 
Smith in Our Lady’s Children’s Hospital in Dublin using the flow cytometry 
laboratory based in the hospital. I believe this will give a more accurate and consistent 
measure of chromosomal fragility in our patient cohort.  
 
It remains unclear why only some of the patients studied showed profound 
susceptibility to infection while others remain relatively unaffected despite all patients 
having evidence of low NK cells. This may reflect genetic co-modifiers that are 
present in these consanguineous families, environmental factors or even epigenetic 
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modifications. I believe this requires further study and plan to use whole exome 
sequencing rather than targeted exome sequencing in a number of my patients as a 
first step to potentially identify any interacting genetic variants.  
 
The mouse model used here is not directly equivalent to the mutation present in the 
Irish travellers. Although MCM4 levels have been reduced, the putative N-terminally 
truncated form is not present and there is also a reduction in MCM3, which is not 
present in patients. I have tried to control for MCM3 heterozygosity by including this 
in our control animals, nevertheless, even though the data are highly indicative that 
MCM4 is required for appropriate differentiation of the adrenal cortex, with a 
presumed resultant impact on steroidogenesis, future studies will attempt to 
recapitulate the human mutation. I will create appropriate mouse models either by 
homologous recombination with mutation of the endogenous locus as mouse MCM4 
has the same alternative splicing or alternatively a human transgene could be 
constructed from one of the patients, and introduced into mice that are null for 
MCM4. This will hopefully generate not only a mouse model of this form of FGD but 
also provide important insights into adrenal development and the control of adrenal 
stem cells.    
 
Finally, epigenetic reprogramming of somatic cells to a pluripotent state has been 
achieved by direct reprogramming by expression of transcription factors. Takahashi 
and Yamanaka demonstrated that the overexpression of four transcription factors 
Oct4, Sox2, Klf4, and c-Myc could convert somatic fibroblasts to pluripotent cells 
(iPSCs) [162]. Subsequently Suga et al. demonstrated self formation of functional 
adenohypophysis in three-dimensional culture from an aggregate culture of mouse 
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embryonic stem cells [163]. I would like to try to create pluripotent stem cells (iPSCs) 
from affected patient fibroblasts or lymphocytes as it has been shown that terminally 
differentiated cells can be reprogrammed to pluripotency in humans [164-166]. 
Examining the differentiation of patient versus control iPSCs to an adrenal lineage 
may provide important information about the role of MCM4 in adrenal stem cell 
differentiation. 
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APPENDIX 1 
 
 
OUR LADY’S HOSPITAL FOR SICK CHILDREN, 
CRUMLIN,  
DUBLIN 12. 
 
 
ETHICS  COMMITTEE 
PROTOCOL  FORM 
 
 
This protocol was developed based on the general principles of medical ethics, the 
control of clinical trials Acts 1987 and 1990, and European Guidelines of Good 
Clinical Practice. 
 
Please read the attached introductory notes, then complete the protocol in typescript. 
 
All relevant sections must be fully completed.  Please place “X” or circle the 
appropriate response in the boxed areas.  NA is the abbreviation for Not Applicable. 
 
1. Title of research project: 
 
Investigating the genetics and mechanisms of ACTH resistance in children with 
Familial Glucocorticoid Deficiency 
 
 
 
2. Name of the Chief Investigator(s) who should ordinarily be  
a hospital consultant: 
 
Dr. Colm Costigan 
 
 
 
3. What are the objectives of the research project? 
 
• Identify further genes responsible for Familial Glucocorticoid Disease in our 
patients 
• Isolate and investigate these genes 
• Examine the relationship between the ACTH receptor, new genes identified, 
and previously identified accessory proteins (MRAP) 
 
4a.  Does the design of the study allow a statistically significant 
       conclusion to be reached?     
   
 
YES 
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4b.  Has statistical advice been sought? 
 
5.   Will the conduct of the project conform to the principles of the  
      Declaration of Helsinki (Recommendations guiding Medical  
      Doctors in  Biomedical Research involving Human subjects).  
 
 If not, elucidate: 
 
 
 
 
 
 
6.    Please itemise here any ethical problems which you perceive  
 to be associated with research project: 
 
We will need to obtain consent for taking blood samples from patients with Familial 
Glucocorticoid Deficiency (during routine phlebotomy to monitor clinical 
progression). We will also need to obtain consent to take blood samples from family 
members, if they are willing. We will then use these samples for research into the 
genetics and mechanisms of disease in FGD, in these families. 
NO 
YES 
 185 
SECTION  A 
 
DETAILS  OF  PROJECT 
 
 
7.    Background 
A) What person or organisation devised this project? 
 
Dr. Colm Costigan, Dr. Claire Hughes and Dr. Adrian Clarke 
 
 
 
 
B) Has a detailed research protocol been drawn up? (If so, such  
documentation must be submitted to the committee).   
 
In progress 
 
 
 
8. 
A) Has the investigator who will present this project to the  
Committee studied all the documentation drawn up for the  
 Project, and will the documentation be studied by all the  
 investigators before the project begins?     
       
 
B) Briefly describe the scientific rationale for the project: 
 
FGD is a genetically heterogeneous, autosomal recessive syndrome of ACTH 
resistance resulting in adrenal failure. The genetic basis of approximately 50% of 
cases of FGD is known.  FGD type 1 (OMIM 202200) results from a mutation in the 
ACTH Receptor gene, Melanocortin 2 receptor (MC2R).  FGD type 2 (OMIM 
609196) maps to a mutation in the melanocortin 2 receptor accessory protein (MRAP). 
This protein may have a role in the trafficking of MC2R from the endoplasmic 
reticulum to the cell surface. The underlying genetic mutation for the remaining 50% 
is unknown, but some cases may map to a locus on chromosome 8q.  
 
We have identified 22 patients with FGD, 12 of these patients have been tested for all 
known mutations and are negative. We intend to use whole genome scanning by 
single nucleotide polymorphism (SNP) array genotyping and linkage analysis to 
identify further potential genes that cause ACTH resistance.  
 
7 of our patients have mutations in the MC2R gene, and 3 patients have a mutation in 
the MRAP gene. We aim to analyse the nature of the interaction between MC2R and 
MRAP and additional proteins or chaperones discovered. This will lead to a better 
understanding of MC2R trafficking and signaling and increase the understanding of G 
protein coupled receptors (GPCRs) and adrenal physiology in general. 
 
YES NO 
YES 
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By identifying further loci linked to this disease, molecular genetic testing will allow 
early diagnosis and treatment in high-risk groups and allow carrier testing. 
 
9. What is the nature and extent of the medical examination  
 that participants and controls are to undergo before  
 participating in this project? 
 
Dr. Colm Costigan is actively caring for the patients with ACTH resistance, with 
clinic reviews 3 – 6 monthly. Some patients are already aware of ongoing research 
through Dr. Sally Ann Lynch, but this new project will be explained to them in detail 
with further consent obtained for all participating families / patients. 
 
 
 
10. How will the health of the participants and controls be 
 monitored during and after the trial? (List clinical,  
 laboratory and other examinations):  
 
NA – The family members are not been “treated” so there is no need to monitor 
health. Regular clinic review is on-going regardless of research. 
 
 
11. Will the participants or controls undergo independent 
 medical examinations, before, during or after the trial?  
 
 
 
12. If a placebo group is to be used, will the group  
 receive the best standard therapy?    
    
 
13. If the project involves the use of radioactive substances  
or of laser therapy has the approval of the Head of  
Radiology been sought? 
  (If not, elucidate) 
    
 
NO 
NA 
NA 
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SECTION  B 
 
INVESTIGATORS  AND  FACILITIES 
 
 
14. Name, qualification and position of each person associated 
With this project: 
 
Dr. Colm Costigan, Consultant Paediatric Endocrinologist, OLHSC, MRCPI (Paed) 
Dr. Claire Hughes, Specialist Registrar Paediatrics, OLHSC, MRCPI (Paed) 
Dr. Adrian Clarke, DSc FRCP, F Med Sci, Professor of Medicine, Bart’s and the 
London School of Medicine and Dentistry 
 
 
 
15. Is each investigator a registered medical practitioner? 
If not, elucidate: 
 
 
 
 
 
16. Is each investigator a member of a major medical defense 
body?  
If not, elucidate: 
 
 
 
 
 
17. What payments, monetary or otherwise, if any, are to be  
made to any of the investigators (include payments to any  
institution or research facility.  Please quote account name and  
number)? 
 
PLEASE  NOTE: 
Non-disclosure of funds may lead to revoking of the Ethics 
Approval for this trial. 
 
Dr. Claire Hughes will receive funding as part of a 2 year research fellowship for a 
salary. The William Harvey institute will receive funding to cover laboratory costs.  
 
 
18. What payments, whether monetary or otherwise, if any, are  
to be made to any person or institution providing facilities  
to be used for the purpose of the clinical trial? 
 
 
The William Harvey Institute will be reimbursed for overheads and consumables from 
the research funding. 
YES 
YES 
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19. In which hospital or facility will the project take place? 
 
The project is a joint project between Our Lady’s Children’s Hospital and the William 
Harvey Institute, Barts and the Royal London School of Medicine and Dentistry. All 
laboratory work will be done in William Harvey Institute. 
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SECTION  C 
 
PARTICIPANTS 
 
 
20. How many subjects and controls from this centre are 
expected to participate in this project?                            NUMBER  
 
 
21. If this is a multicentre trial please indicate: 
 
a) The expected overall number of subjects:                  NUMBER  
 
b) The number and geographical distribution  
  of the centres involved in the study?                            NUMBER  
 
 
22. What criteria are to be used for the selection of  
participants? 
 
The only criteria includes a diagnosis (clinical and biochemical) of FGD. All patients 
have already been identified and are aware of their diagnosis. All samples will come 
from either an affected individual or their family members. 
 
23. Are women of childbearing potential included?   
 
If so, does the protocol/patient information sheet  
address the following 8 points:    
(1 - Scientific justification,  
2 - Negative teratogenic studies, 
       3 - Warning subject that fetus may be damaged,  
       4 - Initial negative pregnancy test, 
5 - Forms of contraception defined, 
6 – Duration of use to exceed drug metabolism, 
7 - Exclude those unlikely to follow contraceptive advice, 
8 - Notify investigator if pregnancy suspected)?    
 
 
24. State any other exclusion criteria  
(age, other illness, other medications etc.): 
 
N/A 
 
25. What are the proposed methods by which participants  
and controls are to be recruited: 
 
All affected individuals are receiving ongoing care within the endocrine department. 
However if a patient is newly diagnosed and wishes to take part we will be happy to 
include their samples in the analysis upon taking appropriate consent. 
 
22 
N/A 
 
NA 
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26. Are inducements or rewards, monetary or otherwise,  
offered to participants and controls: 
If yes, elucidate: 
 
 
 
 
27. What arrangements exist to provide compensation to each 
participant who may suffer injury or loss as a result of this 
research project? 
 
 
N/A 
 
 
28. Have you submitted to the committee, with this form, a      
patient’s information leaflet and consent form prepared by  
a sponsor or other external group, or a patient information  
leaflet and consent form based on the committee’s 
guidelines (attached to this form) to be given to each  
participant and control? 
If no, elucidate: 
 
 
 
 
 
29. What criteria are to be used to ensure that the identity of  
each participant and control remains confidential? 
 
The samples will be kept in a secure DNA bank either in the national centre for 
medical genetics or in the William Harvey Institute.  
 
 
30. Give details of any risks to subjects or to controls from 
investigative or therapeutic procedures or from withholding 
of therapy? 
NOTE: For the protection of both the investigator and the  
subject this list must be comprehensive and must also appear  
in full in the patient information leaflet.  
 
 
The only procedure will be phlebotomy. The risks would include the risk of 
bruising and extremely rarely infection following phlebotomy. 
 
 
31. Indicate how adverse events are to be notified and evaluated: 
 
NO 
YES 
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Those of us who will take blood are trained in phlebotomy and have the OLHSC 
advisory pack on adverse incidents when taking blood. We are also aware of the 
reporting requirements for adverse incidents 
 
SECTION  D 
 
DRUGS  AND  THE  SUBSTANCES 
 
 
32. Is the object of this project to assess the effect of a drug or  
therapeutic substance?  
 
If no, skip to section E: 
 
 
 
33. Name of the substance or preparation which is the subject 
of the proposed project: 
 
 
 
 
 
34. Name of the company or organisation which produces  
this substance or preparation: 
 
 
 
 
 
34a. Code number used by the company or organisation for    
        this trial. 
 
 
35. Does the organisation and performance of this trial   
 conform to European Directives on Good Clinical  
 Practice. 
 
 
 
36. Give details of the pharmacology, dosage, toxicity  
and side effects of the substance or preparation: 
NOTE:  For the protection of both the investigator and the  
subject, the list of side effects must be comprehensive  
and must also appear in full in the patient  information leaflet. 
NO 
 
YES NO 
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PRODUCT  AUTHORISATION 
 
 
37. Is there a Product Authorisation?  
 
 
 
 
38. If there is a Product Authorisation, does the study involve   
a new use not included in the authorisation, or a dose  
in excess of the maximum authorised or otherwise exceed  
authorisation? 
 
 
 
39. Irish Medicines Board: 
Application for approval of the study has been made? 
 
 
 
 
 DATE of application:  
  
 
 
 Approval has been received. 
 
 DATE of approval:  
 
 
 
 
 
 
40. Is this preparation or substance given with therapeutic intent? 
 (Is the principal purpose of its administration to prevent disease in  
  or to save the life, restore the health, alleviate the condition or  
  relieve the suffering of the patient – in contrast to testing a drug  
  in normal controls or volunteers or giving a drug purely to study    
  pharmocokinetics?) 
 
 Note that if the answer is NO patients who are unable to 
  physically sign consent or unable to comprehend the nature,  
 significance, and scope of the consent required, may not participate. 
 
 
YES NO 
YES NO 
YES NO NA PENDING 
 
 
YES NO NA PENDING 
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41. Will the trial begin within 6 days of recruitment?   
 (In order to allow for mature consideration by the participant,  
   a period of 6 days must elapse from the time a subject is  
   invited to participate in a drug trial (and been given appropriate  
   information) at the beginning of the study.  If such a delay is not  
   possible the 6-day rule may be waived by the IMB). 
 
 
42. If YES, has a request for a waiver of the 6 day  
 rule been made to the IMB? 
 
 
43. Indicate what phase (IMB phase 1 – 4) of drug  
testing the trial represents. 
 
Phase 1 – Pharmacokinetics in healthy humans. 
Phase 2 – Early studies (kinetics and dose ranging). 
Phase 3 – Large safety and efficacy studies in population  
                 to be treated. 
Phase 4 – Post-marketing/monitoring.                            Phase 
YES NO 
YES NO NA 
1      2      3      4 
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SECTION  E 
 
FINANCE 
 
 
44. What are the cost/resource implications of this study?  
 
Please elucidate: 
 
Dr. Claire Hughes is applying for funding from the European Society for 
Paediatric Endocrinology and from the Barts Research Advisory Board. The 
funding is to secure a salary to support Dr. Hughes during her research fellowship 
and to cover laboratory overheads and cost of consumables. 
 
 
 
45. Is the cost of running the trial/research study  
covered  in total by the company/sponsor? 
 
N/A 
 
46. Please detail all costs under the following headings: 
 
           Departments             Head of Department 
    Approval Signature 
 
Pathology  N/A    ___________________________ 
 
Radiology  N/A    ___________________________ 
 
Nuclear Medicine N/A    ___________________________ 
 
Pharmacy  N/A    ___________________________ 
 
Any other  N/A    ___________________________ 
 
 
     Staff 
 
Nursing  N/A    ___________________________ 
 
Medical Salaries N/A    ___________________________ 
 
Portering  N/A    ___________________________ 
 
Medical Records N/A    ___________________________ 
 
Secretarial  N/A    ___________________________ 
 
Any other  Salary for Claire Hughes         ______________________  
YES NO NA 
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The Finance Department will assist with providing costings if required. 
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47. Have all tests for this study been discussed with the  
 relevant departments?   
      N/A 
 
48. Have all costs for this study been discussed with the  
 relevant departments?  
 
      N/A 
49. Please detail approval.  
 
Agreed: ____________________________________ 
      Head of Department 
 
 
50. Have all costs been approved by Accountant/Research  
Centre Council Department? 
 
Agreed: __________________________   Date: _____________________ 
   Accountant 
 
 
PLEASE  NOTE: 
 
INSURANCE/INDEMNITY  ARRANGEMENTS 
 
(a) If the clinical trial is sponsored by a pharmaceutical   
company please confirm that the sponsor has agreed  
to accept the Hospital standard Indemnity Form  
(and append a signed copy). 
          N/A 
(b) If the standard Indemnity Form has not been signed  
please explain why. 
 
(c) If there is no sponsor for the clinical trial please specify  
the insurance arrangement in place and furnish appropriate  
certification. 
 
(d) If the research is sponsored by a pharmaceutical company,  
has that company agreed to abide by the current ABPI  
Clinical Trials Compensation Guidelines? 
 
 
 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
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SECTION  F 
 
 
I confirm that the information provided in this protocol is correct.  I also understand 
to undertake an annual report on the anniversary of The Ethics Committee approval 
with details of the number of subjects who have been recruited, the number who have 
completed the study and details of any adverse events. 
 
 
 
Signed: _________________________________________________________ 
(Project Supervisor) 
 
 
Date:  _________________________________________________________ 
 
 
Ethics Committee Comments: 
 
 
 
IMB approval 
 
 
 
Financial approval  
 
 
 
Insurance 
 
 
 
Patient Information  
Sheet approval 
 
 
 
Patient Consent  
Form approval 
 
 
 
 
Approved subject to: 
 
Approved:
 __________________________________________ 
 
YES NA PENDING 
YES NA PENDING 
YES NO 
YES NO 
YES NO 
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DIABETES & ENDOCRINOLOGY CENTRE 
Telephone:  01-4096399 / Emergency:  01-4096121 / Fax:  01-4560953 
Email: diabetes.endocrine@olhsc.ie 
 
 
 
 
Information Leaflet 
 
 
Project title: Investigating the genetics and mechanisms of ACTH resistance in 
children with Familial Glucocorticoid Deficiency 
 
 
I am writing to you to ask if you would like to take part in a research study which aims 
to find the gene responsible for the genetic condition Familial Glucocorticoid Deficiency, 
and examine how this gene works. You and your family have previously been seen by 
the Endocrine Department of Our Lady’s’ Hospital, Crumlin, because your family has 
this condition. A sample of blood may have been taken at that time for genetic testing.  
 
We now wish to try and find the cause for the genetic condition in your family. We are 
asking your consent to take a blood sample, and for this sample and your clinical details 
to be included in this study.  
 
You are under no obligation to take part in this study, and if you do take part, you may 
withdraw at any time without having to give an explanation. Your participation in this 
study will not affect your ongoing medical care. 
 
Your information and sample will be kept confidential at all times. Your blood sample 
may be sent on for further analysis to another laboratory, and if it is, the sample will be 
encoded, and your name will not be passed on to the laboratory. 
 
There may not be any direct results for you from the testing carried out. However, we 
will let you know the outcome of the research project in general and of any specific 
results that are relevant to you. 
 
If you wish to take part in the study, please sign the attached consent form. 
 
 
If you have any concerns, or wish for further information, you may contact Dr. Colm 
Costigan Consultant Paediatrician on 01-4096399, or Dr. Claire Hughes on 01-
4096100. 
 
Principal Investigators  
Dr. Colm Costigan – Paediatric Endocrinology Consultant 
Dr. Claire Hughes – Paediatric Specialist Registrar 
Dr. Adrian Clarke – Professor of Medicine, Bart’s and the London School of 
Medicine and Dentistry 
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DIABETES & ENDOCRINOLOGY CENTRE 
Telephone:  01-4096399 / Emergency:  01-4096121 / Fax:  01-4560953 
Email: diabetes.endocrine@olhsc.ie 
 
 
 
 
Information Leaflet 
 
 
Project title: Investigating the genetics and mechanisms of ACTH resistance in 
children with Familial Glucocorticoid Deficiency 
 
 
 
Familial Glucocorticoid Deficiency is a condition that means you have to take steroids 
every day to keep you well and is why you have to come to see Dr. Costigan and Dr. 
Cody in the hospital.  
 
We want to study this condition and why some children have it and others don’t. 
 
Would you like to take part in this study to help us find the cause of this condition? It 
would mean taking a blood test and allowing us to look at some of your hospital notes. 
 
You only have to take part in the study if you want to and if you want to stop at any 
stage (with or without a reason) it’s no problem. This study may not help you but it 
could help others.  
  
Your information and blood sample will be kept secret at all times.  
 
If you would like to take part in the study, please sign the attached form. 
 
If you have any other questions please ask Dr. Colm Costigan or Dr. Claire Hughes 
on 01-4096100. 
 
 
 
 
 
 
Principal Investigators  
Dr. Colm Costigan – Paediatric Endocrinology Consultant 
Dr. Claire Hughes – Paediatric Specialist Registrar 
Dr. Adrian Clarke – Professor of Medicine, Bart’s and the London School of 
Medicine and Dentistry 
 
 
